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ABSTRACT
Controlled-release drug-delivery systems enable efficient and defined
administration of therapeutic agents to target tissues. However, ultimate drug distribution
and pharmacologic effect are determined by target tissue pharmacokinetics. In muscular
tissues, complex architecture that is further augmented by dynamic motion and
contraction can alter the pharmacokinetics and deposition of locally delivered
macromolecules. We developed a system and applied a quantitative schema to
investigate the impact of controlled mechanical loads applied to skeletal and cardiac
muscle tissue on intramuscular transport of locally delivered drug. In a series of studies,
we examined how the interaction between architectural configuration and functional
mechanics alters the transport of drugs across both physicochemical and binding
properties. We correlated these pharmacokinetic effects with characteristic parameters in
the physiologic range of the tissue to derive mechanistic insight into the fundamental
structural and dynamic elements that underlie these effects. While previous studies have
revealed the unilateral scaling of substrate uptake with mechanical influences, we
elucidated an architecturally defined pharmacokinetic setpoint whereby maximal drug
penetration corresponds with optimal muscle function. Our findings elucidate basic
biologic design in muscle that optimizes the interface between tissue and its physical
environment. The unique insights from our investigations have broad impact on current
understanding of the pharmacokinetic influences of biologic form and function, and
elucidate new clinical strategies for controlled release and local delivery of a wide range
of therapeutic compounds to mechanically active tissues.
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1. INTRODUCTION
1.1 Motivations and Significance
1.1.1 Clinical Problem
Coronary heart disease (CHD) and peripheral arterial disease (PAD), the ischemic
consequences of atherosclerosis, are increasingly dominant causes of chronic disability
and death around the world. In the U.S. alone, CHD currently affects an estimated 16
million people and stands as the single leading cause of death, accounting for over
600,000 deaths - 20% of all deaths - every year [1]. Moreover, the risk of having either
a fatal or nonfatal cardiovascular ischemic event is significantly increased for those who
have PAD. Peripheral vascular disease serves as an independent risk factor for CHD [2],
increasing the risk of mortality from CHD by 6.6 times [3]. However, large-vessel PAD
is frequently asymptomatic and remains both under-diagnosed and underestimated.
Nonetheless, it affects up to 8.5 million Americans [4] and is, in turn, 2 to 3 times as
likely to occur in patients with cardiovascular disease [5]. Ultimately, PAD leads to
progressive disability and risk of limb loss. As a result of their increasing prevalence and
incidence with the increasing mean age of the population, both CHD and PAD present
major scientific and medical challenges for developing advanced therapies that both
successfully treat ischemic damage to tissues, and restore the supply of blood to these
tissues.
1.1.2 Current Treatments
Presently, over 3.3 million interventional procedures are performed each year for
attempted relief of the complications of CHD [1]. Current invasive interventions for
treating cardiac or skeletal muscle ischemia are designed to mechanically restore blood
flow to the compromised tissues. These therapies consist of traditional surgical
revascularization methods like coronary artery bypass grafting (CABG) and the
commonly applied catheter-based intervention of percutaneous transluminal coronary
angioplasty (PTCA) combined with stent placement. However, despite advances in these
therapies, there still remains a significant and apparently increasing number of patients
who are either ineligible for such treatments, or for whom such treatments are ineffective
in salvaging ischemic yet viable tissues. Up to 12% of patients with symptomatic CHD
have diffuse vessel disease, small distal vessels, or other comorbidities that render this
subset of patients poor candidates for revascularization by PTCA or CABG [6].
Similarly, the use of these mechanical interventions for patients with PAD is limited by
the same complications [7]. Unfortunately because of the aging population, the
proportion of CAD and PAD patients who are not amenable to these standard therapies is
estimated to increase. Yet, despite their severe ischemia, such patients may still have a
relatively large enough amount of viable cardiac or skeletal muscle that can be salvaged.
Therefore, it appears warranted to incorporate alternative strategies, either as independent
therapies or as adjuncts to conventional revascularization, for improving blood flow and
mechanical performance to the heart or skeletal muscle.
As a result, research efforts have been directed towards investigating therapeutic
angiogenesis as an alternative treatment for ischemic vascular disease. This promising
therapy uses the local administration of pro-angiogenic growth factors to
pharmacologically promote endogenous blood vessel formation and growth. By
augmenting blood flow to ischemic tissues in this way, therapeutic angiogenesis has the
potential to salvage ischemic myocardium or skeletal muscle, and reduce infarct size.
Such treatment can thus compensate for the apparently inadequate angiogenic response in
patients with advanced vascular disease [8] and may provide them with symptomatic
relief, improvement in quality of life, and perhaps improvement in overall survival.
1.1.3 Therapeutic Angiogenesis
Therapeutic angiogenesis has been proposed since the 1970s [9] to "biologically
bypass" obstructed arteries in order to prevent, compensate for, and treat ischemic
disease. The most extensively studied pro-angiogenic factors have been vascular
endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2), both of which
are key endothelial and vascular mitogens [10-12]. The ability of these polypeptides to
promote blood vessel formation and maturation, as well as their synergistic contribution
to regulating vessel growth, have been well studied in vitro [12-17]. As a result,
numerous experimental animal studies and clinical trials have investigated the potential
for promoting therapeutic neovascularization in myocardial ischemia or PAD using either
protein or gene delivery of VEGF or FGF.
Results from initial studies of VEGF and FGF protein administration to animal
models of hindlimb and myocardial ischemia have raised hopes for the therapeutic
effectiveness of pro-angiogenic growth factor delivery. For example, animal studies by
various groups revealed that VEGF is effective in increasing tissue perfusion and
improving muscle function [18-21], and that bFGF produces dose-dependent increases in
collateral vessel formation and blood flow [22-29]. However, despite encouraging
findings from many animal studies, the results from nearly a decade of human clinical
trials using growth factor delivery have shown mixed success and have raised major
concerns about the potential side-effects of delivering angiogenic growth factors. These
inconsistent findings include, on the one hand, mildly encouraging results from mostly
small and uncontrolled clinical studies. These small studies showed that intramyocardial,
perivascular, or intracoronary administration of FGF2 or VEGF in patients with end-stage
myocardial ischemia can lead to improvements in exercise tolerance and angiographic
scores of collateral growth [30-38]. On the other hand, less successful results have come
from larger multi-center, randomized controlled trials. For example, the 2002 FGF
Initiating RevaScularization Trial (FIRST) [39] showed no significant increase in
treadmill exercise tolerance or myocardial perfusion after intracoronary FGF2 treatment.
Similarly, a comparable pattern of mixed results also emerged from multi-center,
randomized controlled trials for PAD, such as the TRAFFIC study [40] and RAVE trial
[41].
These larger trials for CAD and PAD also revealed the various side-effects that
can result from systemic exposure to growth factors, or when growth factors deposit in
non-target tissues. Gene transfer of VEGF caused transient lower extremity edema [42-
44], intracoronary delivery of FGF2 caused hypotension [39], and systemic intravenous
delivery of FGF2 resulted in severe proteinuria and renal toxicity [45]. These findings
suggested that perhaps optimizing the local delivery of growth factors to target tissues
may potentially bridge the discrepancy between their therapeutic potential and clinical
effectiveness.
1.1.4 Local Delivery
With the idea that proximity of the administration site to the target-tissue can
increase therapeutic effectiveness, many efforts to improve angiogenic therapy have
centered on designing strategies for effective local delivery of growth factors, especially
since ischemic lesions are typically spatially focal in nature. Local delivery offers the
advantage of being able to present growth factor protein directly and efficiently to desired
target tissues at physiologic rather than pharmacologic doses, thus minimizing systemic
losses to non-target tissues [46]. Furthermore, local delivery can potentially achieve a
desired spatial distribution for a temporal duration long enough to accommodate the
typically long time course of new collateral vessel development. With this notion,
various strategies have been employed for local delivery of growth factors. Such delivery
strategies have used intrapericardial, perivascular, and intramuscular routes via various
administration modalities including osmotic pumps, gene therapy, or sustained delivery
polymers [47-52] to yield various degrees of improved results. For example, myocardial
uptake of FGF2 from pericardial administration was shown to be approximately 5 times
that from intracoronary administration [46]. However, even as these local delivery
methods ascend in interest and importance, many still remain unproven in terms of
clinical effectiveness, safety, and superiority. This is because many issues regarding the
local pharmacokinetics of growth factors within their target tissues remain to be
elucidated before an optimal local delivery method can be designed. For example, an
incomplete understanding of intramyocardial transport after intrapericardial delivery may
limit growth factor deposition to only the epicardial layers and result in poor
transmyocardial diffusion and endocardial distribution [53] or lead to local toxicity that
may precipitate plaque growth or destabilization [54, 55]. Thus, elucidating the forces
involved in growth factor handling by target tissues will facilitate a more rational
approach to the design of local delivery strategies.
1.1.5 Local Pharmacokinetics
Controlled released and local delivery strategies provide a means for efficient
administration of therapeutic agents to target tissue with minimal systemic losses;
however, ultimate drug distribution and pharmacologic effect are dictated by target tissue
pharmacokinetics. Local delivery systems must consider that space- and time-dependent
drug distribution, not simply proximity of delivery, also dictate tissue response. The
spatial and temporal distribution of drug in the tissue can be influenced by general
transport effects such as diffusion or convection, as well as charged partitioning, steric
hindrance, or specific binding, which reflect the interaction between tissue and drug
physicochemical and binding properties.
The kinetics of specific binding interaction between the delivered growth factor
and its target tissue environment significantly impacts this drug distribution. Once
released, exogenously delivered heparin-binding growth factors, such as FGF and VEGF,
can interact with several receptors expressed in the extracellular environment. They bind
with high affinity to specific cell-surface tyrosine kinase receptors, and with lower
affinity to the more abundantly found cell-surface, basement-, and extracellular-
membrane co-receptors such as heparan sulfate proteoglycans (HSPG), av13 integrins,
and collagen types I and IV [56-61]. Studies of in vivo organ deposition after
intravascular administration of exogenous growth factor have found the proteins to be
localized to zones of these organs that are rich in HSPGs, such as the extracellular matrix
and vascular endothelium in the heart [46, 62]. Binding of FGFs to these co-receptors
has been found to protect FGFs from proteolytic degradation and denaturation, thereby
stabilizing their local levels and increasing their half-life in tissues [63, 64]. This binding
can also create a spatially distributed storage reservoir, which allows growth factor to
reach higher local amounts and concentration gradients, and from which they can be
released over time to sustain long-term stimulation of surface receptors on endothelial
cells [65-67]. Thus, the interaction with HSPGs, depending on their location and
concentration, may serve to increase both the duration of the biological activity of the
growth factors and their radius of diffusion and action. Or, this interaction may serve to
limit growth factor diffusibility by immobilizing them to the ECM and restricting their
subsequent availability to bind to downstream tyrosine kinase receptors [62, 68].
Furthermore, as dynamic and mutable biological components, these binding sites
can be affected by the physical state of the tissue. In particular, the pathologic changes
during ischemia can result in a significantly different transport environment, with
consequence on growth factor availability and biological activity [59]. One prime
example is the increased expression of cell-surface receptors (FGFR1, VEGR1, VEGR2)
as well as extracellular and basement membrane HSPGs in acutely and chronically
hypoxic or collateral-dependent ischemic border zones [69-73]. But more than this,
studies in both ischemic myocardium and skeletal muscle have shown that changes in
cell-surface receptor expression after an ischemic event follow a characteristic spatial and
temporal kinetic. There is rapid but short-lived receptor upregulation in the non-ischemic
zones, and a slower but steadier upregulation of receptors in the injured area [74, 75].
Therefore, the increase in the number of binding sites during myocardial ischemia may
enhance myocardial deposition and retention of growth factor [53]. However, the early
increase of receptors in non-ischemic tissue may actually limit therapeutic efficacy by
sequestering available drug before it transports to the ischemic border zone. This insight
into binding site mutability during ischemia underscores the need to have a better
understanding of the predominant pharmacokinetic influences exerted by the target tissue
on a drug in order to improve its therapeutic effectiveness.
1.1.6 Influence of Mechanical Loading
Of critical importance especially for local delivery strategies like therapeutic
angiogenesis to mechanically active tissues is the matter of achieving adequate drug
penetration to intramuscular targets. With a fundamental understanding of the influences
of binding and specific interactions on growth factor pharmacokinetics, there is still an
incomplete knowledge of the prevalent transport forces in muscle tissues. Local
pharmacokinetic effects can be pronouncedly compounded by complex architecture and
mechanical function. Interactions between drug and the physical structure of the tissue
can sterically hinder interstitial transport of the higher molecular weight drugs that local
strategies deliver. Muscle tissue presents an exclusive transport environment in which
dynamic mechanical motion and loading can significantly influence the pharmacokinetics
of delivered agents. These loads and motions, which are shaped by both structure and
function of the muscle, can present major, dynamic physical influences on drug transport
by modulating interstitial space permeability, fluid volume distribution, and tissue
deformation. In addition, the influence of such transport effects can be dramatically
altered in pathologic states such as ischemia, hypertension, or hypertrophic
cardiomyopathy, in which muscle tissue undergoes architectural remodeling and
mechanical dysfunction. Thus, a quantitative investigation of the roles of architecture
and loading dynamics in muscle tissue is necessary not only to optimize local drug
delivery, but also to establish a more comprehensive understanding of intramuscular
pharmacokinetics.
A diverse body of work has investigated the transport of agents in mechanically
loaded tissues. Only a subset of this work has focused on the impact of mechanical
loading dynamics. These studies have examined the impact of pressure-induced aortic
distension on transmural transport of low-density lipoprotein and albumin [76]; the
impact of static tensile loading on diffusion of water in Achilles tendon [77]; the effects
of static or cyclic compression on transport of dextran [78, 79], H20, sodium, lithium
[80], insulin-like growth factor I, proline, and sulfate [81] in articular cartilage; the
effects of skeletal muscle fiber contraction on sarcoplasmic protein diffusion [82]; the
role of contraction on glucose uptake in skeletal muscle [83, 84]; the influence of atrial
workload on translocation of secreted atrial natriuretic peptide and extracellular fluid
[85]; the influence of atrial distension on permeability of large macromolecules such as
horseradish peroxidase [86]; the effects of contraction on inulin uptake and washout in
papillary muscle [87]; the role of calcium in regulating glucose uptake in isolated
working rat heart [88]; and the impact of cardiac contractility on interstitial washout of
raffinose [89]. Each study has revealed the influence of mechanical loading on the
transport and uptake of various agents. Diminished transendocardial translocation of
atrial natriuretic peptide (ANP) arises when high atrial workloads reduce the extracellular
space [85]. Increases in apparent diffusion of water in statically tensile-loaded Achilles
tendon are attributed to extrusion of tendon water into a bulk phase along the outside
surface of the tendon during loading rather than to load-related changes in fiber spacing
[77]. And, compression reduces dextran diffusivity in cartilage [78].
Findings from these studies have consistently shown mechanical loading such as
tension, compression, or contraction effects transport. However, a majority of the studies
in skeletal and cardiac muscle have focused on the specific role of metabolic activity-
dependent transport and intracellular import of small metabolic substrates. Aslesen et al.
have shown differential glucose uptake with increasing frequency of contraction in rat
skeletal muscles with different metabolic demand [90]. Gissel et al. reported that skeletal
muscle contraction increases sodium and calcium uptake [91], while Abraham et al.
fbund that skeletal muscle uptake of potassium decreases with increasing rate of
contraction [92]. Many groups have documented that contraction and mechanical activity
in both skeletal and cardiac muscle increase glucose uptake [93-96]. Yet, no studies of
this nature have investigated the pharmacokinetic influence of solely tissue architecture
and mechanics. None have compared the influence of mechanical loading on transport in
different muscle types, skeletal and cardiac, which differ in structural design and loading
paradigm. Thus, there is a need for quantitative studies in skeletal and cardiac muscle to
examine the role of mechanical loading in shaping the uptake and local retention of
locally delivered drug. We sought to isolate the distinct transport and steric effects
presented by muscle architecture and mechanical dynamics on locally delivered drug and
to derive the physiologic significance of these effects by correlation to functional
parameters of the tissue.
1.2 Fundamental Thesis and Aims
The fundamental thesis of this work is that the functional architecture of muscular
tissues impacts drug transport. The structure and mechanical function of muscle tissues
may alter the pharmacokinetics and deposition of locally delivered agents independently
of physicochemical and binding properties.
This work sought to elucidate a quantitative understanding of how the mechanical
loading conditions, which depend on tissue architecture and function, present in skeletal
and cardiac muscle affect the penetration and distribution of locally delivered drug. This
work uses a systematic approach - starting with component events and building up to
complicated phenomena - to study the unique pharmacokinetic and steric effects of
intramuscular architectural configuration and mechanical loading, exclusive of specific
binding interactions. Prior to quantifying the transport of proteins or specifically binding
drugs, it is necessary to analyze the pharmacokinetics of an inert tracer such as dextran.
Both skeletal and cardiac muscles support dynamic mechanical loading conditions
and are susceptible to pathologies such as ischemia that produce structural and
mechanical dysfunction. However, each muscle type presents a distinct architectural
environment and mechanical loading paradigm, which prompts the questions of:
1) "What is the role of uniaxial stretch and contraction on drug transport in
linearly structured muscle tissue composed of longitudinally aligned fibers?"
2) "What is the role of multidimensional mechanical loading on drug transport in
muscle whose structure is 3-dimensionally complex?"
A rigorous, quantitative schema was applied to address these questions experimentally in
a rat animal model by investigating:
1) the transport effects of static and cyclic tensile loading, and contraction in
soleus skeletal muscle, and then mathematically modeling these effects.
2) the transport effects of multidimensional ventricular distension and in vivo
cardiac contraction, which are analogous to the static and contractile loading
conditions in skeletal muscle.
Ultimately, a conceptual paradigm was formulated to elucidate the mechanistic
underpinnings and physiologic significance of the impact of architectural configuration
and its interaction with mechanical loading on drug transport in skeletal and cardiac
muscle.
1.3 Background
1.3.1 Pharmacokinetics in Skeletal Muscle: Uniaxial Mechanical Loading
Drug transport after intramuscular delivery is thought to be affected by many
physiological variables whose quantitative contributions to total absorption and
therapeutic efficacy are not well understood [97]. Interstitial diffusivity, for example, is
dictated by tissue architecture as well as binding site density, capillary permeability, and
local blood flow. In dynamic tissues like skeletal muscle, intramuscular
pharmacokinetics of growth factors can also be greatly influenced by mechanical loading,
whose characteristics are largely dictated by muscle structure. As a result, both the
structure and mechanical function of muscle interact coordinately to influence drug
transport.
The elongated muscle fibers in a skeletal muscle such as the slender fusiform
soleus muscle are organized and bound together in a simple, uni-pinnated, parallel
alignment (Figure 1.1), by a continuous network of supportive connective fibers
containing both collagen and elastic fibers [98]. These intramuscular connective tissues
provide lateral connection and support between parallel muscle fibers that extend
throughout the entire length of the muscle. Their framework is structured into three
discrete but interconnected sheaths that compartmentalize the muscle. The tough outer
collagenous epimysium, composed mostly of collagen type I and a thin layer of type III,
surrounds and enfolds the whole muscle as a functional unit. The epimysium extends
smaller bundles of coarse collagen fibers inward to form a tough, thick perimysium. The
perimysium, which is ubiquitously composed of both collagens type I and III, forms a
network of septa that binds groupings of individual muscle fibers into functional bundles,
or fascicles. As a result, the whole muscle is made up of many fascicles, with polygonal
cross-sections (Figure 1.2). From the perimysium, thin partitions of delicate connective
tissue extend into each fascicle to establish an endomysium that invests individual muscle
fibers.
Figure 1.1. Uniaxial structure of soleus skeletal muscle.
A B
Bone Perimysium Blood
vessel
Muscle fiber
S(cell)
Tendon Epimysium Endomysium Fascicle(between (wrapped by
fibers) perimysium)
Figure 1.2. Skeletal muscle architecture. (A) A schematic illustration of skeletal muscle
shows how it is compartmentalized by its connective tissue network. (B) A cross-section of
rat soleus skeletal muscle, stained with Hematoxylin and Eosin, shows muscle
compartments.
The endomysial connective tissue is composed mainly of collagen type III, with small
random traces of type I and other types of collagen. Finally, the inner most layer of the
endomysium, the basement membrane, lies immediately adjacent to the plasma
membrane, or sarcolemma, of the muscle fiber. It consists of collagen type I, type III,
type IV, and heparan sulfate proteoglycans [99]. Both the endomysium and perimysium
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exhibit dense networks of collagen fibers that run in various directions, with no clear
main orientation, during a relaxed muscle state. Endomysial fibrils run both
longitudinally along the surface of muscle fibers and perpendicularly to them, forming
connections between adjacent muscle fibers. Perimysial fibrils further wrap around
muscle fiber fascicles to bind them to each other [100]. Thus, as a structural element,
these connective tissue septa not only define the extracellular space and establish
channels for transport, but also introduce barriers that hinder free passage of drug through
this space. This general network of connective tissue also presents a spatially complex
scaffolding of potential collagen binding sites that can localize delivered growth factors
that are penetrating into the muscle. For example, intramuscular FGF has been found to
be associated with the endomysial layer, likely bound to heparan sulfate proteoglycans
and collagen [101].
This connective tissue network also serves to sustain the integrity of the muscle,
and in turn can be affected by mechanical loading. The endomysium has been considered
to be involved in both stress resistance and transmission of the active force of
contraction. And, the perimysium is considered to distribute force associated with
passive stretch along the muscle fiber. It also mediates lateral force transmission between
fibers via shear while maintaining the relative position of the fibers [100, 102]. As a
consequence of their mechanical role, the collagen fibrils in both the endomysium
(Figure 1.3) and perimysium (Figure 1.4) are pulled from a normally non-specific
orientation during muscle relaxation toward the circumferential direction during muscle
Figure 1.3. Distribution of collagen fibril orientations in the endomysium of skeletal muscle
while (A) at rest length, (B) in a shortened state, and (C) in an extended state. SEM view
(12,200x) in which the muscle fiber axis runs in the horizontal direction.
Extended Shortened
Figure 1.4. Collagen fibril orientations in the perimysium of skeletal muscle while (A)
extended position and (B) in a shortened position. SEM view (1300x) in which muscle
M, runs in the vertical direction.
in an
fiber,
shortening, or toward the longitudinal direction of the muscle axis during muscle
lengthening [103-105]. As a result, such changes to connective tissue architecture
brought about by mechanical loading may influence the permeability of the intramuscular
interstitial space for the transport of drug.
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Further mechanical loading effects such as intramuscular pressure and convective
forces generated during muscle function and deformation can have an even greater
influence on drug transport. Much of the deformation that occurs during either fiber
shortening or lengthening results from fiber incompressibility, which keeps fiber volume
constant and plays an important role in volume displacement. Consequently, lengthening
results in flattening of the muscle and decrease in interstitial volume. Oppositely,
contraction in a parallel-fibered muscle causes cytoplasmic volume displacement from
the smaller end-regions of a fiber towards the middle region. This results in fiber angle
changes at their attachment ends, forces and strains with significant perpendicular
components, and a buildup of intramuscular pressure concomitant with cross-sectional
bulging of the fiber and muscle [106]. Ultimately, the changes in muscle fiber cross-
sectional area and internal pressure during either contraction or lengthening may be
associated with water redistribution within the muscle and changes in interstitial space
[107]. These changes can lead to convective forces that influence drug transport during
muscle function.
Given the structure, constitution, and mechanical activity of skeletal muscle, it is
reasonable to suspect drug transport is a function of not only physicochemical properties
of the drug, but also tissue properties of the muscle. In particular, the complex material
composition of connective tissue may lead to differential local retention of drug. This
may induce large variations in drug concentration that can potentially be incompatible
with achieving clinical efficacy. Ultimately, a major impact on drug distribution may
come from mechanical loads that are intrinsic to the function of the muscle. Structural
deformations associated with loading, such as those during passive stretch or contraction,
can alter the available interstitial space for drug uptake, intramuscular transport, and
subsequent distribution. The dynamic forces, interstitial convective effects, and pressures
generated by mechanical function can modulate the spatial and temporal characteristics
of such drug distribution. This then raised the fundamental question of: "What is the role
of uniaxial stretch and contraction on drug transport in linearly structured muscle tissue
with longitudinally aligned fibers?" We sought to investigate the intramuscular
penetration of locally delivered drug in skeletal muscles undergoing different mechanical
loading conditions. Findings from this study may provide a quantitative scheme to tailor
local delivery to skeletal muscle tissue and optimize drug deposition.
1.3.1.1 Static Tensile Strain
A quantitative evaluation of drug transport was conducted by examining the
intramuscular distribution of drug that was applied from a delivery source at the muscle
surface. Drug uptake was assessed from this distribution by quantifying the depth of
drug penetration into the muscle from the surface. Intramuscular diffusion under these
conditions is influenced by strain-dependent, structurally mediated, steric hindrance.
Ultimately, this study determined how uptake, as quantified by penetration depth, was
affected by the amplitude of statically imposed tensile strain on ex vivo soleus muscle
preparations.
1.3.1.2 Cyclic Tensile Loading
A quantitative evaluation of drug transport in ex vivo soleus muscle undergoing
cyclic mechanical loading determined how penetration depth and effective drug transport
were affected by the amplitude and frequency of cyclic stretch. In this case, the effective
interstitial transport associated with dynamic loading is influenced by not only
architecturally mediated steric hindrance, but also dynamic forces resulting from cyclic
mechanical and structural loading. The contribution of these dynamic forces to effective
transport were evaluated along with the effective diffusivity under static loading
conditions to determine the impact of cyclic forces and dynamic structural deformations
relative to mere structural resistance on interstitial drug transport.
1.3.1.3 Electrically Paced Contraction
Significant transport forces may be introduced during muscle contraction. Cyclic
fiber shortening and relaxation can affect interstitial space and dynamic forces differently
than cyclic elongation and release. Thus, this study determined how penetration depth
and effective transport of drug in ex vivo soleus skeletal muscle was affected by
electrically paced contraction. A comparison of transport associated with muscle
shortening and contractile function to transport associated with stretch of passive muscle
determined the significance of contractile compared to tensile loads on interstitial drug
transport.
1.3.2 Pharmacokinetics in the Heart: Multidimensional Mechanical Loading
The practical realization of angiogenic therapy is bounded by concerns over
limiting delivered growth factor concentrations in order to avoid both local and systemic
side effect profiles. Since angiogenic growth factors can induce a destabilizing mitogenic
response when exposed to neighboring atherosclerotic plaques, a primary concern when
delivering to the heart is to limit the local distribution of delivered proteins to the
ischemic regions of the myocardium. Another concern when delivering to the heart is to
avoid spillover into the systemic circulation upon exposure to coronary arteries or the
intraventricular chamber. Moreover, as angiogenesis requires a tightly controlled
exposure to physiologic levels of growth factors, an intimate understanding of the local
pharmacokinetics in the myocardium is necessary. However, unlike the 2-dimensionally
arrayed, linear architecture of skeletal muscle, heart muscle forms an elliptical chamber
that is 3-dimensionally complex and has multiaxial mechanics. Thus, macromolecular
transport in the heart is likely to be influenced by more complex loading conditions than
those in the uniaxially loaded skeletal muscle, and remains very poorly understood.
Unlike the longitudinally aligned fibers in skeletal musculature, the myocardium
is composed largely of tightly knit bundles of elongated muscle fibers, each composed of
several cardiac muscle cells joined end-to-end or end-to-side in an interdigitating step-
like manner by junctional complexes called intercalated disks (Figure 1.5). This manner
of construct results in fibers that bifurcate longitudinally and connect with ends of
adjacent fibers to form a complex, three-dimensional, branching network. Moreover,
these knit cardiac bundles of fibers are wrapped together to form three major concentric
layers in the cardiac wall, with each layer of fibers directed in a different orientation. The
innermost layer forms the central portion of the left ventricle, and the outer two, which
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Figure 1.5. The branched myofiber network of the myocardium.
are oriented obliquely, wrap around to form the left and right ventricles. Yet, far from
being discrete from each other, these layers are actually part of a contiguous strip that
forms a left-handed helix in the subepicardium that progresses smoothly inward into a
right-handed helix in the subendocardium. This orients the muscle fibers along figure-of-
eight pathways. In the left ventricle for instance, the pattern is characterized by a train of
muscle cells adjacent to the epicardium that spirals both apically and into the wall, past
midwall to the endocardial side, and then spirals upon the inside past the equator, and
past midwall to return back to the epicardial side. This completes the figure-of-eight by
starting another figure-of-eight without actually joining it [108] (Figure 1.6) [109]. As a
result of the winding circuit that these fibers take, a transmural section through the central
region of a ventricular wall would show that the orientation of the muscle fibers tends to
change. It would show an oblique muscle fiber orientation in the subepicardial region,
transverse orientation in the midwall, and a near vertical orientation in the subendocardial
region. For an epicardially applied drug that is penetrating transmurally into the
ventricular wall, such transitions in fiber orientation in these intramural sheets can
introduce a local shift in mechanical loading and transport paradigm as the drug
encounters each successive layer.
Figure 1.6. The course of left ventricular muscle fibers shown in a preparation of the
human heart and as a schematic viewed from the dorsal aspect. The internal and external
muscle investments of the ventricular chambers are composed of the same fiber bundles,
which are strongly twisted at the apex and spiral in opposite directions towards the base. A
transmural section through the ventricular wall shows that the twisting course of muscle
bundles results in three major wall layers with different fiber orientations.
For another reason, penetration of drug past these myocardial fiber layers may not
be as predictable as it would be if it were transporting simply past skeletal muscle
bundles. This lies in the fact that the characteristically layered structural motif of
myocardial tissue is comprised of multiple layers, each consisting of parenchymal and
supportive tissue bounded by mechanically protective and biologically functional
"membranes."' In particular, this refers not only to the fact that cardiac muscles fibers are
bundled together by extracellular matrix, as with fibers in the soleus skeletal muscle, but
also by the fact that cardiac muscle fibers tend to be organized transmurally into distinct
layers, or laminae, of fibers separated by thin sheets of collagen. As there are relatively
sparse muscle bridges between adjacent lamina, the demarcation between the layers of
"collagen-muscle fiber-collagen" units is referred to as cleavage planes (Figure 1.7),
which tend to open naturally upon dissection of the cardiac muscle [110].
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Figure 1.7. Architecture of cleavage planes and muscle fiber orientations in a cross-section
through the ventricular wall.
Defined by these cleavage planes, the laminar organization of myocytes has
approximately a radial (R) orientation when viewed from a longitudinal-radial cross-
section. It becomes more longitudinal (L) in the subendocardial and subepicardial
regions, with a pinnation pattern in the circumferential (C)-radial aspect. But regardless
of orientation pattern, the myocyte axis in the subepicardium is always nearly tangential
to the epicardial surface [111]. Ultimately, these cleavage planes may serve to interrupt
the transport of drug to downstream target sites, create local regions of drug
accumulation, or channel the drug away along the extent of the cleavage space, thus
preventing therapeutic agents from reaching ischemic targets.
In addition to architecture, the constitution of the heart may impact drug
penetration into the tissue. In particular, the connective tissue network in the
myocardium, as in skeletal muscle, exhibits sites that may potentially bind growth factor,
localizing them and complicating their transport. The fibrous network of the heart is
composed of collagen types I and III. And, the basement membrane of the
cardiomyocytes contains collagen type IV, laminin, fibronectin, and heparan sulfate
proteoglycans. The connective tissue serves to anchor the origin and insertion of muscle
fibers, support vascular tissues, and absorb the effects of stretch before they are
transmitted to myocytes. The convoluted collagen cords of the connective tissue network
increase in density near the epicardial and endocardial surface, where they join a delicate
sub-layer of collagenous tissue, and lie on top of a more robust fibro-elastic layer. The
perimysial connective tissue in the ventricle consists of large and small spring-like,
helically-coiled fibers that are arrayed parallel to the long axis of myocytes in the
interstitial space. These fibers serve to interconnect fascicles of myocytes as well as
whole mural layers between their extensive cleavage planes. The connective tissues
forming the endomysial network, which also consists of elastin and fibronectin, connect
adjacent muscle cells, wrapping them in complex pericellular weaves [112]. Thus, as in
skeletal muscle, the connective tissue network may serve to bind drug and lead to local
concentration gradients. For example, the collagenous and robust fibro-elastic layer
beneath the epicardial surface may localize drug while limiting its initial mural
penetration.
Ultimately, the connective tissue network may act under the influence of
mechanical loading to modulate drug transport. The interplay of these structures with
waves of space-dependent strain during ventricular dilation presents a formidable
challenge to studying drug uptake in the myocardium. The coiled fibrous networks,
which are anchored at both the fibrous annulus and the apex, undergo progressive
straightening of the tightly coiled configuration as the ventricular wall is stretched during
filling with increasing ventricular cavity pressures. However, there is a spatial variation
to this because they undergo straightening in only focal regions at low pressures, and
generalized straightening and disruption at the highest pressures, while exhibiting the
most pronounced changes in the mid-ventricle. This suggests that the mid-ventricle is the
most susceptible to bulging associated with increased cavity pressure. And, collagen
fibers in epicardial regions undergo more straightening than collagen fibers in
endocardial regions, as expected from the curved shape of the heart [113]. Furthermore,
the layered motif of the ventricular wall plays an integral part in its mechanics. With
increasing intraventricular pressure, connective tissue struts and strut-like fibers between
ventricular laminae are stretched from a perpendicular orientation to a co-alignment with
muscle fibers. However, the contiguous struts within an individual lamina that join
individual myocytes are often slackened during ventricular filling. This stretching and
disruption of connective tissue fibers between layers of the ventricular wall permit
slippage of mural layers relative to each other, accounting for a major portion of the
mural thinning that occurs during ventricular filling [114].
Moreover, spatially distributed effects of contraction may have a profound effect
on drug transport. During systolic contraction, in which simultaneous contraction of
adjacent muscle fibers is mediated by their intercalated disk junctions, significant
transmural gradients in wall strain occur in order to produce a contraction of the
ventricular chamber that favors longitudinal over circumferential chamber shortening.
The direction of the helically oriented left ventricular myofibers, which is maintained by
the extensive collagenous network supporting the myocytes, is also affected to some
degree by contraction - changing about 20 degrees in the transition from diastole to
systole at any transmural position. In particular, because of the transmurally rotational
splay of muscle fibers, the coordination of global contraction elicits a great deformation.
This deformation occurs in a direction of shortening that is not aligned with the axes of
local myofibers to result in an overall torsional effect on the ventricular chamber. And,
although fiber direction and shortening direction are not substantially different in the
epicardial half, they are virtually orthogonal to each other in the endocardial half of the
ventricular wall. Therefore, the structural changes that occur during contraction are the
result of various processes. These involve not only volume-conserving axial shortening
of individual muscle fibers that cause cross-sectional shape changes of both myofibers
and the interstitium, but also reorientation of the helically oriented myofibers that is
accompanied by shear and extension of the transmural laminar sheets. These processes
ultimately result in planar circumferential compression, especially in the inner half of the
ventricular wall. This compression contributes to the unidirectional radial lengthening
deformation, or mural thickening, of the ventricular wall that provides the powerful
mechanism for ejection during contraction [115-121].
The multi-oriented branching fiber arrangement, the transmural variation in fiber
orientation, and the laminar myofiber architecture in the heart all contribute to create the
dimensionally complex deformations that occur during cyclic myocardial function. The
characteristic results of torsion during chamber wall contraction followed by torsional
recoil during relaxation generate a heterogeneous distribution of strains in the ventricular
wall and non-axial strains across muscle fibers with every heartbeat. And ultimately, the
significant mural thickening and thinning during the contractile cycle introduces a
distinct dimension of transport forces oriented along the direction of transmural
penetration. As this complex mechanical loading paradigm presents a dramatic contrast
to the uniaxial effects found in skeletal muscle, drug delivery in the heart faces a uniquely
different transport environment. This then raised the question of: "What is the role of
multidimensional mechanical loading on drug uptake and transport in muscle, and how
does this compare to transport in muscle of uniaxial loading pattern?" Another question
was whether transport of drug in a multiaxially loaded environment could be extrapolated
from a summation of the transport behavior in a uniaxially loaded environment. Using a
simplified model to answer this question, we elucidated to a first approximation how
ventricular dilation, contractility, and heart rate affected the penetration depth and
transport of epicardially delivered drug. Findings from this study may provide a better
understanding of how pharmacokinetics in the heart differs from that in skeletal muscle.
1.3.2.1 Ventricular Distension
Multidimensional strains presented by the rotationally splayed laminar
architecture of myofibers in the heart during systolic ejection and diastolic filling of the
ventricular chamber may complicate intramuscular drug transport. Such transport may
differ from that influenced by only uniaxial loads. Thus, this study determined how
penetration and effective transmural diffusivity of both inert and specifically binding
drug in the myocardium were affected by the amplitude of statically imposed ventricular
distension. A comparison between drug penetration in uniaxially stretched skeletal
muscle and volumetrically loaded ventricular myocardium elucidated the unique
pharmacokinetic effects and physiologic significance of tensile strains applied to different
structural paradigms.
1.3.2.2 In Vivo Cardiac Contraction
As in skeletal muscle, cyclic mechanical loading can introduce cyclic
architectural deformations that result in dynamic forces and interstitial space variations.
However, in ventricular myocardium, loading patterns are multidimensionally complex
and often directed non-axially along muscle fibers. Mural thickening presents a further
dimension of mechanical loads in the direction of drug penetration. These effects may
transform the ventricular mural muscle into a significantly complex transport
environment. This study determined how drug penetration and effective transport were
affected by heart rate and contractility. Findings from this study may provide an
understanding of how multidimensional contraction impacts transport.
2. STRUCTURAL BIOMECHANICS MODULATE INTRAMUSCULAR DRUG
DISTRIBUTION: A BIOMECHANICAL LOADING SYSTEM
2.1 Abstract
Introduction: As local drug delivery continues to emerge as a clinical force, so
does understanding of its potentially narrow therapeutic window. Classic molecular
transport studies are of value but do not typically account for the local nature of drug
transport or the regional dynamic function in target tissues like muscle that may undergo
cyclical and variable mechanical motion and loading. We examine the impact of
dynamic architecture on intramuscular drug distribution.
Methods and Results: We designed a tissue mounting technique and mechanical
loading system that uniquely enables pharmacokinetics investigations in association with
control of muscle biomechanics while preserving physiologic tissue architecture. The
system was validated and used to elucidate the influence of architecture and controlled
cyclic strain on intramuscular drug distribution. Rat soleus muscles underwent controlled
deformations within a drug delivery chamber that preserved in vivo physiology.
Penetration of 1 mM 20 kDa fluorescein isothiocyanate (FITC)-dextran at planar surfaces
of the soleus increased significantly from 0.52 + 0.09 mm under 80 min of static (0%)
strain to 0.81 + 0.09 mm under cyclic (3 Hz, 0-20% peak-to-peak) strain, demonstrating
the driving effect of cyclic loading on transport. Penetration at curved margins was 1.57-
and 2.53-fold greater than at planar surfaces under static and cyclic strain, respectively,
and was enhanced 1.6-fold more by cyclic strain, revealing architecturally dictated spatial
heterogeneity in transport and modulation of motion dynamics.
Discussion: Architectural geometry and dynamics modulate the impact of
mechanical loading on local drug penetration and intramuscular distribution. Future
work will use the biomechanical test system to investigate mechanisms underlying
transport effects of specific loading regimens. It is hoped that this work will initiate a
broader understanding of intramuscular pharmacokinetics and guide local drug delivery
strategies.
Keywords: Mechanical; Strain; Muscle; Delivery; Transport
2.2 Introduction
Muscle tissue presents an exclusive drug transport environment in which dynamic
mechanical motion and loading may be a predominant influence on the pharmacokinetics
of locally delivered agents. These motions and loads, which are shaped by both structure
and function of the muscle, can present significant and variable physical influences on
aqueous drug transport by means of their effect on modulating extracellular space or fluid
distribution [122].
The effects of mechanical loading on transport of local agents have been
investigated in a variety of load-bearing tissues. Studies have examined the effects of
tension-compression on solute and dextran transport in cartilage [78, 123], static tensile
loading on diffusion of water in Achilles tendon [77, 124], and stretch on transmural
transport of albumin, LDL, and Evans Blue in the arterial wall [76, 125]. Similar studies
in skeletal muscle have investigated the impact of contraction on total uptake of glucose
[94, 96]. However, no studies have investigated the interrelated effects of architecture
and mechanical loading on the regional distribution - not just volumetric uptake - of
local agents in skeletal muscle. With the advent of local drug delivery to contractile
tissues, and the present clinically motivated need for effective strategies to locally deliver
therapeutic angiogenic growth factors to ischemic muscles [126], a quantitative
knowledge of the pharmacokinetics in muscle is critically important. Thus, the goal of
this study is to elucidate the combined influences of architecture and dynamic mechanical
loading on the regional distribution of aqueous drug in skeletal muscle.
A tissue mounting technique and biomechanical loading system were designed to
investigate intramuscular distribution of locally delivered drugs in association with
control of muscle biomechanics. The preparation uniquely enables muscles to be secured
in a natural, physiologic configuration and undergo in vitro mechanical testing while
incubated in drug under functionally viable conditions to preserve accurate drug
transport.
2.3 Tissue Handling and Mechanical Loading System
2.3.1 Surgical Isolation Protocol
Experiments were conducted within the animal welfare regulations and guidelines
of Massachusetts. Male Sprague-Dawley rats (450-470 g) were administered 1000 U of
Heparin via intraperitoneal injection 5 min prior to euthanasia with inhaled CO2.
Thoracotomy was performed immediately after euthanasia, and 60 ml of Krebs-
Henseleit-Butanedione Monoxime (KH-BDM) (118.1 mM NaCI, 4.7 mM KC1, 2.5 mM
CaC12, 1.2 mM MgSO 4, 1.2 mM KH2PO 4, 25 mM NaHC0 3, 11.1 mM Glucose,
supplemented with 1 mM Sodium Pyruvate, 1 mM Isoleucine, 1 mM Leucine, 1 mM
Valine, and 5 mM BDM, pH 7.4) oxygenated with 95% 02-5% CO 2 was infused down
the aorta to relax and preserve the lower extremities.
The soleus was surgically exposed in one of the distal hindlimbs. The tendons of
overlying muscles at the tuber calcanei and fibular head were dissociated from the
tendons of the soleus. The in situ length of the soleus was measured using a Mitutoyo
Digimatic caliper with + 0.01 mm precision between the proximal and distal
myotendinous junctions while flexing the knee and ankle at 90*. This in situ length is
referred to as nominal length. Because rats were selected in a narrow weight range, all
soleus muscles were of uniform size and measured 28 mm in nominal length. The soleus
was isolated from surrounding fascial connections and tissues, and resected with its
tendons and segments of the calcaneus and fibula still intact.
During isolation, the soleus was regularly superfused with KH-BDM to prevent
drying. Surgical isolation was repeated for the contralateral soleus while the excised
soleus was held at nominal length in KH without BDM that was oxygenated and chilled
on ice. After excision, soleus samples equilibrated in KH for at least 15 min before
mechanical loading.
2.3.2 Mounting Configuration
A mounting technique and associated mechanical loading system were invented to
investigate accurate intramuscular drug transport under mechanical loading. The excised
whole muscle is secured onto specially-designed mounting blocks by inserting its intact
bone segments into angled slots in the blocks (Figure 2.1). The slots secure the bone
segments by mechanical fit and leverage to hold them at an acute angle to the muscle axis
without using additional fastening mechanisms that physically disrupt the soft tissues and
could result in drug transport artifacts. The innovation of the blocks and mounting
configuration is that they hold a muscle sample in an in situ configuration via its own
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Figure 2.1. Mounting configuration and blocks. (A) Mounting configuration of an isolated
soleus muscle and its natural bone attachments in the mounting blocks. The angled slots
are sized specifically for either the calcaneus or fibula to secure the respective bone
segments without using traditional mounting techniques such as sutures, hooks, clamps,
pins, or other fixtures, which lead to tissue distortion, disruption of anatomic integrity and
natural force transmission, and development of non-physiologic mechanical properties that
could result in drug transport artifacts. (B) Solidworks design and rendering of the
mounting blocks. (C) Cross-sectional view of the mounting blocks showing the internal
course of the angled slots through the blocks (arrows). The two Lexan blocks of equal size
each have two primary through-holes that run at a 100 angle from the top surface of the
block to serve as mounting holes for bone segments.
physiologic attachments, and allow forces to be transmitted from the bones through the
muscle in a physiologic manner to preserve the natural physical dimensions of the
)-.
muscle. The mechanical loading system consists of two major components: mounting
blocks and a dynamic loading system.
2.3.3 Mounting Blocks
The conjugate mounting blocks can be secured in a static mounting assembly as a
standalone device to impose static tensile strain on a pair of mounted muscle samples
(Figure 2.2).
Figure 2.2. Static mounting assembly. (A) In the static mounting assembly, a lead screw
adjusts the separation distance between the conjugate blocks. Set screws lock each block at
a user-defined fixed position along the guide-rails. (B) Static tensile strain can be applied to
a pair of mounted soleus muscles while they incubate in oxygenated drug source. (C) The
simple mounting method allows muscles to incubate in a minimal volume of solution to
conserve drug source and avoid the use of excessive, suprapharmacologic doses in transport
studies.
The assembly enables samples to be stretched while incubated in drug solution. The
blocks can be disengaged from the static assembly and individually attached onto the
dynamic loading system to serve as mounting fixtures that hold samples in a physiologic
configuration for dynamic tensile loading (Appendix A & B).
2.3.4 Dynamic Loading System
The dynamic loading system enables automated, oscillatory, linear strains to be
imposed on mounted samples while they incubate in drug solution (Figure 2.3)
(Appendix A & B). Mechanical loading is driven directly by a LinMot®
PO1-37x240/60x260 linear servo motor that can achieve a peak force, velocity, and
acceleration of 72 N, 0.45 m/s, and 8.5 m/s2, respectively (Appendix C). Motor position
is tracked by an internal sensor with 20 Am resolution and controlled by proportional-
integral-derivative (PID) logic that enables execution of a 0.7 mm peak-to-peak
displacement with ± 60 Am positional error (Appendix D). Total mechanical compliance
of the series combination of motor, rack and pinion assembly, and mounting blocks is
less than 0.0057 ± 0.002 mm/N and linear over a 75 N force range. This enables more
precise force transmission than other systems developed to apply high frequency
vibrations concurrent with larger amplitude elongations, which have 2.5- to 116-fold
greater compliance [127-130]. All static and dynamic strains in our experiments were
applied using the static and dynamic loading assembly, respectively.
Figure 2.3. Dynamic loading system. (A) A PID-controlled linear servo motor actuatesdynamic loading. (B) The dynamic mounting assembly incorporates a rack and pinion
arrangement that enables the symmetric and simultaneous displacement of the ends of
mounted tissue samples to impose strain. (C) A connecting block offsets the mounting blockfrom the dynamic assembly to enable mounted samples to be submerged in solution during
cyclic mechanical loading. (D) The dynamic mounting assembly with mounting blocks
attached. (E) Mounted soleus muscles. (F) In the experimental setup, mounted samples are
stretched either statically or dynamically while incubated in well-mixed and oxygenateddrug solution at room temperature under architecturally physiologic and functionally
viable conditions.
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2.4 Methods
2.4.1 Force-Length Relationships
Using a reconfigured static assembly (Figure 2.4), individual muscles (n = 7) were
pre-strained to 0%, 5%, 10%, 15%, and 20%, and stimulated to produce isometric twitch
contractions using a biphasic stimulus (15 V, 50 ms pulse) applied to opposite tendons
using stainless steel electrodes. Passive and total tensions were measured. Active twitch
force was calculated by subtracting passive from total tension. Between recordings,
samples incubated in oxygenated KH. Assessment of in vitro viability demonstrated
samples maintained a minimum isometric twitch force of 0.19 N for at least 2 h and
contractile activity at 3 Hz for at least 1 h, thereby validating our choice of the soleus as
our experimental muscle model for its fatigue resistance characteristics.
Figure 2.4. The static assembly reconfigured for force measurement. A thin-beam load cell(Omega Engineering, Inc., LCL-227G, 0-227 g) secured to one of the guide-rails wasattached to the fibula mounting block, which was allowed to slide freely on the rails. Thecalcaneus block was fixed to the guide-rails. Electric stimulus was generated and forcemeasurements were recorded using a National Instruments DAQPAD-6062E dataacquisition board controlled by LabView 7.0.
2.4.2 Drug Transport
Soleus muscles (n = 5) were continuously, cyclically stretched between 0% and
20% strains at 3 Hz. Controls (n = 5) were held fixed at 0%. Samples were loaded for 80
min while incubated in 16 ml of 1 mM 20 kDa neutrally charged fluorescein
isothiocyanate (FITC)-dextran (Sigma-Aldrich) in KH. Drug source was kept well-
mixed by magnetic stir bar and oxygenated at room temperature, which is optimal for
maintaining physiologic stability and functional performance of muscles in vitro [131-
133] without inhibition of drug binding or transport properties. Fluorescence intensity of
the bulk source, sampled before and after an 80-min incubation using fluorometry,
remained constant. Therefore, drug source concentration remained constant throughout
incubations.
Preliminary histologic assessment of tissue porosity (ratio of extracellular space
area to total tissue area) demonstrated that permanent tissue degradation and injury was
only a function of time and independent of mechanical loading conditions. Thus baseline
architecture was consistent among all samples incubated for the same duration, and
differences in extracellular transport [134, 135] of soluble dextran can be attributed to the
dynamic influences of mechanical loading on architecture.
Preliminary transport studies validated the bulk uptake [136] and non-binding
properties [135] of FITC-dextran in soleus tissue. Fractional volume of distribution,
which defines an effective transport space reflecting the effects of both steric interaction
and charged partitioning on soluble (not bound) drug distribution, was determined by the
slope of the empiric relationship between equilibrium drug concentration in tissue versus
the corresponding bulk source concentration. The fractional volume of distribution (E),
defined as the ratio of the equilibrium tissue concentration of soluble drug (cs) per unit
total tissue volume (VT) to bulk phase concentration (cbulk): e = C, /C,,lk, reflects the
partition coefficient, Ktissue/bulk = Ctot Cbulk (where ctot is the tissue concentration of soluble
and bound drug in the accessible tissue volume), scaled by the ratio of the tissue volume
accessible for drug distribution (Va) to Vr (which represents sterical effects):
S = Ktissue'bulk Vfl/VT [137]. Equilibrium incubation studies demonstrated a fractional
volume relationship that was linear over 0.1 tM-1 mM bulk concentrations with a slope
of 84%, indicating bulk uptake of dextran. A fractional volume approximating 100%
suggests minimal reduction of source concentration by charged partitioning or steric
hindrance of dextran to freely diffuse throughout the muscle. Using an equilibrium
distribution analysis [137] of the fractional volume relationship, bound fraction of
dextran was calculated by subtracting cs from the empiric tissue concentration. This
demonstrated a spread about zero across the range of source concentrations, indicating
that binding site density for dextran in the soleus was lower than the scatter in the data,
and therefore insignificant. These transport characteristics and the in vitro stability of
FITC-dextran [138, 139] enable investigation of transport that is unaffected by drug-
tissue interactions and accurate demonstration of the isolated transport effects of tissue
structure and mechanical loading.
2.4.3 Tissue Processing and Drug Measurement
After loading, samples were rinsed twice in 15 ml of fresh KH and snap-frozen at
nominal length in -145TC Isopentane. 8 jpm axial cross-sections from the midpoint of the
samples were cut using a Leica CM1850 cryotome. FITC-dextran was imaged using
epifluorescence microscopy (Leica DMRA2, 50x magnification, Hamamatsu ORCA 286,
Metamorph 6.3, ex: 450-490 nm bandpass/ em: 515 nm longpass). An exposure rate was
chosen that eliminated tissue autofluorescence and avoided intensity saturation of the
system by the drug source. Images were analyzed using Matlab. A preliminary
calibration confirmed the linear relationship between image fluorescence intensities and
tissue drug concentrations for 0.01 mM-1 mM bulk source concentrations of 20 kDa
FITC-dextran. This is in accordance with Beer's Law for very low source
concentrations, I=cCQ, in which I is fluorescence intensity, e is the molar absorption
coefficient, C the molar concentration, and Q the quantum yield [140]. Drug distribution
and unidirectional penetration were quantified in the muscle cross-section. Intramuscular
penetration depth was defined as the perpendicular distance from the muscle surface at
which fluorescence intensity decreased to 5% of the surface intensity (Appendix H).
2.4.4 Statistical Analysis
Results are presented as mean ± SD. Student's t-Test and Two-Factor Analysis of
Variance (ANOVA) with Replication were applied to assess significance in force-length
relationship and drug penetration data, respectively.
2.5 Results
2.5.1 Force-Length Relationships
The classic exponential curve characterizing the passive extensibility of skeletal
muscle was observed (Figure 2.5). Active twitch tension demonstrated a classic
parabolic increase, by 1.5-fold, to a maximum at 10% strain and fell off thereafter.
Nominal length corresponds to initial length and 10% strain the optimal 
length of the
soleus. Peak twitch tension (0.35 ± 0.06 N) agrees with values measured by previous 
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Figure 2.5. Force-length relationships of the soleus. (A) Total, active, and passive tensions
of a single soleus muscle (n = 7). 0% strain is the nominal length, 5% strain is elongation 
to
105% of the nominal length, etc. Active twitch tension increases from 
0.24 ± 0.06 N at 0%
strain, to a maximum of 0.35 ± 0.06 N at 10%, and decreases to 0.19 
± 0.06 N at 20%.
Twitch tensions measured at each strain in both the increasing and 
decreasing halves of the
parabolic force-length relationship are statistically significantly different 
(T-test, p<0.05).
Because the nominal in situ length, or 0% strain, is the length at which 
the first passive
resistance to stretch occurs, it is equivalent to the initial length of the 
muscle. Maximal
active force is developed at 10% strain, defining it as the optimal or resting 
length, Lo, of the
muscle. Optimal length is the physiologically defined muscle length 
at which maximal
active force is produced and reflects the optimal overlap of myosin and 
actin contractile
myofilaments in the muscle. (B) Isometric twitch tension of 7 different single soleus
samples, showing reproducibility of force measurements and consistency 
of muscle
preservation in our drug delivery preparation. (C) Strain-dependent overlap of myosin
(orange) and actin (blue) contractile myofilaments. Optimal overlap of myosin and actin 
at
Lo, at which maximal muscle tension is produced, is depicted within the 
physiologic range of
muscle lengths.
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vitro (0.35 ± 0.02 N) and in situ (0.30 + 0.10 N) studies using rats of similar size [141,
142]. Passive force (0.12 ± 0.06 N) at optimal length (10%) also agrees with previous
findings (0.15 N) [142].
2.5.2 Drug Transport Under Mechanical Loading
Drug distribution and penetration was quantified at the planar and curved surfaces
of the muscle cross-section (Figure 2.6). Two-Factor ANOVA revealed that while
penetration (Figure 2.7) was equivalent at opposing surfaces with similar geometry
(p>0.05), it was significantly impacted by differences in regional tissue geometry and
architecture (penetration was 1.57- to 2.53-fold greater at curved than planar surfaces,
p<0.05, under static and cyclic strain, respectively), as well as enhanced by cyclic strain
(p<0.05). Dynamic loading interacted with regional architecture to enhance penetration
at curved margins by 1.6-fold more than at planar surfaces (p<0.05).
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Figure 2.6. Quantification of fluorescent drug transport in statically and dynamically
strained soleus. Fluorescence intensity values in images of the elliptical soleus cross-section
were quantified using Matlab. Drug distribution was visualized and penetration depth was
measured at the planar (Top, Bottom) and curved (Left, Right) surfaces. Planar surfaces are
the dorsal and ventral surfaces, and curved surfaces are the medial and lateral margins of
the muscle. Surfaces are referred to as top, bottom, left, and right based on their location in
the images. Drug distribution is influenced by the regional geometry of the muscle surface.
The impact of dynamic strain on drug distribution is modulated by local tissue geometry
and architecture.
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Figure 2.7. Impact of regional architecture and mechanical loading on drug transport.
Penetration was equivalent at opposing planar surfaces for each loading condition,
averaging 0.52 ± 0.09 mm under static strain and 0.81 ± 0.09 mm under dynamic strain.Similarly, penetration was equivalent at opposing curved surfaces, averaging 0.82 - 0.19
mm under static strain and 2.1 + 0.24 mm under dynamic strain. Penetration was
significantly greater at curved than planar surfaces by 1.57- and 2.53-fold under static anddynamic strain, respectively. Penetration at both groups of surfaces was significantly
enhanced by dynamic strain. Dynamic strain enhanced penetration at curved surfaces
more than at planar surfaces by a factor of 1.6 - penetration increased by 1.56- and 2.51-
fold at planar and curved surfaces, respectively.
2.6 Discussion
A quantitative knowledge of the impact of architecture and structural dynamics on
local drug transport is critical to a complete understanding of intramuscular
pharmacokinetics and pharmacodynamics. To date much work on intramuscular
transport has focused on measuring volumetric changes in interstitial space or total tissue
volume induced by strain or contraction using tritiated water [143]; molecular markers
like inulin [143, 144]; albumin [145, 146]; or solutes like EDTA [145], sodium, and
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potassium [122, 147]. Studies have measured contraction-induced diffusion of water
[107] or myoglobin [82], but only intracellularly in single myofibers. While studies have
investigated how strain or contraction in whole muscles affects total uptake of glucose
[83, 84, 90, 94-96], lactate [148], phosphate [92], calcium [149, 150], and sodium [91],
they focused only on the pharmacokinetic influence of activity-dependent metabolism on
substrate uptake. Using and validating a robust mechanical loading preparation designed
for local drug delivery in association with accurate biomechanical testing in vitro, this
investigation visually quantified structural and mechanical loading effects on regional
intramuscular drug distribution. The mounting preparation uniquely eliminated
disruptive tissue handling artifacts and preserved physiologic architecture and force
transmission to enable accurate drug transport while muscle samples underwent
mechanical loading in vitro.
2.6.1 Transport Environment
As tendons exhibit minimal length extensibility within a physiologic strain range
[151], the length range from 0% to 20% strain reflects the physiologic range of muscle
function and viscoelastic extensibility. Drug transport within this range reflects the
pharmacokinetic environment dictated by physiologic architectural configurations.
2.6.2 Intramuscular Pharmacokinetics
2.6.2.1 Regional Drug Distribution
Equivalent penetration at both sets of opposing surfaces suggests homogeneity of
morphology for transport with respect to both the dorsal-ventral and medial-lateral
orientation. Assuming an isotropic transport environment based on histology, greater
penetration at curved margins than at planar surfaces may result from both geometry of
the curved surface and the edge effect on drug distribution occurring at the margins of a
nearly flat muscle cross-section. Curvature of the margin results in a semi-
circumferential exposure to drug, which increases the surface area and directionality for
drug entry into a fixed tissue space. Furthermore, drug transporting from the margins
readily encounters drug penetrating at planar surfaces due to the elliptical geometry of the
cross-section. Thus, penetration at planar surfaces can contribute significantly to drug
distribution at the margins, especially when penetration is enhanced at all surfaces by
dynamic loading.
2.6.2.2 Impact of Dynamic Loading
In the absence of an external convective force driving bulk fluid flow into the
muscle, and particularly as drug penetration proceeds against an increasing intramuscular
pressure gradient [152] and decreased muscle volume [153] during stretch, enhancement
of drug penetration by oscillatory loading is unlikely due to bulk convection. Cyclic
strain may modify intramuscular accessible space, interstitial permeability, and transport
kinetics. Dynamic loading between 0% and 20% strain may cyclically expose drug to
strain-dependent architectural configurations with larger accessible volumes than that at
nominal length. This may result from myofiber deformation, displacement, and thinning
due to conservation of volume during elongation that increase tissue porosity. Cyclic
increase in accessible space may create spatially and temporally heterogeneous
concentration gradients that increase diffusional driving force. Interstitial permeability
may increase due to alignment of collagen fibers in their dense interstitial networks that
form the endomysium and perimysium during stretch [103, 104], which reduces their
screening effect on soluble drug [154]. Such changes may result in a greater time-
averaged porosity and permeability that increases penetration.
The dynamics of oscillatory loading may impact transport kinetics by creating
dispersive influences on soluble drug that increase transport beyond molecular diffusion
alone [155]. Cyclic displacement and deformation of myofibers compress and expand
extracellular space and impose normal and shear forces on interstitial fluid, resulting in
pulsatile agitation of soluble drug in the absence of bulk convective fluid flow. Such
pulsatile agitation can disperse or spread drug in a rate-dependent manner over a greater
extracellular volume and thereby drive greater penetration.
2.6.2.3 Interaction Between Loading and Architecture
Greater enhancement of penetration at curved margins than at planar surfaces by
dynamic loading may be attributed to spatially heterogeneous strain dynamics and
heterogeneous extracellular space changes during stretch that are likely shaped by muscle
structure and local geometry.
The uni-pinnated, parallel-fibered soleus has an elliptical cross-section that
flattens and widens during muscle stretch. Studies of uni-pinnated muscle have revealed
that they experience geometry changes during isometric contractions at various initial
muscle lengths that consist of spatially heterogeneous changes in aponeurosis length,
angle ofpinnation ofmyofibers, and fiber length [156]. One study observed transverse
(perpendicular to muscle surface) strains in superficial myofibers during isometric
contraction and aponeurosis surface area decreases with increasing initial muscle length
[157]. It can be extrapolated from these studies, which assessed strains and geometry
changes only from the muscle surface, that flattening and widening of the soleus resulting
from conservation of muscle volume during elongation translate into heterogeneous
internal fiber rearrangements and intramuscular forces that can alter local drug
distribution space and dynamic dispersion effects. While superficial myofibers at planar
surfaces tighten with muscle flattening, those at the curved margins of the soleus may
experience increased outward transverse strains with widening. Furthermore, because
superficial fibers at the margins occur more peripheral to the center of the muscle, they
have more obtuse angles of insertion relative to the muscle axis compared to fibers at
planar surfaces, which are located towards the midline. These differences in local muscle
geometry, fiber arrangement, and angle of insertion likely dictate heterogeneous local
strain dynamics and changes in extracellular space during stretch or contraction. These
architectural and dynamic heterogeneities may result in greater porosity or dispersive
effects at curved margins that significantly impact the heterogeneous drug distribution
observed under dynamic stretch.
2.6.3 Conclusions
Dynamic loading increases drug penetration and impacts drug distribution based
on the dictates of muscle structure and geometry. These findings yield broad
implications for pharmacokinetics investigations and clinical drug delivery strategies to
mechanically active target tissues, which should now consider the intimate interplay
between tissue architecture and functional dynamics that underlies tissue
pharmacokinetics. Modulation of mechanical activity in muscle tissues may possibly
serve as a physiological means for controlled drug delivery. A robust biomechanical
testing preparation designed for drug transport studies was validated. Further
pharmacokinetics studies using this system intend to investigate the mechanisms
underlying transport effects of different mechanical loading regimens.
3. PHARMACOKINETICS IN SKELETAL MUSCLE:
UNIAXIAL TISSUE ARCHITECTURE AND MECHANICAL LOADING
3.1 Abstract
Introduction: Dynamic tissue architecture and motion in mechanically active
target tissues can influence the pharmacokinetics of locally delivered agents. We
investigated drug transport in skeletal muscle under controlled mechanical loads.
Methods and Results: Static (0%-20%) and cyclic (+ 2.5% amplitude, 0%-20%
mean strains, 1 Hz-3 Hz) strains, and electrically paced isometric contractions (0.1 Hz-3
Hz, 0% strain) were applied to rat soleus while incubated in 1 mM 20 kDa FITC-dextran.
Dextran penetration, tissue porosity, and active force-length relationship over 0%-20%
strain correlated (r = 0.9-1.0), and all increased 1.5-fold from baseline at 0% to a
maximum at 10% (Lo), demonstrating biologic significance of Lo, and impact of fiber
size and distribution on function and pharmacokinetics. Overall penetration decreased
but relative enhancement of penetration at Lo increased with drug size (4 kDa, 20 kDa,
150 kDa). Penetration increased linearly dependently (0.084 mm/Hz) with cyclic stretch,
demonstrating dispersion. Penetration increased with contraction rate by 1.5-fold from
baseline to a maximum at 0.5 Hz, revealing architectural modulation of dispersion.
Impact of architecture and dispersion on intramuscular transport was computationally
modeled.
Conclusions: Mechanical architecture and function underlie intramuscular
pharmacokinetics and act in concert to effect biological resonance between optimal
performance and drug uptake. Therapeutic management of characteristic function in all
tissue targets may enable a physiologic mechanism for controlled drug transport and
efficacy.
Keywords: Muscle; Strain; Contraction; Porosity; Diffusion; Pharmacokinetics
3.2 Introduction
Mechanically active tissues such as skeletal muscle present a unique
pharmacokinetic environment in which transport of locally delivered drug can be
influenced by not only physicochemical interactions, but also dynamic architectural
configurations and mechanical function. The continuous network of force-transmitting
and connective perimysial and endomysial collagen fibers [99, 100, 102] between
myofibers can hinder interstitial diffusion in a strain-dependent manner. Dynamic
physical effects such as intramuscular pressure, fluid redistribution, and structural
deformations [106, 107] during mechanical function can alter transport kinetics.
Whereas local delivery strategies minimize systemic losses and enable efficient
administration of therapeutic agents to target tissues [51, 158-160], ultimate drug
distribution and pharmacologic effect are determined by target tissue pharmacokinetics.
Controlled release technologies must consider the transport effects of functional
architecture and mechanical activity to optimize defined release kinetics [48, 161-163]
for therapeutic effect. A quantitative understanding is critical for strategies like
therapeutic angiogenesis to ischemic muscle, in which lesions are spatially focal [164],
therapeutic windows are narrow [165-167], therapeutic response is complex [168-170],
biologic half-lives of delivered proteins are short [50, 171-173], and systemic side-effects
of therapies are detrimental [39, 44, 45, 54, 174].
Whereas studies have investigated how strain or contraction in whole skeletal
muscles affects total uptake of glucose [83, 84, 90, 94-96], lactate [148], phosphate [92],
calcium [149, 150], and sodium [91], they have predominantly elucidated the
pharmacokinetic influence of activity-dependent metabolism on substrate uptake. We
apply a rigorous, quantitative framework to investigate the characteristic and synergistic
impact of architecture and mechanical forces on intramuscular transport of locally
delivered soluble macromolecules. Having previously demonstrated that cyclic
mechanical loading influences drug distribution based on the dictates of muscle
geometry, we systematically investigate the transport effects of static and cyclic strain
and isometric contraction, and their unique correlation with structure and function. We
validate the mechanisms at hand through computational models.
3.3 Methods
3.3.1 Surgical Protocol
Experiments were conducted within the animal welfare regulations and guidelines
of Massachusetts. Male Sprague-Dawley rats (450-470 g) were administered 1000 U of
Heparin via intraperitoneal injection 5 min before euthanasia with inhaled CO2.
Thoracotomy was performed immediately after euthanasia, and 60 ml of Krebs-
Henseleit-Butanedione Monoxime (KH-BDM) (118.1 mM NaCl, 4.7 mM KC1, 2.5 mM
CaC12, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO 3, 11.1 mM Glucose,
supplemented with 1 mM Sodium Pyruvate, 1 mM Isoleucine, 1 mM Leucine, 1 mM
Valine, and 5 mM BDM at pH 7.4) oxygenated with 95% 02-5% CO 2 was infused down
the aorta to relax and preserve tissues of the lower extremities during surgery.
The soleus was surgically exposed in one of the distal hindlimbs. The tendons of
overlying muscles at the tuber calcanei and fibular head were dissociated from the
tendons of the soleus. The in situ length of the soleus was measured using a Mitutoyo
Digimatic caliper with + 0.01 mm precision between the proximal and distal
myotendinous junctions while flexing the knee and ankle at 90". This in situ length is
referred to as the nominal length in our study, and was found to correspond to the initial
length, the length at which the first passive resistance to stretch occurs. Because rats
were selected in a narrow weight range, all soleus muscles were of uniform size and
measured 28 mm in nominal length. The soleus was isolated from surrounding fascial
connections and tissues and resected with its tendons and segments of the calcaneus and
fibula still intact.
During isolation, the soleus was regularly superfused with KH-BDM to prevent
drying. Surgical isolation was repeated for the contralateral soleus while the first excised
soleus was held at nominal length in KH without BDM that was oxygenated and chilled
on ice. After excision, soleus samples equilibrated in KH for at least 15 min before
mechanical loading. For electrically paced groups, regular KH instead of KH-BDM was
used in all parts of the protocol above.
3.3.2 Mechanical Loading and Drug Delivery
All static and cyclic strains were applied on pairs of whole soleus muscles using a
mounting technique and mechanical loading system developed by our group, which
enable static (fixed strain) or dynamic (cyclic) linear loading to be performed without
artifactual injury or distortion of the soft tissues while samples are incubated in a drug
bath. For all loading conditions described below, soleus muscles were stretched
according to their respective protocol for 1 h while incubated in 16 ml of 1 mM 20 kDa
neutrally charged FITC-dextran (Sigma-Aldrich) in KH. Drug source was oxygenated
with 95% 02-5% CO2, maintained at room temperature, and kept well-mixed by magnetic
stir bar.
3.3.2.1 Static Strain
Soleus samples (n = 6) were held stretched to 0%, 5%, 10%, 15%, or 20% strain.
In all loading conditions, 0% strain corresponds to nominal length, 5% strain corresponds
to 105% of the nominal length, etc., (Figure 3.1A). 10% strain was found previously to
correspond to the optimal length, Lo, the length at which maximal active force is
generated. Samples (n = 6) were similarly stretched to 0%, 10%, or 20% strain and
incubated in 1 mM 4 kDa or 1 mM 150 kDa neutrally charged FITC-dextran.
3.3.2.2 Cyclic Stretching
Soleus samples (n = 6) were cyclically loaded to sinusoidal strains with a fixed
amplitude of 2.5% of the nominal length oscillating about mean strains of 0%, 5%, 10%,
or 20%, at 1 Hz, 2 Hz, or 3 Hz frequencies (Figure 3.1B). Samples (n = 6) were also
loaded at 1 Hz for 1 h, 2 Hz for 30 min, and 3 Hz for 20 min at both 0% and 5% strain.
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Figure 3.1. Tensile loading conditions. (A) Static tensile strain. (B) Cyclic loading.
3.3.2.3 Contractions
Soleus samples (n = 6) were continuously paced by electric field stimulation to
produce isometric twitch contractions at nominal length at a rate of 0.1, 0.5, 1, 2, or 3 Hz.
Biphasic electric stimulus (15 V, 50 ms pulse) was applied by 2 stainless steel foil plates
situated in the drug bath at either end of the static loading assembly, spanning a
separation distance of 10 cm. Stimulus was generated using a National Instruments
DAQPAD-6062E data acquisition board controlled by the Arbitrary Waveform Generator
virtual instrument in LabView 7.0 (Figure 3.2). A preliminary experiment investigated
the transport effects of 1 Hz twitch contractions at nominal length after 2 h. Incubated
samples produced a minimum isometric twitch force of 0.19 N for at least 2 h and
maintained contractile activity at 3 Hz for at least 1 h, thereby validating our choice of
the soleus as our experimental muscle model for its fatigue resistance characteristics.
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Figure 3.2. Electrically paced isometric contractions. (A) Soleus samples were rhythmically
paced to elicit isometric twitch contractions by electric field stimulation. (B) Electric
stimulus profile, showing pacing at 1 Hz and 3Hz, generated in LabView.
3.3.3 Tissue Processing and Measurement of Drug Transport
After loading, samples were rinsed twice in 15 ml of fresh KH and snap-frozen at
nominal length in -145°C Isopentane. 8 gm axial cross-sections from the midpoint of the
samples were cut using a Leica CM1850 cryotome. FITC-dextran was imaged using
epifluorescence microscopy (Leica DMRA2, 50x magnification, Hamamatsu ORCA 286,
Metamorph 6.3, ex: 450-490 nm bandpass/ em: 515 nm longpass). An exposure rate was
chosen that eliminated tissue autofluorescence and avoided intensity saturation of the
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system by the drug source. Images were analyzed using Matlab. A preliminary
calibration confirmed the linear relationship between image fluorescence intensities and
tissue drug concentrations for 0.01-1 mM bulk source concentrations of 20 kDa FITC-
dextran. This is in accordance with Beer's Law for very low source concentrations:
I=eCQ, in which I is fluorescence intensity, e is the molar absorption coefficient, C the
molar concentration, and Q the quantum yield [140]. Unidirectional drug penetration at
the planar surface of the muscle cross-section was quantified and analyzed.
Intramuscular penetration depth was defined as the perpendicular distance from the
surface at which fluorescence intensity decreased to 5% of the surface intensity.
Effective diffusivity, D, associated with measured penetration depth was calculated based
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on the equation for diffusion in a semi-infinite solid, D = , where x is
4. t. (erf- (0.95) 2)
penetration depth, and t is the 3600 s duration of incubation. Effective diffusivity is used
to describe the observed transport, which encompasses the impact of steric forces,
potential specific and non-specific binding interactions within the tissue interstitium, and
cellular internalization, in addition to the diffusive random thermal motion of solutes
down concentration gradients.
3.3.4 Histology and Tissue Architecture
Soleus muscles (n = 6) were excised and immediately snap-frozen while held
fixed at 0%, 5%, 10%, 15%, or 20% strain. 8 gm thickness axial cross-sections from the
midpoint of the samples were cut and stained with Hematoxylin and Eosin (HE). Light
microscopy images (100x magnification) were processed using CellProfiler [175], an
image analysis program written in Matlab. Myofiber arrangement and distribution were
qualitatively assessed. Tissue porosity ((p, the ratio of interstitial space area between
myofibers to total area), average myofiber cross-sectional area, and myofiber density
(total number of myofibers per image) were quantified at each strain. Tissue degradation
and injury were found to be only a function of time, thus baseline architecture was
consistent among all samples incubated for the same duration, and differences in drug
transport can be attributed to the distinct influences of mechanical loading.
3.3.5 Statistical Analysis
Results are presented as mean ± SD. Student's t-Test, Single Factor Analysis of
Variance (ANOVA), and Two-Factor ANOVA with Replication were applied to derive
significance in empirical transport results. Propagation of uncertainty in normalized data
was calculated using the formula, A -( Ax 2 ()2 , where A,, A,, and A z is the
z x y
standard deviation of the numerator (x), denominator (y), and normalized value (z = x/y),
respectively.
3.3.6 Mathematical Model
3.3.6.1 Static Case
Intramuscular diffusion of soluble drug in the tortuous interstitial space between
myofibers can be characterized as diffusion in a porous medium composed of an
impermeable solid phase and a permeable fluid phase [176, 177]. A mathematical model
used to evaluate effective diffusion in tumor cells [178] and brain tissue [179-181] was
modified to derive the relationship between effective diffusivity and strain-dependent
tissue porosity.
Diffusion of inert, soluble macromolecules like dextran in the interstitium is
dictated by tissue porosity, (p, and interstitial fluid characteristics [178, 182].
Intramuscular effective diffusivity, Deff, of drug was defined as:
Def =(D, .D2).Dw  (1)
where Dw is the free diffusivity of drug in water, and reducing factors D, .D2<= 1. DI
accounts for p, fiber geometry, and arrangement and is independent of drug molecular
weight. D2 accounts for interstitial fluid characteristics and is independent of ( when
drug size is considerably smaller than the interspacing between myofibers. Because the
3.2 nm hydrodynamic radius of 20 kDa dextran [183] used in our transport experiments is
two orders of magnitude less than the 0.43 gtm minimum interstitial spacing measured
histologically in the soleus, and because interstitial fluid is assumed to be water in vitro,
D2 = 1. Thus, the dependence of Deff on tissue porosity and fiber arrangement as they
change with static muscle strain was investigated by modeling D1.
Because the uniaxial soleus was exposed to constant drug source equally along its
length during loading, drug transport in the radial, or cross-fiber, direction was
investigated. D1 was determined using a homogenization procedure on the diffusion
equation within the tissue (Appendix E). Homogenization averages diffusion on the
micro length scale of cellular structures to compute effective diffusion on the macro
length scale of the entire tissue. This technique characterizes macroscopic behaviors in a
composite material by averaging microscopic details in a representative periodic control
volume [ 184]. The macroscopic domain describing the axial cross-section of the soleus
was a porous medium represented by a two-dimensional, regularly repeating pattern of
staggered diamond-shaped elements that define myofibers (Figure 3.3B) [182, 184]. The
direction of macroscopic drug diffusion, defined by a vector e, runs in the negative y-
direction and reproduces radial drug penetration across fibers. Diffusion in the direction
of e was determined by solving the Laplacian equation in the reduced domain, f2, formed
by a single lattice arrangement of staggered diamonds (Figure 3.3B, inset):
S2 X = 0 (2)
where the function X represents the small periodic component of the macroscopic drug
concentration field under boundary conditions determined by e. The boundaries of Q
consisted of two parts, F, and F2 (Figure 3.3C). F1 corresponds to the interstitial space
between lattice domains where symmetric and periodic boundary conditions are imposed.
F2 corresponds to the interface between the fiber and interstitial space where the
following non-homogeneous Neumann condition is prescribed:
n. V = n e (3)
where n is the outward unit normal vector on the fiber surface. D1 in the direction of e
was computed by:
D
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where A is the area of the single lattice arrangement.
Equation 2 was solved using COMSOL Multiphysics®, a finite element
numerical solver. Porosity changes were modeled by changing diamond size while
maintaining their lattice positions fixed and the total area of the lattice constant. Values
used for <p at each static strain were taken from empirical measurements of porosity in
histologic images.
A regular lattice domain was used to model the homogeneous myofiber and
interstitial architecture produced by 0% and 20% strains (Figure 3.3A). However, 5%,
10%, and 15% strains produced an inhomogeneous fiber arrangement with wide
interstitial spaces separating groups of myofibers (Figure 3.3D). Thus, a widened
interstitial channel aligned with the direction of transport was added to the regular lattice
domain to model this architecture (Figure 3.3E). The regular lattice portion in this
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Figure 3.3. Static model. (A) HE image of a soleus axial cross-section showing the isotropic
and homogeneous porous architecture and uniform interstitial spacing under 0% and 20%
muscle strains. A single myofiber is outlined. (B) Two dimensional depiction on
dimensionless Cartesian axes of the homogeneous muscle axial cross-section. Myofibers are
idealized by a regularly repeating lattice of staggered diamonds (white) interspaced with
interstitial channels (pink) of consistent width. The direction of macroscopic drug diffusion,
e (red arrow), is in the negative y-direction. Symmetry of the mathematical problem enables
the computation to be carried out on a reduced domain, fl, formed by a single lattice
arrangement of diamonds (inset). (C) Schematic of a single diamond element depicting
boundary conditions. A symmetric or periodic condition is imposed on components of r1
that are respectively parallel or perpendicular to e. The non-homogeneous Neumann
condition is imposed at F2. (D) HE image of the inhomogeneous fiber arrangement with
wide interstitial channels (green) separating fascicles (black) of myofibers that occur under
5%, 10%, and 15% strains. (E) Depiction of the muscle axial cross-section composed of an
inhomogeneous arrangement of myofiber elements. A wide interstitial channel running in
the direction of transport was added to the regular lattice domain to model wide interstitial
spaces. Location of the channel with respect to the diamonds did not significantly influence
transport.
domain was modeled with a porosity that equaled the local porosity measured in 
a single
fascicle. The width of the channel was calculated so that average porosity 
of the entire
domain equaled the average porosity measured in the entire histologic cross-sectional
image.
3.3.6.2 Dynamic Case
Many studies have experimentally investigated [185] and theoretically modeled
[155, 186, 187] the dispersive effects of pulsatile mechanical loading on the movement of
soluble agents (Figure 3.4).
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Figure 3.4. Effect of mass dispersion. (A) A reservoir holding soluble drug that is isolated
to the left half at time t = 0. (B) After a time T, soluble drug diffuses towards the right half
of the reservoir. (C) Pistons at each end of the reservoir oscillating in phase produce no net
convection but cause molecular agitation or perturbation of drug so that it spreads farther
across the reservoir within the same time T. Mass dispersion increases transport beyond
molecular diffusion alone.
Our experiments demonstrate a linear relationship between increase in drug
penetration and frequency of cyclic stretch, suggesting cyclic deformation of muscle
architecture potentially results in dispersive agitation of soluble drug. The uniaxial
soleus muscle was modeled as a cylinder with a circular cross-section. A two-
dimensional mathematical model was used to investigate the dispersive effects of radial
deformations on radial drug penetration.
Drug transport was described by the diffusion equation on a continuous domain
characterizing the entire axial cross-section of the muscle:
Dstatic, RnV2C = 0 in KD(t) (5)
at
where c is the drug concentration field, Dstatic, Rn is the empirical effective diffusivity
associated with static stretch to the mean strain with mean radius Rn, and 92D(t) is the
moving, continuous axial cross-sectional domain of the muscle. Equation 5 was solved
on the moving domain, OD(t), which is defined as:
D (t) = nr(t) 2 = t(Rn)2 (1 + asin(ot))2  (6)
where r(t) is the radius of the cross-section, a is the radial strain amplitude centered about
the mean radius Rn (with n = 0, 5, 10, 20), and o is the radial frequency of pulsation or
deformation (where co = 2n, 4n, 6n rad/sec). Theoretical values of the radius and radial
deformations resulting from axial stretch were calculated from tensile strains applied
experimentally based on conservation of volume and tissue incompressibility (Poisson
ratio=0.5) [188] (Appendix F).
The Arbitrary Lagrangian Eulerian (ALE) formulation [189], based on the
simultaneous solutions of motion and material behavior, was used to express Equation 5:
acD static,RnV 2 c -. Vc = 0 in QD(t) (7)
where w is the velocity of 2D(t) (Appendix G). Equation 7 was solved using COMSOL
to obtain the drug concentration profile in the muscle cross-section after 1 h of transport.
Drug source concentration at the boundary of •D(t) was a constant value fixed at 1 and
penetration depth was taken as the distance from the boundary at which concentration
decreased to 0.05.
3.4 Results
3.4.1 Static Strain, Cyclic Stretching, and Contractions
Tensile strain increased intramuscular drug penetration and effective diffusivity
(Figure 3.5A). Penetration increased by 1.45-fold to a maximum at 10% strain and fell
off thereafter. This drug penetration profile correlates with the isometric twitch force-
length relationship of the muscle (r = 0.87, Figure 3.5B), suggesting that architectural
configuration, which is the physiologic correlate of mechanical function, simultaneously
mediates a transport environment with characteristics reflecting contractile efficiency.
Maximal drug penetration thus correlates with optimal length Lo, the physiologically
defined length at which maximal active force is produced and reflects the optimal overlap
of myosin and actin contractile myofilaments in the muscle. Dextran penetration
decreased with increasing molecular weight and polymer size at baseline and with strain
(Figure 3.5, C and D). Whereas 10% strain enhanced penetration past that at 0% by an
increasingly greater distance for smaller molecules that are less sterically hindered
(Figure 3.5, E and F), this relative enhancement effect was most evident for larger
molecular sizes that encounter greater steric hindrance (Figure 3.5F).
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Figure 3.5 (A-D). Drug transport under static strain. (A) Penetration depth and effective
diffusivity of 20 kDa FITC-dextran in soleus muscle over 0%-20% elongating strains from
nominal length. Penetration increases with strain from 0.44 ± 0.09 mm (D = 7.1x10 "6 ±
2.0x10 -6 mm2/s) at 0% strain to a maximum of 0.64 + 0.11 mm (D = 1.5x10 s5 ± 3.6x10-6
mm 2/s) at 10%, and decreases to 0.47 ± 0.13 mm (D = 8.0x10 6 ± 3.1X10 6 mm 2/s) by 20%.
Depths at each strain in the increasing and decreasing halves of the profile, except 5% and
10%, are statistically significantly different (T-test, p<0.05). (B) Drug penetration profile
correlates positively with isometric twitch force over 0%-20% strains (r = 0.87). Maximal
drug penetration occurs at 10% strain, or optimal length Lo, as defined by peak twitch
force. (C) Penetration depth decreases with increasing molecular weight at 0%, 10%, and
20% strains (Two-Factor ANOVA, p<0.05 between penetration depths, p<0.05 between
molecular weights). (D) Penetration of 4 kDa, 20 kDa, and 150 kDa dextrans normalized to
4 kDa penetration. 4 kDa dextrans penetrate approximately 2-fold and 10-fold farther than
20 kDa and 150 kDa dextrans, respectively, at each strain.
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Figure 3.5 (E-F). Drug transport under static strain. (E) The rate of increase (slope) of
diffusivity with decreasing molecular size (increasing 1/Rh) at 10% strain is 1.4-fold greater
than the rate at 0% and 20% strain. Hydrodynamic radius (Rh) of dextrans was computed
from molecular weight (MW) using the relationship Rh = 0.305*(MW)o. 47 [190]. Effective
diffusivities of dextrans vary inversely with hydrodynamic radius, as expected for the
mobility of inert macromolecules in a simple fluid based on the Stokes-Einstein equation
[191]. (F) The difference between penetration depths at 10% and 0% strain decreases with
increasing molecular weight, demonstrating a difference of 0.22 mm for 4 kDa, 0.20 mm for
20 kDa, and 0.12 mm for 150 kDa dextran. The relative enhancement of penetration at
10%, or the ratio of penetration at 10% to 0%, increases with increasing molecular weight
from 1.25-fold for 4 kDa, to 1.45-fold for 20 kDa, to 3.18-fold for 150 kDa. The difference in
penetration and relative enhancement change oppositely (r = -1) with molecular weight.
The effects of dynamic loading were isolated from that of architecturally
modulated steric hindrance observed under static strain by loading samples to the same
cyclic profile at each of the static strain conditions. Cyclic loading enhanced the drug
penetration produced by static strain (Figure 3.6A). At each mean strain, cyclic loading
consistently increased penetration by an average of 0.084 mm for every 1 Hz increase in
cycling rate (Figure 3.6B). As a result, the penetration profile across mean strains for
each cycling rate shares the same shape as the static strain profile (Figure 3.6C). As
penetration was linearly dependent on cycling rate, it was directly dependent on the
number of cycles of loading. Drug penetration was identical over a range of frequencies
when the product of loading duration and frequency was held constant such that all
tissues were subjected to 3600 cycles of loading (Figure 3.6D).
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Figure 3.6. Impact of cyclic strain on drug penetration. (A) Cyclic tensile loading at 1 Hz-3
Hz increases drug penetration at each mean strain linearly proportionally to the frequency
of loading. 0 Hz groups received no cyclic loading and are the same statically stretched
cases shown in Figure 3.5A. Penetration depths produced by each loading frequency
applied at each mean strain are statistically significantly different (T-test, p<0.05) except for
groups with an * between them. (B) The slopes of the linear relationship between
penetration and loading frequency at each mean strain are statistically the same, averaging
0.084 mm/Hz (Single-Factor ANOVA, p>0.05). (C) Penetration at each frequency of
loading follows the same trend dictated by static stretch. (D) Penetration is directly
dependent on the number of cycles of strain. Penetration is statistically the same at each
mean strain over a range of loading frequencies when the imposed number of loading cycles
is held fixed at 3600 cycles (Two-Factor ANOVA, p<0.05 between 0% and 5%, p> 0.0 5
among loading groups). The 1 Hz, 60 min group for 0% and 5% strain are the same cases
shown in Figure 3.6A.
Isometric twitch contractions increased drug penetration above that occurring
without contraction. Preliminary findings demonstrated the pharmacokinetic impact of
the presence of contraction (Figure 3.7). Quantitative studies of contraction rates from
0 1 2 3
0.8
S0.6-
0.4-
0.2 -
0-
0
0.1-3 Hz showed that penetration increased with contraction rate by 1.52-fold to a
maximum at 0.5 Hz and fell off thereafter (Figure 3.8).
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Figure 3.7. Impact of contraction on drug transport. Rhythmic contraction increases
intramuscular penetration of 20 kDa FITC-dextran, suggesting dynamic forces created by
contraction increase interstitial drug transport. Fluorescence intensity images of axial
cross-sections of the soleus show drug distribution under non-contractile and contractile
loading conditions.
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Figure 3.8. Impact of contraction frequency on drug penetration. Isometric twitch
contractions of 0.1 Hz-3 Hz at nominal length increase penetration above that occurring
with static strain, 0 Hz. The 0 Hz group received no electric pacing and is the same 0%
group shown in Figure 3.5A. Penetration increases with contraction rate from 0.44 ± 0.09
mm at 0 Hz to a maximum of 0.67 ± 0.10 mm at 0.5 Hz and decreases to 0.52 ± 0.09 mm by 3
Hz. Penetration depths measured at each frequency in both the increasing and decreasing
halves of the profile are statistically significantly different (T-test, p<0.05).
3.4.2 Tissue Architecture
3.4.2.1 Myofiber Arrangement
Minimum interstitial spacing between myofibers in histologic images was 0.43
gm, which is comparable to experimental values (- 0.1 gm) found previously [192].
Myofiber arrangement was isotropic at 0% and 20% strains (Figure 3.9A). This
homogeneous distribution was interrupted by enlarged intercellular channels, of 11.1 jim-
34.7 gm width, at 5%, 10%, and 15% strains. Fiber rearrangement by channels, which
cleave muscle bundles in orientations that correlate with fascicular borders, not only
increases porosity, but is also an independent parameter that significantly impacts drug
transport, as shown in our computational model.
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I
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3.4.2.2 Tissue Porosity
Tissue porosity was 0.12 ± 0.01 at 0% strain (Figure 3.9B). This is in agreement
with inulin distribution space, which characterizes the volume of extracellular space,
found previously in rat soleus (0.14 ± 0.01, 0.12 ± 0.01, and 0.13 ± 0.01) [143, 193, 194].
Porosity increased with tensile strain by 1.5-fold to a maximum at 10% strain, or optimal
length Lo, and fell off thereafter. That this porosity profile correlates with the isometric
twitch force-length relationship of the muscle (r = 0.87) and exactly with the drug
penetration profile with static strain (r = 1) suggests that tissue porosity, which is the
architectural correlate of functional state, is a direct determinant of drug transport in
contractile tissues (Figure 3.9C).
3.4.2.3 Average Fiber Cross-Sectional Area and Fiber Density
Whereas average cross-sectional area of myofibers decreased to an asymptotic
value, fiber density increased from an asymptotic value with increasing strain (Figure
3.9D). Both profiles inflected symmetrically at Lo, indicating the significant
correspondence of architectural state with muscle function and pharmacokinetics. The
product of average area and density represents the fractional space occupied by myofibers
(Figure 3.9E) and demonstrated a profile that was the mathematical complement of
porosity (r = -0.99). Fiber density plotted against fiber area was a nonlinear curve
(Figure 3.9F), demonstrating the presence of porosity changes with strain, as constant
porosity would have produced a linear relationship between fiber density and average
area. These findings suggest porosity, fiber area, and fiber density are distinct parameters
that change interrelatedly to affect the transport environment.
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Figure 3.9 (A-C). Architectural parameters over 0%-20% strains. (A) Axial cross-sections
of HE stained soleus muscles undergoing (i) 0%, (ii) 5%, (iii) 10%, (iv) 15%, and (v) 20%
static strain. Myofibers are pink and interstitial space is white. (B) Porosity increases with
strain from 0.12 ± 0.01 at 0% strain to a maximum of 0.18 ± 0.02 at 10% and decreases to
0.13 ± 0.01 by 20%. (C) The porosity profile correlates with the isometric twitch force-
length relationship (r = 0.87) and exactly with the drug penetration profile over static strain
(r = 1). Profiles are normalized to their respective peak values at Lo.
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Figure 3.9 (D-F). Architectural parameters over 0%-20% strains. (D) Average cross-
sectional area of a single myofiber and density of myofiber distribution change inversely
with static strain. The average area decreases to an asymptotic value with increasing strain
from 3397.6 ± 125.2 m'2 at 0% strain to 2296.3 ± 24.4 pm' at 20%. Density increases from
an asymptotic value of 2.67x10 " + 1.86x105- m 2 at 0% strain to 3.76x10 "4 ± 2.46x10
s5 Rm2
at 20%. (E) Fractional space occupied by myofibers is calculated from the product of
average area and density. Fractional space is the mathematical complement of porosity.
(F) Change in porosity is demonstrated by the nonlinear relationship between fiber density
and average fiber area.
3.4.3 Numerical Results
3.4.3.1 Static Strain
Drug transport under static strain was influenced by the combined effects of
porosity and fiber arrangement (Figure 3.10). The theoretical upper bound of diffusivity,
Deff/Dw = p, is along the myofiber axis [178]. Transport through the homogeneous fiber
arrangement under 0% and 20% strains (Figure 3.9A) was accurately characterized as
diffusion perpendicular to the axis of a homogeneous arrangement of myofibers (Figure
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Fiber arrangement is also a significant parameter influencing transport [178]. Diffusion
was greater across an inhomogeneous fiber arrangement with the presence of an enlarged
channel aligned in the direction of transport (Figure 3.3E) than across a homogeneous
fiber arrangement (Figure 3.3B) with uniformly widened interspaces even when both
arrangements had identical average porosities. Transport through the inhomogeneous
fiber arrangement produced by 5%, 10%, and 15% strains (Figure 3.9A) was accurately
characterized by diffusion perpendicular to the axis of a myofiber arrangement with an
enlarged channel aligned in the direction of transport (Figure 3.10, Medium with
Channel) and the relationship, Deff/Dw = 1.0449 - 0.0442, which had a slope that
approximated the upper limit of diffusivity (diffusion along the myofiber axis). A slope
approximating the upper bound likely reflects channel alignment in the direction of
transport. These results demonstrate that in addition to average porosity, fiber area, and
density, the arrangement and distribution of myofibers significantly impacts transport.
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itionship between effective diffusivity and porosity over 0%-20%
strains. Numerical results were compared to experimental data in terms of Deff/Dw versus
porosity (9() for the range of 0.1 5 <( 5 0.2. The computational lower limit of drug diffusivity
is transport through a porous medium represented by a homogeneous, repeating lattice of
staggered diamonds (Figure 3.3B) in which the macroscopic direction of diffusion is across
myofibers and perpendicular to their axis. The theoretical upper limit of drug diffusivity,
Deff/Dw = 9, represents diffusion in a unit cross-sectional area through straight, non-
tortuous channels that run parallel to the myofiber axis and occupy a fraction 9q of the unit
area. The plot of Medium with Channel is the numerical result for diffusion across a
diamond lattice with the addition of an enlarged interstitial channel running in the direction
of effective drug diffusion (Figure 3.3E). General lattice interspacing was determined based
on the local porosity measured in a fascicle in images of 5%, 10%, and 15% strain (0.087,
0.091, and 0.078, respectively). Computational channel widths for 5%, 10%, and 15%
strain were calculated such that overall average porosity in the domain was 0.172, 0.179,
and 0.155, respectively, to match histologic measurements. For a domain (f) size of lx1
dimensionless values and diamond size of 0.34 x 0.34, channel widths were 0.099, 0.103, and
0.077 for 5%, 10%, and 15%, respectively. Thus, calculated channel sizes used in the
numerical plot of Medium with Channel were 23%-30% of myofiber size, predicting widths
of 11 pm-15 pm, which fall within the range of empirically measured channel widths.
3.4.3.2 Dynamic Strain
Dispersion resulting from cyclic structural oscillations in the radial direction
likely explains the enhancement of radial drug penetration under dynamic loading. The
presence of dispersion was computationally validated by the linear dependence of
cY
penetration on frequency and number of loading cycles, independent of mean strain
(Figure 3.11). Discrepancies between numerical and experimental results may be
attributed to simplifying assumptions of model geometry, as a circular cylinder, and of
the dynamics of mechanical behavior. Consideration of the
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Figure 3.11. Dynamic loading. Dispersion increases drug penetration with linear
dependence on the frequency of oscillation. (A) 0% and 5% mean strains. (B) 10% and
20% mean strains. (*) Numerical results lie within the confidence limits of experimental
data. (C) Dispersive effects are dependent on the number of loading cycles, independent of
the mean strain.
complex dampening effects of muscle viscoelasticity, which reduce the dispersive effects
of structural deformations, during dynamic loading may more completely characterize
muscle mechanics and mass transport. Interstitial fluid extrusion, which may initially
counteract drug penetration, can subsequently produce a wicking effect that draws drug
into the tissue as a result of the transposition of interstitial and source fluid. These effects
during dynamic loading may further compound the enhancement of drug penetration.
3.5 Discussion
Intramuscular drug transport is not simply a function of the physicochemical
properties of the drug. Characteristic dynamic architecture, motion, and contraction in
skeletal muscle targets significantly influence intramuscular pharmacokinetics. Before
quantifying the transport of proteins or specifically binding drugs, it was necessary to
analyze the pharmacokinetics of an inert tracer such as dextran. Using a mechanical
loading system designed for in vitro drug transport studies in association with muscle
biomechanics, we investigated the impact of controlled mechanical loading on dextran
penetration in soleus muscle. A computational model of interstitial drug transport
accurately elucidated the architectural and dispersive influences underlying the transport
effects of static and dynamic strain.
3.5.1 Static Strain
Muscle lengths from 0% to 20% strain span the physiologic range of muscle
function and extensibility [195]. Drug transport within this range reflects the
pharmacokinetic environment dictated by physiologic architectural configurations and
function. The exact correlation between effective diffusivity and porosity over static
strain confirms the extracellular transport of soluble dextran [134-136, 196, 197] and
indicates that architectural changes like muscle stretch influence transport through impact
on porosity.
Whereas previous studies have shown that passive stretch unilaterally increases
glucose uptake [95], we have elucidated an architecturally defined optimal setpoint
rendering maximal drug penetration at the physiologic configuration for peak muscle
performance, optimal length Lo. Characteristic changes in fiber size, density, and
organization suggest that strain-dependent porosity, which mediates this parabolic
increase in transport, results from the asynchronous progression of conservation of
myofiber volume and myofiber packing density with strain. Through conservation of
volume, myofibers undergo continuous reduction in cross-sectional size with elongation.
Upon initial stretch, this fiber thinning opens interstitial space, increasing porosity and
transport. Interstitial enlargement is accompanied by space and myofiber redistribution
along fascicular borders, likely corresponding with muscle volume changes known to
occur during muscle activity [153]. Thus, increased tissue-averaged porosity results from
not only homogeneous space enlargement, but also myofiber redistribution that can
connect interstitial spaces and precipitate the formation of enlarged channels with low
tortuosity. As demonstrated by our static model, these widened channels are likely
aligned in the radial direction of drug penetration to greatly facilitate diffusion and render
maximal penetration at Lo. With elongation past Lo, fiber density increases as the entire
muscle bundle tightens and increasingly thin fibers compact together, resulting in
contraction of interstitial space, recession of open channels, and reduction of tissue-
averaged porosity and diffusion. These changes likely correspond to muscle volume
decrease [153] and intramuscular and interstitial pressure increase [198] known to occur
with passive stretch beyond Lo. Through the structural changes depicted by the
asymptotic profiles of fiber size and density, porosity is modulated predominantly by
local effects such as fiber size at strains less than Lo, and by global effects such as fiber
distribution at strains greater than Lo.
Correlation between transport, porosity, and the active force-length relationship,
whereby all three increased 1.5-fold from baseline to a maximum at Lo, suggests the
physiologic nexus ascribed to Lo, whose architectural configuration enables optimal
interface between the tissue and its external environment. The profiles of fiber area and
density over 0%-20% strain suggest that the architectural configurations within the
physiologic range of muscle extensibility and function are defined by the passive material
limits of myofibers and connective tissue. Fiber size asymptotes to a minimum by 20%
strain, suggesting the extent of myofiber incompressible elasticity. Fiber density
asymptotes to a minimum at the initial length, indicating the resting state of fiber
aggregation and maximal mechanical compliance of the muscle bundle rendered by the
connective collagen fascial framework. Between these physical limits, the profiles of
both fiber size and distribution progress inversely with elongating strain and have a
critical inflection point at Lo, where these parameters correlate maximal porosity and
drug penetration with optimal mechanical performance. Perhaps maximal extracellular
space is functionally related to optimal activity to increase vascular perfusion by reducing
intramuscular pressure [152, 199] or to maximize the available volume surrounding fibers
to enable maximal fiber swelling and thickening [107, 145] during contraction.
3.5.2 Dextran Molecular Weight
FITC-dextran is a neutrally charged [200, 201], highly branched, randomly coiled
polysaccharide [202] with non-protein binding [135] properties. Size-dependent mobility
of dextran in the interstitium captures the effect of steric interaction with architecture on
transport. The continuous, dense network of collagen fibers forming the endomysium
and perimysium sterically hinders soluble drug diffusion [97]. As this network provides
support and force transmission between myofibers [100, 102], structural deformations
associated with mechanical loading can modulate the screening effect on drug transport
mediated by the network. The collagen fibers, which are randomly orientated in relaxed
muscle, align circumferentially to myofibers with muscle shortening and axially with
muscle elongation [103-105]. Because permeability is greater through a periodic, rather
than a random, distribution of obstacles [154, 203], alignment of collagen fibers with
strain increases interstitial permeability. These changes define mobility within the
accessible volume to drug that is dictated by macro-scale tissue-averaged porosity. The
extent of steric hindrance and interstitial mobility was demonstrated by the penetration of
dextrans of various sizes. Results showed the transport effects of strain-dependent
architecture were consistent across different physicochemical properties.
The architectural configuration at Lo defines an interstitial collagen and myofiber
alignment that optimally reduces steric hindrance and enhances penetration. This
transport effect likely varies, like Lo and its associated maximal force, among different
muscles. Physical properties of the drug, namely molecular size, further dictate the
ultimate effect on penetration presented by intramuscular fiber alignment. Diffusivity
was observed to increase with decreasing dextran size. For lower molecular weight
molecules that penetrate farther in general, steric hindrance likely becomes negligible
because the effective radius of such drugs is substantially smaller than the minimal
barrier to diffusion posed by fiber alignment. Penetration of such small molecules would
be the maximum achievable under the static, architecturally defined transport
environment and could only be enhanced further by dynamic forces such as dispersion or
convection induced by muscle activity. Whereas net penetration decreases with
increasing dextran size, the relative enhancement of penetration at Lo increases. For
150kDa dextran, which has an 8.3 nm radius, penetration at Lo is significant compared to
penetration at 0% strain. For this and larger sizes, penetration into muscle is minimal
under static conditions and enhancement at Lo is therefore significant, enabling
penetration of large molecules that otherwise would not have been able to enter the
tissue. Molecules of even greater size may be altogether sterically excluded even at Lo
and thus also derive no enhancement of penetration from the dynamics of muscle activity.
3.5.3 Cyclic Stretching
In the absence of a net external convective force driving bulk fluid flow into the
muscle, and particularly as drug penetration proceeds against an increasing intramuscular
pressure gradient during stretch [ 152], enhancement of penetration by oscillatory loading
is unlikely the result of bulk convection. Dynamic loading may cyclically expose drug to
strain-dependent architectural configurations with larger accessible volumes and result in
a greater time-averaged porosity that increases penetration. However, this mechanism
depends only on static architectural states, and average porosity over a single loading
cycle remains the same regardless of loading frequency. Enhancement of transport that
readily superposes on the static strain transport profile suggests a dynamic process rather
than further reduction of architectural exclusion. Thus, dispersion is likely a significant
driving force because penetration was shown both experimentally and computationally to
be enhanced linearly dependently on loading frequency and independently of mean strain.
Dispersion impacts the transport kinetics of soluble drug by increasing transport
beyond molecular diffusion alone [155]. Axial strain translates into radial deformation
due to conservation of volume and lateral force transmission by interstitial connective
tissues [204, 205]. Cyclic displacement of myofibers compresses and expands
extracellular space and imposes normal and shear forces on interstitial fluid, resulting in
pulsatile agitation and movement of soluble drug in the absence of net bulk convective
fluid flow. Such agitation can disperse or spread drug in a rate-dependent manner over a
greater extracellular volume, thereby driving greater penetration.
3.5.4 Contractions
Unlike studies of contraction-induced substrate transport, which have shown that
contraction increases glucose transport based on metabolic changes [94, 96], or that
glucose [84, 90] or calcium [149] uptake scales unilaterally with frequency of
contraction, we have elucidated a functionally-associated optimal setpoint rendering
maximal drug penetration at 0.5 Hz isometric contractions at nominal length. Cyclic
dynamics alone can increase penetration through dispersive effects that scale with
frequency. However, decreasing penetration with contraction rates above 0.5 Hz
suggests competing transport effects that predominate at higher frequencies. Contraction,
which is functional tissue activity, imposes more complex transport effects than those
introduced by static or cyclic stretch of passive tissue that reflect the combined and
interacting effects of architectural configuration and loading dynamics. We propose the
bimodal trend in penetration with contraction rate results from time-dependent
competition between dispersion and steric hindrance, whereby dispersion predominates
below, and steric hindrance predominates above a critical contraction rate determined by
the isometric muscle length.
Even under isometric conditions, contraction-associated myofiber thickening
[206] occurs as a result of cytoplasmic volume displacement from the smaller end-
regions of myofibers toward the middle [106]. Fiber thickening produces transverse
forces and a squeezing effect that decreases porosity and increases interstitial fluid
pressure [198, 199]. Fiber swelling resulting from interstitial water movement into the
fibers [145] reduces interstitial space available for drug in the absence of vascular
perfusion in vitro [146, 153]. These effects resist drug penetration. Fiber relaxation after
contraction results in fiber thinning that re-opens interstitial space, restores porosity, and
relieves interstitial fluid pressure. Cyclic transitions between the contracted and relaxed
architectural states create dispersive effects that increase drug penetration. At contraction
rates less than 0.5 Hz, muscle contracts infrequently and tissue architecture spends the
majority of the duration of drug delivery in the relaxed state, which enables dispersive
effects that do occur as a result of contraction to dominate. This in agreement with
findings that low frequency isometric contractions (3 contractions/min) increase both
inulin uptake and washout in papillary muscle [87]. At contraction rates greater than 0.5
Hz, muscle architecture spends an increasingly greater amount of time in the contracted
state. More contractions occur over the duration of drug delivery, which exposes drug to
a greater temporal resistance to penetration and progressively swelling fibers. At these
frequencies, the effects of increased temporal steric hindrance and elevated interstitial
pressures outweigh the effects of dispersion, thereby precluding enhancement of drug
penetration. At the extreme limit of complete tetani, elicited by 55 Hz electric pacing at
room temperature [131], muscle architecture spends the entire extent of a given duration
in the contracted state, thus eliminating cyclic transitions between structural states and
associated dispersive effects altogether, and would likely reduce penetration to a depth
even less than that occurring under static conditions in the relaxed state.
As static strain affects tissue porosity, it is likely that this contraction rate
dependence of maximal penetration shifts with the isometric length of the muscle. This
possibility is supported by the finding that the extent of contraction-associated muscle
volume decreases varies with initial length of the muscle, becoming greater with greater
initial lengths beyond Lo [153]. We predict that the optimal frequency may increase with
isometric lengths that effect greater porosities.
3.5.5 Conceptual Paradigm
Mechanical loading and contractile function produce myofiber deformations,
rearrangements, and extracellular pressure changes associated with interstitial space and
fluid redistributions that can affect the intramuscular distribution of locally delivered
drug. Histologic assessment of architecture and drug penetration findings that reflect
structurally influenced steric interactions provided insights on strain-dependent
architectural configuration. From these findings, we propose that myofiber cross-
sectional area and packing density undergo an asynchronous progression of changes with
strain based on conservation of volume to render a spectrum of architectural
configurations with muscle elongation spanning contraction through initial length to
extreme tensile strain (Figure 3.12). Moderate passive stretch from initial length up to
optimal length reduces myofiber thickness and opens or widens interstitial space to reach
a maximal porosity at Lo that enables optimal drug transport. With extreme stretch past
Lo, increasingly thin fibers compact together as the entire muscle bundle tightens,
resulting in contraction of interstitial space that reduces drug transport. Muscle fiber
swelling and thickening during isometric contraction can result in a squeezing effect that
narrows interstitial space and increases interstitial fluid pressure, thus impeding drug
penetration. Fiber relaxation and relief of contractile tone, which recreates muscle stretch
t
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Figure 3.12. Conceptual paradigm of strain-dependent architecture. The spectrum of
architectural configurations spanning contraction to extreme strain that is modulated by
myofiber cross-sectional area and packing density. Porosity is maximized by moderate
elongation to the architectural state at Lo.
and associated fiber thinning, results in an opening effect on interstitial space, increase in
porosity, and relief of interstitial fluid pressure that reestablishes greater drug penetration.
Within this spectrum of architectural changes, the screening effect of mechanically
influenced interstitial connective tissue can further modify drug mobility.
Structural configuration provides the foundation of architecture-induced changes
in drug transport while enabling dynamic loading effects to be superposed either
additively or competitively. Dynamic effects from cyclic tensile strain augment drug
transport linearly dependently on loading frequency beyond the effects of architectural
configuration imposed by static strain. Rhythmic contraction, however, enables a rate
dependent maximal drug penetration, suggesting the transport effects of architectural
configuration and cyclic transition between relaxed and contracted configurations may
compete to modulate drug transport. Findings from cyclic strain experiments indicate the
impact of dynamic loading on transport depends directly on the number of cycles of
loading. Thus, it is likely that the rate dependent influences of contraction on drug
penetration are related to competition between the total number of transitions between
relaxed and contracted configurations, whose kinetics produce dispersive effects that
accumulate with each set of transitions to enhance transport, and the duration of time the
muscle spends in one configuration or the other, which determines time-averaged
porosity over the duration of drug delivery. In this setting, as in cyclic tensile loading,
transport effects of structural mechanics can be further compounded by fluid dynamics.
Structural transition to a state or configuration that reduces interstitial space can produce
fluid extrusion that resists drug entry. In contrast, transition to a configuration that
reopens interstitial space can generate wicking or milking effects that draw bulk phase
fluid and drug into the tissue. Likely with such fluid dynamics, as with structural
mechanics, is the potential competition between interstitial fluid extrusion and influx that
may be time or rate dependent, and a consequent equilibrium setpoint at which these
opposing effects balance to effect a pivotal degree of drug transport.
3.5.6 Perspectives
Our findings elucidate opportunities for diagnostic techniques and therapeutic
windows for improved drug delivery to load-bearing tissues. Whereas static strain and
isometric contraction enable adaptable physiologic mechanisms for modulating or
maximizing drug transport, cyclic strain enables an easily scalable physical means for
further increasing drug penetration. The consistent effect of strain-dependent steric
hindrance across drugs of different physicochemical properties demonstrates a
physiologic means for selective drug uptake. Strain to Lo could facilitate maximal
penetration of low molecular weight drugs, or filter drugs delivered in mixed
formulations to allow selective entry of drugs below a certain size at desired temporal
windows. Insights on the pharmacokinetic role of fiber arrangement indicate the
anisotropic nature of intramuscular drug transport with preference for the least tortuous
pathway. The calculated upper limit for diffusion, which occurs parallel to the myofiber
axis, suggests transport across fibers is the limiting direction in drug distribution. As
axial drug transport outweighs radial penetration, focal application of drug along the
muscle axis may possibly achieve delivery to the entire length of the muscle but come at
the expense of reduced drug penetration into the tissue. Moderate strain towards Lo may
precipitate the formation of widened interstitial channels aligned in the radial direction of
drug penetration that reduce radial tortuosity, attenuate transport anisotropy, and enhance
drug penetration. Dispersion presents a physically controlled mechanism by which drug
transport can be enhanced. It can be readily applied in combination with architectural
control of tissue porosity to modulate drug penetration. These physiologic mechanisms
engender physical therapies that stretch or stimulate muscle targets in controlled
regimens as strategies for improving controlled drug delivery.
The relationship between drug uptake and target tissue functional architecture and
activity presents new insights on the significance of biologic form and function. We
hypothesize that maximal porosity occurs at the strain associated architectural
configuration that dictates peak contractile performance because this, in fact, represents a
true physiologic and evolutionary advantage rather than a coincidence of nature. One can
readily envision how optimized transport is related to peak contractile performance by
structural states in which energy conservation is maximized and muscle mechanics cycle
most readily through relaxation and recovery after contraction. Greater porosity and
reduced intramuscular and extravascular pressure at Lo may allow optimal muscle blood
flow to sustain the necessary rate of metabolic substrate delivery and waste removal to
meet the demands of peak contractile performance, thus optimizing functional efficiency.
Reciprocally, peak contractile performance occurs at the structural configuration that
facilitates optimal blood inflow to not only sustain the production of such peak function,
but also to maximize venous outflow through the squeezing effect of peak muscle activity
on intramuscular veins to match the rate of maximal blood inflow. The aim of such
architectural design to maximize tissue function is also exemplified by biologic
adaptation that centers the physiologic range of skeletal muscle extensibility and
operation on Lo. Central placement of peak contractile performance within the
physiologic range of function maximizes contractile effectiveness during locomotion and
postural stability. Correlation of maximal drug penetration with optimal muscle function
reflects biologic design that harmonizes the reciprocal interaction between tissue and its
physical environment. Just as optimal biologic responsiveness to pulsatile fluid flow in
different cell types occurs at the inherent frequencies to which they are exposed in their
physiologic environments [207], optimal intramuscular pharmacokinetics center within
the range of physiologic tissue extensibility and operation at the length of maximal force
generation and contractile efficiency, Lo. Architecturally and functionally dictated
optimal pharmacokinetic conditions suggest the existence of potential therapeutic
windows that correspond to unique setpoints in the physiologic operating range of all
target tissues and organs.
3.5.7 Conclusions
Mechanically active and load-bearing tissues present an active pharmacokinetic
environment in which permeability and drug transport are influenced by the interrelated
effects of architectural configuration and functional dynamics. The dispersive effects of
cyclic loading can be superposed on the structural dependence of tissue permeability to
enhance drug penetration. The correlation of both Lo and an architecturally modulated
optimal contractile rate with a respective maximal drug penetration elucidates the
biologically resonant nature of skeletal muscle interaction with the physical environment.
This biologic design not only introduces new strategies for controlled drug delivery, but
also elucidates the pharmacokinetic impact of functional architecture in all target tissues.
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TABLE OF SYMBOLS IN COMPUTATIONAL MODELS OF SKELETAL
MUSCLE
Symbol Definition Units
a normalized amplitude of radial deformation during cyclic
stretch, AR/Rn
c(r,t) concentration of the drug in the tissue (g/mm3 )
(c) average concentration in the periodic unit (g/mm 3)
X(x,y) the small periodic component of the macroscopic drug
concentration field
6ij Kronecker delta
D(X) diffusivity tensor of the drug in the extracellular space (mm2/s)
Deff effective diffusion coefficient of the drug in the tissue (in (mm2/s)
the direction e)
Dint diffusion coefficient of the drug in the interstitial space (mm2/s)
Dw free diffusion coefficient of the drug in water (mm2/s)
D1 dimensionless reducing factor of Dw due to porosity and
fiber arrangement
D2 dimensionless reducing factor of Dw due to interstitial
characteristics
e direction of macroscopic diffusion
eax axial strain
tr, transverse strain
Fi symmetric and periodic boundaries of K
F2  boundaries of Q at the fiber interface with the interstitial
space
ic periodicity of myofibers on the microscopic level
AL change in length of the muscle (mm)
Ln length of the muscle at the mean strains defined by index n (mm)
v Poisson ratio
n index of mean strains = 0, 5, 10, 20
n outward unit normal vector at the solid boundaries, fiber
surfaces, of 2
co radial frequency of pulsation of K2D (rad/s)
Gf(x,y) computational domain for solving the homogenized
equation of the static model
9D(r,O,t) computational domain for the dynamic model
K0o(R,O) reference domain used in the ALE formulation of the
transport equation
9P tissue porosity; the ratio of the area or volume of interstitial
space to the total area or volume, respectively, of the tissue
P periodic unit
r(t) radius of the muscle cross-section in •D (mm)
R radius of the muscle cross-section in Z0o (mm)
AR amplitude of radial deformation during cyclic stretch (mm)
RD maximum or minimum radius of the muscle section during (mm)
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Rn
t
T
Tf
V
AV
Vp
w
Wr
X=(XI, X2, X3)
x= (xl, X2, X3)
cyclic stretching
radius of the muscle at the mean strains defined by index n
time
period of pulsation of 2D
simulation time (3600s)
initial volume of the muscle
change in volume of the muscle
volume of the periodic unit
velocity vector of the moving domain nD
radial component of the velocity vector w
Cartesian coordinate system used to describe the
microscopic scale
Cartesian coordinate system used to describe the periodic
unit (f(x,y)
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(mm)(s)
(S)
(s)
(mm3)
(mm3)
(mm3)
(mm/s)
(mm/s)
4. PHARMACOKINETICS IN CARDIAC MUSCLE:
MULTIDIMENSIONAL ARCHITECTURE AND MECHANICAL LOADING
4.1 Abstract
Introduction: Dynamic tissue architecture, mechanics, and presentation of specific
binding sites in contractile tissues can influence the pharmacokinetics of locally delivered
agents. We investigated drug transport in the myocardium under controlled mechanical
loads.
Methods and Results: Dextran (20 kDa) and fibroblast growth factor 2 (FGF2)
solutions were delivered epicardially to ex vivo rat hearts in contracture-arrest with
complete ventricular evacuation, and in diastolic arrest under static ventricular distension
from 100 to 800 glL. Dextran and FGF2 penetration were maximal at the minimal
equilibrium volume devoid of principal mural strain by either contractile tone or
ventricular distension, and were reduced by both contracture and progressive left
ventricular (LV) filling. Dextran penetration, tissue porosity, and active LV pressure
correlated (r > 0.98) over both mural thickening (+37% principal radial strain) and
thinning (-78%), and were all maximal in the absence of strain, demonstrating
physiologic significance of the equilibrium dimensions and constitutive porosity of the
heart, and their impact on function and pharmacokinetics. Effective diffusivity of non-
specifically binding dextran exceeded that of FGF2 by more than 5.5-fold (p<0.05) at all
volume states, demonstrating the effect of architectural strain on drug penetration was
consistent across binding properties. Dextran penetration within in vivo beating hearts
was enhanced above the maximum observed ex vivo at equilibrium volume under static
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conditions alone. Drug penetration increased with increasing heart rate, LV pressure,
contractility, and stroke volume in hearts whose inotropy was modulated by Esmolol,
Ringer's lactate solution, or Dobutamine, demonstrating the dispersive effects of cyclic
cardiac function.
Conclusions: Mechanical architecture and function underlie intramyocardial
pharmacokinetics and act in concert to modulate drug transport across different binding
properties. Therapeutic management of functional mechanics in myocardial targets may
enable a physiologic mechanism for controlled drug delivery.
Keywords: Mechanical; Pharmacokinetics; Myocardium; Contraction; Binding
4.2 Introduction
Myocardial tissue presents a unique pharmacokinetic environment in which
transport of locally delivered drugs can be influenced by not only physicochemical
interactions, but also dynamic architectural configurations and mechanical function. The
laminar architecture of the ventricular wall, composed of branching networks of
interconnected myofibers layered in multiple transmural orientations [109] and defined
by cleavage planes [111], presents a uniquely complex physical environment that can
impact interstitial drug transport in a strain-dependent manner. Multi-dimensional
dynamic effects such as intramuscular pressure [208], local myofiber deformations [209],
shear of laminae [114, 210], and cross-fiber strains associated with mural thickening
[115, 119] and thinning [114] during the coordinated wall mechanics of cyclic cardiac
function can further alter transport kinetics. While local delivery strategies minimize
systemic losses [163] and enable efficient administration of therapeutic agents to target
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tissues [211], ultimate drug distribution and pharmacologic effect are determined by
target tissue pharmacokinetics.
Strategies for controlled release of drugs to the myocardium must consider the
transport effects of functional architecture and mechanical activity to optimize defined
release kinetics [48] for therapeutic effectiveness. A quantitative understanding is critical
for strategies like therapeutic angiogenesis to ischemic muscle, in which lesions are
spatially focal [164], therapeutic windows are narrow [ 165], biologic half-lives of
delivered proteins are short [50], and systemic side-effects of therapies are detrimental
[174]. Knowledge of how specific binding of angiogenic therapies such as fibroblast
growth factor 2 (FGF2) modulates drug transport in the context of mechanical loading is
essential for delivery technologies to achieve accurately sustained and localized
administration of pharmacologic doses to ischemic targets.
Whereas studies have investigated how myocardial stretch or contraction affects
total uptake of L-arabinose [212] and amino acid [213, 214], they have elucidated
primarily the influence of activity-dependent metabolism on substrate uptake. Few
literature reports have focused on the pharmacokinetic impact of mechanical strain and in
vivo cardiac dynamics on drug transport. Some have demonstrated atrial distension
increases endocardial endothelial permeability [86] and atrial contraction and distension
increase translocation of atrial natriuretic peptide and extracellular fluid [85]. Yet, there
remain conflicting data on how myocardial contraction affects uptake of drugs like
ouabain [215, 216], or how heart rate affects uptake of intravenously administered drugs
[217, 218]. We applied a rigorous, quantitative framework to investigate the
characteristic and synergistic impact of architecture and mechanics on intramyocardial
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transport of locally delivered soluble macromolecules. Having previously demonstrated
the pharmacokinetic impact of functional architecture in skeletal muscle, we
systematically investigate the effects of mural strain, specific binding of heparin-binding
FGF2, and dynamic mechanical loading intrinsic to cardiac function on drug transport.
4.3 Methods
4.3.1 Ventricular Distension
Experiments were conducted within the animal welfare regulations and guidelines
of Massachusetts. Male Sprague-Dawley rats (380-400 g) were administered 1000 U of
Heparin via intraperitoneal injection 5 min prior to euthanasia with inhaled CO2.
Thoracotomy was performed immediately after euthanasia, and 30 ml of Krebs-
Henseleit-Butanedione Monoxime (KH-BDM) cardioplegia (118.1 mM NaCl, 20 mM
KC1, 1.2 mM CaCl 2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO 3, 11.1 mM
Glucose, supplemented with 15 mM BDM at pH 7.4) oxygenated with 95% 02-5% CO2
at room temperature (RT) was retrogradely infused down the ascending aorta to perfuse
the coronary vasculature and arrest the heart in diastole. The left atrium was excised and
a fluid-filled balloon (Harvard Apparatus, Size 6 or 10) was inserted into the left ventricle
(LV) via the mitral opening and inflated by syringe to 100 jtL, 200 gL, 400 gL, or 800 giL
to simulate distending mural strains produced by ventricular filling (Figure 4.1). Hearts
for a 0 gLL group were perfused with regular KH containing 5 mM KCl and no BDM and
allowed to undergo contracture to complete LV emptying without the presence of a
balloon. Hearts (n = 6) were excised and rinsed twice with their respective perfusate to
remove epicardial blood. Hearts were immersed for 1 h in 15 ml of 1 mM neutrally
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charged 20 kDa FITC-dextran in PBS that was oxygenated with 95% 02-5% CO 2 and
kept well-mixed by magnetic stir bar at RT.
T
Figure 4.1. Ventricular distension. LVs were distended by a fluid-filled balloon to simulate
chamber filling. Hearts were distended by incubated in drug source.
4.3.2 FGF
The LVs of diastolically arrested hearts (n = 6) were distended to 100 gL and 800
gL. 400 gL of 0.02 mM FGF2 conjugated to Alexa Fluor 488 in PBS was delivered to
the myocardium for 1 h at RT from a drug releasing reservoir affixed to the epicardium of
the anterior wall using a liquid tissue adhesive (Glustitch). The rest of the epicardium
was kept moist by regularly dripping PBS.
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4.3.3 Recombinant FGF2 Production
Recombinant human FGF2 (155 residue) was expressed from cDNA in
Escherichia coli strain FICE-127 transformed by expression vector pFC80, which confers
resistance to ampicillin and encodes FGF2 under the control of the tryptophan promoter
(constructed by Dr. Antonella Isacchi, Amersham Pharmacia Biotech and Upjohn, Milan,
Italy; donated by Dr. John Heath, School of Biochemistry, University of Birmingham,
Edgbaston, Birmingham, UK). FICE-127 bacteria were inoculated into 100 ml of LB
Medium (MP Biomedicals) containing 100 jig/ml of Ampicillin (Invitrogen) and
incubated overnight at 370C, shaking at 250 RPM. The inoculum was diluted 1:100 in
antibiotics-free M9 Minimal Medium (Bioworld) containing 1 g/L of casamino acids
(Becton Dickinson Diagnostic Systems) without tryptophan to induce protein production.
Bacteria were incubated for 6 h at 370C and 250 RPM. The broth was centrifuged at
8,000 RPM and 40C for 10 min, supernatant was discarded, and pellets of cells were
collected and stored overnight at -800C. Frozen pellets were resuspended in GET buffer
(50 mM Tris, 10 mM EDTA, 100 mM Glucose, pH 8.0) containing 1 mg/ml lysozyme
and 1% Triton X-100, mixed for 5 min, and lysed by homogenization (Polytron;
Kinematica AG, PT10/35 Drive) 3 times for 10 s each with 5 s resting periods on ice to
prevent protein denaturation. The cell lysate was centrifuged at 9,000 RPM and 40 C for
10 min. Lysate supernatant was loaded into a Heparin-Sepharose affinity
chromatography column (5 ml HiTrap Heparin HP, GE Healthcare) and allowed to bind
for 1 h at 4°C. Using FPLC (Pharmacia Biotech), the column was washed with PBS and
a linear gradient of NaCl concentration (0.15-2 M). Elution was collected at 1 ml
fractions. FGF2 was present in fractions eluted with 1.5-1.8 M NaCl. FGF2 solution was
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desalted, exchanged into PBS buffer, and concentrated by centrifugation using centrifugal
filter devices with 9 kDa cut-off (ICON Protein Concentration, Pierce Biotechnology).
Presence of FGF2 was confirmed by Western blot as a band of 18 kDa reacting to rabbit
polyclonal anti-FGF2 antibody (Abcam). Bioactivity of FGF2 was confirmed by
proliferation assay using bovine aortic endothelial cells. Final FGF2 concentration was
determined by bicinchoninic acid assay (BCA, Pierce Biotechnology).
4.3.4 Fluorescent Labeling of FGF2
A 1 ml Heparin-Sepharose column was loaded with 1 ml FGF2 (5 mg/ml in PBS)
and allowed to bind for 1 h at 40C. The column was washed with 5 ml of 0.1 M sodium
bicarbonate to change pH to 8.3 and loaded with 1 ml of 1 mg/ml Alexa Fluor 488
(AF488) succinimidyl ester (Molecular Probes). Binding reaction of AF488 to FGF2 was
allowed for 10 min at RT. Using FPLC, the column was washed with PBS and a linear
gradient of NaCl concentration (0.15-2 M). Elution was collected at 1 ml fractions.
Labeled protein and fluorescence intensity in eluted fractions were verified by measuring
absorbance at 280 nm and fluorescence emission (ThermoLabsystems Fluoroskan
Ascent®FL, ex: 485 nm/ em: 538 nm). AF488-FGF2 fractions were exchanged into PBS
buffer and concentrated by centrifugation. AF488-FGF2 concentration was determined
by BCA.
4.3.5 Heart Rate and Contractility
Male Sprague-Dawley rats (380-400 g) were anesthetized with intraperitoneal
injection of Pentobarbital (25 mg induction, 12.5 mg/h maintenance), intubated with a 14
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gauge (2 mm diameter) endotracheal tube, and ventilated under positive pressure with 02
(96 breaths/min, 1.3 ml tidal volume). The right jugular vein was cannulated with PE50
tubing. A 2-Fr Pressure-Volume catheter (Mikro-Tip® Ultra-Miniature PV Catheter,
SPR-869, Millar Instruments) was introduced into the right carotid artery and advanced
into the LV. Thoracotomy was performed with minimal bleeding by an incision from the
diaphragm to the 3 rd intercostal space just left of the sternum. The ribcage was held open
by an Alm retractor, and the pericardial sac was resected to expose the beating heart. A
drug releasing reservoir was affixed to the epicardium of the LV anterior wall with
Glustitch. Rat temperature was monitored by rectal probe and maintained at 370C by
heat pad and lamp. After a 5 min stabilization period, proper PV catheter position in the
LV was established by monitoring pressure-volume loops. 400 gLL of 1 mM 20 kDa
FITC-dextran in PBS was added to the reservoir and exposed to the epicardium for 1 h at
RT. Pressure-volume loop behavior and hemodynamic parameters were monitored and
recorded throughout drug delivery using an MPVS-300 system (Millar Instruments,
PowerLab 8SP A/D Data Acquisition System, PVAN 3.6 Analysis). Heart rate and
inotropy of hearts (n = 4) were modulated by intravenous (IV) infusion (1.2 ml/h) via the
right jugular vein of Esmolol (300 pg/kg/min), Dobutamine (40 jig/kg/min), or Ringer's
lactate solution.
4.3.6 Quantification and Microscopy
After drug delivery, hearts were rinsed twice in 15 ml of PBS and snap-frozen in -
145°C Isopentane. 8 gim thickness cross-sections on the short-axis of the heart were cut
using a Leica CM1850 cryotome. FITC-dextran or AF488-FGF2 in sections was imaged
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using epifluorescence microscopy (Leica DMRA2, 50x magnification, Hamamatsu
ORCA286, Metamorph 6.3, ex: 450-490 nm bandpass/ em: 515 nm longpass). An
exposure rate was chosen that eliminated tissue autofluorescence and avoided intensity
saturation of the system by the drug source. Images were analyzed using Matlab. A
preliminary calibration confirmed the linear relationship between image fluorescence
intensities and tissue drug concentrations for 3 orders of magnitude of source
concentrations. This is in accordance with Beer's Law for very low source
concentrations, I=eCQ, in which I is fluorescence intensity, e is the molar absorption
coefficient, C the molar concentration, and Q the quantum yield [140]. Unidirectional
drug penetration from the epicardial surface was quantified. Intramuscular penetration
depth was defined as the perpendicular distance from the surface at which fluorescence
intensity decreased to 5% of the surface intensity. Effective diffusivity, Def, associated
with measured penetration depth was calculated based on the equation for diffusion in a
2
semi-infinite solid, Dg = , where x is penetration depth, and t is the4 -t -(erf '(0.95)
3600 s duration of incubation. Effective diffusivity is used to describe the observed
transport, which encompasses the impact of steric forces, potential specific and non-
specific binding interactions within the tissue interstitium, and cellular internalization, in
addition to the diffusive random thermal motion of solutes down concentration gradients.
4.3.7 Histology and Tissue Architecture
Hearts (n = 4) were contracture-arrested or diastolically arrested and immediately
excised. Contracture-arrested hearts were allowed to undergo complete LV emptying
without the presence of an intraventricular balloon. LVs of diastolically arrested hearts
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were distended by an OCT-filled (Optimal Cutting Temperature Compound, Tissue-Tek)
balloon to 100 ptL, 200 1gL, 400 gL, or 800 giL. Hearts were snap-frozen with balloons in
place. 8 gim thickness cross-sections on the short-axis of the heart were cut and stained
with Hematoxylin and Eosin. Light microscopy images (90x magnification) were
processed using Matlab. Tissue porosity (ratio of extracellular space area between
myofibers to total area) in LV regions comprised of axial cross-sections of myofibers was
quantified. LV mural thickness was measured. Epicardial surface markers (1 x 0.5 x
0.05 mm) were placed onto the LV of contracture-arrested or diastolically arrested hearts
(n = 6). The minimum equilibrium dimension of the LV was determined in diastolically
arrested hearts as the volume at which balloon inflation first encounters LV resistance
and produces mural strain. Circumferential and longitudinal surface strains relative to the
minimum mural dimension were measured as contracture-arrested hearts underwent
complete emptying and diastolically arrested hearts underwent distension to 100 gL, 200
jgL, 400 gL, or 800 giL. Principal strains in the radial, circumferential, and longitudinal
axes were calculated by the equation: el_Pricipal = .1 - 012 - uc 3, in which Poisson's ratio u
= 0.5 for an incompressible material, and index 1 = radial, circumferential, or
longitudinal axis while indices 2 and 3 were the two other axes. Total strain was
determined by the amplitude of the three-dimensional strain vector:
Stotal = . +g2 + 3  •
4.3.8 LV Mechanical Properties
Hearts (n = 5) were immediately excised and the coronary arteries were
retrogradely perfused with KH at 370C and oxygenated with 95% 02-5% CO2 in a
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Langendorff setup. A fluid-filled balloon connected to a pressure transducer (Kent
Scientific) was inserted into the LV and used to measure intraventricular pressure. LVs
were distended to 0 pL, 100 [L, 200 gLL, 400 gtL, or 800 pL and electrically stimulated to
produce isovolumetric twitch contractions at 1 Hz. Biphasic electric stimulus (15 V, 50
ms pulse) was applied by 2 stainless steel electrodes contacting the base and apex of the
LV. Stimulus was generated using a National Instruments DAQPAD-6062E data
acquisition board controlled by LabView 7.0. Pressure was continually recorded during
stimulation in the MPVS-300. Elastance of the balloon was subtracted from minimum
pressures recorded at each LV volume to calculate the passive LV pressure-volume
relationship. Active LV pressure developed was calculated by subtracting the minimum
pressure from the maximum pressure during stimulated contractions.
4.3.9 Statistical Analysis
Results are presented as mean + SD. Student's t-Test, Single Factor Analysis of
Variance (ANOVA), and Two-Factor ANOVA with Replication were applied to
determine statistical significance in empirical data. Propagation of uncertainty in
normalized data was calculated using the formula, Az - (Ax) 2 + ( , where Ax, AAz x y
and Az is the standard deviation of the numerator (x), denominator (y), and normalized
value (z = x/y), respectively.
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4.4 Results
4.4.1 LV Strain and Mechanical Properties
The minimum equilibrium dimension of the LV occurs 
at 100 jiL, which is
devoid of constitutive or residual strain. Smaller volumes can 
be observed only in
contracture-arrested states. Contracture produces radial 
thickening with concomitant
circumferential and longitudinal mural shortening (Figure 4.2). LV distension 
produces
exponential radial thinning with concomitant circumferential 
and longitudinal extension.
While circumferential extension reaches an upper limit with moderate 
LV filling,
longitudinal extension continues with greater filling in agreement 
with cardiac mechanics
that favor longitudinal dimension changes [116]. The Frank-Starling relationship,
LV Volume (gL)
Figure 4.2. Principal radial, circumferential, longitudinal, and total 
mural strains
associated with LV contraction and distension. Strains were measured 
relative to chamber
dimensions at 100 piL, the equilibrium volume devoid of intrinsic mural 
strain (0% total
strain). Contracture to full LV evacuation (0 itL) produces mural thickening (37 ± 10%
radially) and shortening (-17 ± 9% circumferentially, -20 ± 9% longitudinally). LV 
filling
produces exponential mural thinning (to -78 ± 8% at 800 FtL) and extension (to 30 ± 8%
circumferentially, 48 ± 10% longitudinally at 800 ItL).
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expressed in reference to tissue strain, correlates development of peak contractile force
with the absence of strain (Figure 4.3). Thus, optimal overlap of myosin and actin
contractile myofilaments occurs at equilibrium volume. Isovolumetric active
0.6 0.4 0.2 0 -0.2 -0.4
Principal Radial Strain
-0.6 -0.8 -1
Figure 4.3. Total, active, and passive pressure-volume relationships of the LV plotted
against principal radial strains associated with each intraventricular volume. Isovolumetric
active pressure increases from 44.22 ± 9.82 mmHg at complete LV evacuation (37% mural
thickening), to a maximum of 88.83 ± 8.02 mmHg in the absence of constitutive mural
strain, and decreases thereafter with further chamber filling to 5.42 ± 1.26 mmHg at 78%
mural thinning. Active pressures in both the increasing and decreasing halves of the profile
are statistically significantly different (T-test, p<0.05).
pressure at complete LV evacuation increases by twofold to a maximum in the absence of
mural strain and decreases thereafter with further chamber filling. The classic
exponential curve characterizing the passive extensibility of muscle is observed.
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4.4.2 Transport with LV Distension
Ventricular diffusion of dextran in contractured and diastolically arrested hearts is
influenced by volume-modulated mural strain (Figure 4.4B). Drug penetration is
bimodally related to total mural strain, peaking in the absence of strain at the equilibrium
volume (Figure 4.4C). Maximal penetration is reduced by the presence of strain
introduced by either contracture or LV filling, decreasing linearly with increasing
distension. Drug penetration correlates with the Frank-Starling relationship (r = 0.98,
Figure 4.3), suggesting architectural state and its functional correlate are significant
indicators of the pharmacokinetic environment in contractile tissues. Maximal drug
penetration correlates with peak contractile efficiency.
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Figure 4.4. LV mural transport of dextran versus static intraventricular volume. (A)
Fluorescent images of dextran penetration. (B) Fluorescent profiles of epicardial dextran
penetration demonstrate diffusion (determined by fit to error function) modulated by static
LV distension. (C) Drug penetration is maximal (0.45 ± 0.04 mm) in the absence of tissue
strain and is reduced by contracture (0.34 ± 0.02 mm at complete LV evacuation) and
diastolic filling, decreasing linearly with LV distension (-0.38 mm/compressive radial strain
to 0.15 ± 0.03 mm at extreme distension). Penetration depths in the increasing and
decreasing halves of the profile are statistically significantly different (T-test, p<0.05).
4.4.3 FGF
Two-Factor ANOVA reveals that penetration is significantly influenced by
ventricular distension ()D4,g at 100 pL exceeds that at 800 pL by 8.9- and 9.1-fold for
dextran and FGF2, respectively, p<0.05) and drug binding (Dýrf of 20 kDa dextran
exceeds that of FGF2 by 5.5- and 5.7-fold at 100 pL and 800 1iL, respectively, p<0.05)
(Figure 4.5). While specific binding significantly reduces macromolecular diffusion,
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mural strain consistently influenced drug penetration across different physicochemical
and binding properties.
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Figure 4.5. Pharmacokinetic impact of ventricular distension in the presence of drug
binding. Effective diffusivity of 20 kDa dextran is greater than that of FGF2 at both 100 pLI
and 800 pL. Dff at 100 pL and 800 pIL is 7.36x10 -6 ± 8.46x10 -7 mm2/s and 8.28x10 -7 ±
2.07x10 -7 mm2/s, respectively, for dextran and 1.33x10 -6 ± 2.33x10-7 mm 2/s and 1.46x10 -
7
4.78x10-" mm2/s, respectively, for FGF2.
4.4.4 LV Architecture
Myofiber arrangement (Figure 4.6A) is isotropic and densely packed in the
presence of significant total tissue strain (contracture, 400 il, and 800 ýtl). This
homogeneous distribution is interrupted by enlargement of intercellular channels and
separation of myofiber bundles at cleavage planes when total strain is relieved
(equilibrium volume and 200 p1A). Fiber rearrangement by channels, which cleave muscle
bundles in orientations that correlate with fascicular borders, not only increases porosity,
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but is also an independent parameter that significantly impacts drug transport, as we have
shown previously.
Tissue porosity, used as a measure of interstitial space, is maximal (0.27 ± 0.07)
in the absence of strain (Figure 4.6B). This porosity is in agreement with an inulin
distribution space, which characterizes the volume of extracellular space, of 26.4% found
previously in rat myocardium [219]. Porosity is reduced by the presence of strain
introduced by either contracture or LV filling, decreasing linearly with increasing
distension. That the porosity profile correlates with the isometric active pressure (r =
0.99) and dextran penetration (r = 0.98) profiles (Figure 4.6C) suggests tissue porosity,
which is the architectural correlate of functional state, is a direct determinant of drug
transport in contractile tissues. There is significant correspondence of architectural state
with both muscle function and pharmacokinetics.
119
B C
C
0s
A.
0.6 0.4 0.2 0 -0.2 -0.4 -0.6 -0.8 -1 0.6 0.4 
0.2 0 -0.2 -0.4 -0.6 -0.8 -1
Principal Radial Strain Principal 
Radial Strain
Figure 4.6. Architectural parameters in relationship to intraventricular volume. (A) Cross-
fiber (i-v) and along-fiber (vi-x) regions in short-axis cross-sections of Hematoxylin and
Eosin stained LV undergoing (i, vi) contracture, or distension to (ii, vii) 100 pL, (iii, viii) 200
pL, (iv, ix) 400 pL, or (v, x) 800 pL. Myofibers are pink and extracellular space is white.
(B) Porosity is maximal (0.27 ± 0.07) in the absence of strain and is reduced by contracture
(0.13 ± 0.05) and diastolic filling, decreasing linearly with LV distension (-0.34 /compressive
radial strain to 0.004 ± 0.002 at extreme filling). Porosity values in both the increasing and
decreasing halves of the profile are statistically significantly different (T-test, p<0.05). (C)
Normalized drug penetration, porosity, and active pressure profiles correlate positively (r =
0.98, penetration/porosity; r = 0.98, penetration/pressure; r = 0.99, porosity/pressure). Peak
drug penetration, porosity, and pressure occur at the equilibrium volume (0% strain).
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4.4.5 Heart Rate and Contractility
The kinetics of contraction were modulated with IV administration of an
antagonist (Esmolol) and agonist (Dobutamine) of f31-adrenergic receptors in the heart,
which respectively decreases and increases heart rate, contractility (dP/dt), and peak
systolic LV pressure (Figure 4.7). The physiologic range of intraventricular volumes
through the cardiac cycle demonstrates increasing end-diastolic volume and stroke
volume and decreasing end-systolic volume with increasing adrenergic activity. End-
diastolic volumes in hearts do not exceed the equilibrium volume even with increased
adrenergic stimulation.
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Figure 4.7. Inotropic modulation of cardiac performance. (A) Hemodynamic
measurements and pressure-volume loops in the MPVS-300 showing cardiac function under
pharmacologic effects of Esmolol, Ringer's lactate, and Dobutamine. (B) Heart rate (343.4
+ 21.5 BPM, 423.6 + 26.4 BPM, 524.1 + 39.2 BPM), (C) contractility (4207.7 ± 744.7
mmHg/s, 5956.2 + 1248.0 mmHg/s, 10,176.9 + 2507.9 mmHg/s), and (D) LV pressure (97.2 +
11.4 mmHg, 114.6 + 15.2 mmHg, 225.0 ± 79.2 mmHg) increase with increasing adrenergic
activity (Esmolol, Ringer's lactate, and Dobutamine, respectively). (E) End-diastolic
volume (67.9 ± 33.2 ItL, 86.4 ± 36.7 pL, 99.2 ± 41.0 pL) and stroke volume (35.7 ± 18.7 ptL,
56.4 ± 18.0 pL, 85.9 ± 20.2 pL) increase while end-systolic volume (32.1 ± 18.6 tL, 30.1 ±
29.2 IpL, and 13.3 ± 30.4 FLL) decreases with increasing adrenergic activity. (F) Relaxation
time constants calculated from the regression of log(pressure) vs. time (Tweiss, = 12.0 ± 2.3 ms,
10.2 ± 3.2 ms, 7.4 ± 1.9 ms) and dP/dt vs. pressure (gantz = 16.6 ± 1.4 ms, 13.6 ± 1.7 ms, 11.9
± 3.6 ms) decrease with increasing adrenergic activity. All hemodynamic parameters
occurring with each level of adrenergic activity are statistically significantly distinct (T-test,
p<0.05).
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Multi-dimensional mechanical loading inherent to cyclic cardiac function
enhances drug penetration above that mediated by mural strain alone (Figure 4.8).
Dextran penetration increases linearly with inotropic stimulation and heart rate (r = 1),
contractility (dP/dt, r = 0.99), LV peak pressure (r = 0.95), diastolic volume (r = 0.98),
and stroke volume (r = 1) and correlates negatively with relaxation time constants (r = -
0.98) (Figure 4.7). Even with positive inotropic intervention, end-diastolic volumes are
all less than the equilibrium volume, 100 pL, demonstrating a physiologic range of LV
volumes bounded by a minimum equivalent to contracture to full LV emptying and a
maximum equivalent to the equilibrium volume. This volume range not only confirms
physiologic operation occurs on the ascending portion of the Frank-Starling curve [220],
but also reveals through anatomic correlation that it occurs on the ascending and
descending portions of the tissue porosity and total strain curves, respectively, which
significantly influence the pharmacokinetic environment.
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Figure 4.8 Mural drug penetration under myocardial function. Cyclic cardiac function
enhances dextran penetration above the maximum occurring at static equilibrium volume.
Penetration increases significantly (T-test, p<0.05) with increasing adrenergic activity to
0.48 ± 0.04 mm with Esmolol (32.1-67.9 pl volume range, 343.4 ± 21.5 BPM, 4207.7 ± 744.7
mmHg/s), 0.57 ± 0.04 mm with Ringer's lactate (30.1-86.4 pll, 423.6 + 26.4 BPM, 5956.2 ±
1248.0 mmHg/s), and 0.68 ± 0.05 mm with Dobutamine (13.3-99.2 pl, 524.1 ± 39.2 BPM,
10176.9 ± 2507.9 mmHg/s).
4.5 Discussion
Intramyocardial pharmacokinetics is greatly influenced by characteristic dynamic
architecture, motion, and mechanical function in cardiac tissue. Within this paradigm,
drug transport is further modulated by binding interactions dictated by specific
pharmacology. Using both ex vivo and in vivo heart preparations, we compared transport
of an inert tracer to a specifically binding protein to investigate the impact of controlled
mechanical loading and specific binding on drug penetration in cardiac muscle.
124
h_
4.5.1 Ventricular Distension
Drug transport investigated over the range of principal radial strains from 37%
thickening (0 tiL) to -78% thinning (800 ptL) reflects the pharmacokinetic environment
spanning physiologic LV architectural configurations and functional states throughout the
cardiac cycle. Contracture to complete LV emptying (0 giL) represents architecture under
extreme contraction while LV filling to the highest balloon volumes in relaxed hearts
represents architecture under excessive distension. Within this range, 100 gL
characterizes an equilibrium volume associated with mural architecture devoid of either
contractile tone or ventricular distension and therefore total strain. This equilibrium
configuration reflects the resting state of myofiber aggregation and maximal mechanical
compliance of the ventricular wall rendered by the connective collagen fascial framework
[112]. While myocardial distension has been shown to increase transport of atrial
natriuretic peptide by enlarging the extracellular space [85], we have elucidated an
architecturally defined optimal setpoint whereby maximal drug penetration corresponds
with myocardial architecture absent of residual strain and primed for peak contractile
efficiency. We previously showed that uniaxial strain in parallel-fibered soleus skeletal
muscle influenced drug penetration through characteristic strain-dependent changes in
myofiber cross-sectional area, fiber packing density, and tissue porosity that rendered
maximal drug penetration at the physiologic configuration for peak muscle performance,
Lo. Similarly, the bimodal pharmacokinetic environment in the myocardium likely
results from characteristic strain-dependent changes in fiber arrangement [210], tissue
porosity [221], and intramuscular pressure [208] associated with ventricular contraction
and filling on either side of the equilibrium configuration that reduce drug penetration.
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Myocardial tissue is formed of tightly knit bundles of elongated, multi-nucleated
myofibers joined in an interdigitating manner to create a three-dimensional, branching
network. This arrangement comprises a contiguous muscular strip that is wrapped
helically to form the ventricular chambers and produces three major concentric layers,
each with a different orientation, in the cardiac wall [109]. Within this global structural
motif, myofibers are organized transmurally into distinct layers, or laminae, separated by
connective membranes of collagen fibers in interposing demarcations known as cleavage
planes [111]. While differences in myofiber arrangement and thus loading dynamics
exist between regions such as the apex and mid-ventricle, local myofiber structure and
mechanics are generally consistent. Through volume conservation, myofibers undergo
thinning with elongation. With progressive mural stretch, fiber density increases and
mural thickness decreases as increasingly thin fibers compact together and mural laminae
slide relative to each other [114]. These rearrangements result in contraction of
interstitial space, recession of cleavage plane interspaces, reduction of tissue-averaged
porosity, and increase of intramuscular and interstitial pressure [208]. Such increases in
interstitial steric hindrance reduce drug penetration during passive LV distension from
the equilibrium volume. Similarly, contraction-associated fiber and cross-fiber
shortening and myofiber thickening [209] produce transverse forces, mural thickening,
and a squeezing effect that decrease extracellular space [221] and increase interstitial
fluid pressure [222]. These effects during systolic contraction likewise increase
interstitial steric hindrance and resistance to drug penetration. Therefore, both
contraction and distension relative to the equilibrium configuration introduce total mural
strain that compresses interstitial space and reduces interstitial permeability.
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Correlation between drug penetration and tissue porosity indicates mechanically
mediated architectural changes influence transport through impact on porosity.
Correlation between transport, porosity, and the Frank-Starling relationship, whereby all
three reach a maximum in the absence of total mural strain, suggests the physiologic
nexus ascribed to the equilibrium volume, whose architectural configuration enables
optimal interface between tissue and external environment. The functional range of LV
volumes in beating hearts, even with inotropic stimulation, reached capacities no greater
than the equilibrium volume during diastolic filling. A physiologic range of LV volumes
within the decreasing half of the total strain profile does not simply agree with previous
findings [223] that mural tone persists during physiologic diastolic filling, but reveals that
physiologic diastolic distension reduces rather than augments constitutive material strain
of the chamber until equilibrium volume is reached. A physiologic range of LV volumes
within the increasing half of the porosity, active pressure, and transport profiles also
suggests that physiologic cardiac function dictates a mural transport environment that
enables drug penetration to vary proportionally with LV distension and contractile
efficiency. Within this range, penetration is reduced during systolic contraction and
maximized during diastolic filling, suggesting physiologic architectural states that
functionally reduce intramuscular pressure [224] and increase tissue porosity [221] to
favor coronary perfusion during diastole [220] consequently also enable a transport
environment that enhances interstitial drug transport. While equilibrium dimensions and
associated contractile performance will vary among different individuals, such biologic
design suggests that distended hearts within the physiologic volume range may be more
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receptive to drug uptake and engenders clinical therapeutic strategies that manipulate LV
volumetric state to modulate mural permeability to drug.
4.5.2 FGF
Therapeutic effectiveness of FGF depends on its specific binding interactions with
extracellular receptors [225], which can also influence drug pharmacokinetics. FGF
binds specifically with high affinity to cell-surface tyrosine kinase FGF receptors and
with lower affinity to more abundant cell-surface, basement- and extracellular-membrane
co-receptors such as heparan sulfate proteoglycans (HSPG), avP33 integrins, and collagen
types I and IV [58, 59, 226]. Thus, the fibrous, force-transmitting, connective tissue
network in the myocardium, which is composed of collagen types I and III and increases
in density near the epicardial and endocardial surfaces [112], can not only modulate
interstitial drug mobility through strain-influenced steric hindrance and screening, but
also contribute to sequestering soluble FGF from the interstitial space dictated by macro-
scale tissue-averaged porosity.
While 18 kDa FGF2 and 20 kDa dextran share similar molecular weights, they
differ in physiochemical and binding properties. FGF2 is a positively charged, globular
protein [227] with specific binding properties, while FITC-dextran is a neutrally charged
[200, 201], highly branched, randomly coiled polysaccharide [202] with non-protein
binding [135] properties and is used in studies to capture the effect of steric interaction
alone on transport. Because of its physicochemical properties, FGF2 has a hydrodynamic
radius of 1.5 nm [227], which is two-fold less than the 3.2 nm [183] radius of 20 kDa
dextran. Based on size alone, a smaller hydrodynamic radius would have enabled FGF2
128
to penetrate farther than 20 kDa dextran as suggested by our earlier finding of greater
penetration for smaller dextrans in skeletal muscle. However, the specific binding
properties of FGF2 reduced its effective diffusivity nearly 6-fold relative to that of non-
specifically binding dextran of greater hydrodynamic size, demonstrating the spatially
localizing effect of binding interactions with the target environment.
Receptor interaction has been shown to protect FGF from proteolytic degradation
and denaturation, thereby stabilizing its local levels and increasing its biologic activity
and half-life in tissues [63]. Local retention of FGF can create a spatially distributed
storage reservoir, which allows growth factors to reach higher local concentrations and
enables sustained local release of accumulated drug [66, 67]. However, binding
interactions also serve to retard growth factor diffusion [227], which can reduce
therapeutic efficacy by restricting subsequent availability of the growth factor to
downstream targets [62] or lead to local toxicity by causing suprapharmacologic
accumulation. Expectedly, the ability of specific binding to dynamically modulate
growth factor bioavailability [62] and radius of diffusion and action [68] depends on the
spatial distribution and concentration of receptors. Our results demonstrate the
consistency of the pharmacokinetic impact of architectural configuration across
physicochemical and binding properties such that extreme radial thinning to -78%
resulted in a similar relative reduction of diffusivity for both specifically binding FGF2
and inert dextran. Within this paradigm of strain-dependent structural modulation of
drug mobility, mechanical strain and architectural configuration may likely also impact
the spatial presentation and pharmacokinetic distribution of tissue binding sites to the
extent that these sites are mechanically influenced architectural elements. In addition to
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extracellular receptors and HSPGs, the connective tissue network, which serves to anchor
myofibers, support vascular tissues, and enable force transmission [112], presents a
network of collagen binding sites whose spatial distribution is functionally influenced by
mechanical loading. Circumferential stretch of the LV during filling, which compacts
myofibers and contracts interstitial space, can concentrate cell-surface and extracellular
binding sites as well as collagen fibers, which are known to straighten and align from
coiled configurations in their interstitial networks during ventricular stretch [114],
especially in mid-ventricular and epicardial regions. Increased density and spatial
presentation of binding sites with distension enable more efficient FGF retention by
tissue and reduce mural drug penetration.
The ability of the binding environment to be modulated mechanically has
significant consequence on growth factor pharmacokinetics and biological activity.
Growth factor pharmacodynamics may be further dictated by the characteristics of
mechanically modulated sustained release from tissue reservoirs subsequent to initial
exogenous delivery. These dynamics can uniquely impact drug efficacy in the proximity
of ischemic lesions, which experience heterogeneous gradients in mechanical loading and
strain resulting from regional contractile dysfunction and wall motion abnormalities [228,
229], as well as increased expression of receptors and HSPGs [69, 230]. Thus, the
ischemic heart can present both a disrupted loading and complicated binding environment
compared to the globally coordinated environment of the healthy heart that requires
further investigation.
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4.5.3 Heart Rate and Contractility
Mural architectural dynamics introduced through cyclic systolic contraction and
diastolic relaxation during cardiac function enhanced drug penetration beyond that
occurring with static LV distension to the same intraventricular volumes. Cardiac
beating can cyclically expose drug to strain-dependent architectural configurations
associated with diastolic filling up to the equilibrium volume that have larger accessible
volumes and result in a greater time-averaged porosity that increases penetration.
However, a greater time-averaged porosity enhances penetration only within the range
established by static LV distension and independently of loading frequency.
Enhancement of penetration above the maximum associated with static distension to the
equilibrium volume suggests a dynamic process resulting from the kinetics of cyclic
cardiac strain rather than further reduction of steric exclusion.
In the absence of an external convective force driving bulk fluid flow into the
epicardium, and particularly as penetration proceeds against an increasing intramuscular
pressure gradient during contraction [231] along with an overall transmural pressure
gradient [222], enhanced penetration during cardiac beating is unlikely the result of bulk
convection. Dispersive effects introduced by cyclic architectural transitions are likely the
predominant driving force because enhanced penetration scaled linearly dependently with
heart rate and contractility, and linearly inversely with relaxation time constants.
Dispersive effects may arise from the combination of various mural architectural
processes that occur during cyclic cardiac function. Locally, systolic contraction leads to
myofiber shortening and thickening, increased interstitial pressure, and reduced porosity,
while diastolic relaxation results in fiber thinning that re-opens interstitial spaces, restores
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porosity, and relieves interstitial fluid pressure. Globally, coordinated systolic
contraction of helically oriented LV myofibers produces ventricular contraction favoring
longitudinal over circumferential chamber shortening. Myocardial contraction in this
manner results in an overall torsion of the ventricular chamber accompanied by shear of
mural laminar sheets and reorientation of LV myofibers by -20' in the transition from
diastole to systole at any transmural position [210]. The processes that create ventricular
ejection of blood during contraction and are modulated by stroke volume and contractility
result in circumferential compression, especially in the inner half of the ventricular wall,
and mural thickening [115-117, 119]. Torsion and significant mural thickening followed
by torsional recoil and mural thinning during diastolic relaxation generate non-axial
cyclic strains across myofibers in the ventricular wall. These strains introduce a distinct
dimension of transport forces oriented along the direction of transmural drug penetration
that modulates dispersive effects.
Dispersion impacts the transport kinetics of soluble drug by increasing transport
beyond molecular diffusion alone [155]. Cyclic displacement of myofibers and
compression and expansion of interstitial space and fluid result in pulsatile agitation of
soluble drug in the absence of bulk fluid flow. Such agitation can disperse or spread drug
in a frequency-dependent manner over a greater interstitial volume, thereby driving
greater penetration. Thus, cardiac beating influences transport through the combined
effects of active muscle function and architectural configuration. Dispersive
enhancement of drug penetration agrees with findings that isometric contractions increase
both inulin volumetric uptake and washout in papillary muscle [87], and electric pacing
accelerates the washout of interstitial norepinephrine [232] and extracellular markers [89]
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from the myocardium. This physiologic mechanism engenders potential therapeutic
strategies leveraging administration of cardioactive agents or interventions concomitant
with local administration of primary therapies to improve controlled drug delivery.
4.5.4 Conceptual Paradigm
As in skeletal muscle, strain-dependent structural configuration enables optimal
porosity and associated maximal drug penetration at the physiologically defined state for
peak contractile performance. Histologic assessment of architecture and drug penetration
findings that reflect structurally influenced steric interactions provided insights on strain-
dependent architectural configuration. These findings elucidate the similarity in strain-
dependent local changes in myofiber cross-sectional area and packing density between
skeletal and cardiac muscle. LV distension from the equilibrium volume results in
circumferential stretch and radial compaction of muscle fibers, which progressively
reduce porosity and narrow interstitial space as occurs analogously under extreme stretch
from optimal length in skeletal muscle (Figure 4.9). LV contraction from the equilibrium
volume results in circumferential shortening and radial thickening, which produce a
squeezing effect that narrows interstitial space and increases interstitial fluid pressure as
occurs analogously with contraction from optimal length in skeletal muscle. Ultimately,
in either uniaxially structured and loaded skeletal muscle or multidimensionally
structured and loaded cardiac muscle, structural configuration underscores drug transport
while enabling dynamic loading effects to be superposed.
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Figure 4.9. Architectural configurations under ventricular distension and contraction.
Local changes in myofiber cross-sectional area and packing density during ventricular
distension and contraction are analogous to changes occurring in skeletal muscle under
extreme elongation and contraction, respectively.
4.5.5 Perspectives
Our findings elucidate opportunities to meet therapeutic windows and potential
strategies to improve local drug delivery to the myocardium. Ventricular distension
enables an adaptable physiologic mechanism for modulating or maximizing drug
transport. Cyclic cardiac contraction in vivo enables a scalable physical means, which
readily superposes on the structural dependence of tissue permeability, for further
increasing drug penetration. Strain-dependent steric hindrance by functional architecture
demonstrates a physiologic means for selective drug uptake based on the
physicochemical and binding properties of the drug. Modulation of growth factor local
distribution by ventricular distension could facilitate optimal deposition and retention of
drug in strategies like therapeutic angiogenesis such that they meet the spatial and
temporal therapeutic windows demanded by complex regenerative biologic processes and
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thus achieve desired pharmacologic results. The presence of residual contractile tone
during physiologic diastole reveals an LV volumetric range between end-diastolic
volume and equilibrium volume that can be recruited by ventricular filling, which
reduces mural strain in this range, to enhance drug penetration. Such recruitment could
be mediated by therapeutic modulation of the volume status of the heart in the setting of
intrapericardial controlled drug release. The pharmacokinetic impact of ventricular
distension could be harnessed in the cardiac surgical setting during cardiopulmonary
bypass and requisite diastolic cardiac arrest such that static ventricular filling could be
employed to enhance local epicardial drug uptake. Moreover, the capacity of dynamic
effects from cardiac beating to enhance drug penetration engenders both peri-operative
and ancillary therapies that pharmacologically manage cardiac inotropy and chronotropy
as strategies for controlled drug uptake.
While contraction dynamics augment drug mobility, tissue structural
configuration is intimately linked to transport. As not only porosity, but also myofiber
arrangement influences transport, the pharmacokinetic impact of functional cardiac
architecture can be significantly dictated by its physiologic and pathophysiologic state.
Drug penetration occurring in the setting of normal cardiac architecture comprised of
organized and aligned myofibers may be potentially altered in the setting of a heart
conditioned for athletic performance. Transport in this setting may be inhibited by
myocyte hypertrophy that constricts interstitial space but enhanced by improved diastolic
function [233] that enables a time-averaged porosity closer to equilibrium volume. In
contrast, transport may be altogether significantly reduced in pathologic states such as
hypertrophic obstructive cardiomyopathy, which exhibits not only myocyte hypertrophy,
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but also considerable regional myocyte disarray, architectural disorganization, interstitial
fibrosis, and ischemic scarring [234] that disrupt normal myofiber arrangement. Drug
transport may be hindered especially as a result of the irregular and random versus
aligned pattern of interstitial obstacles [154, 203] presented by myofiber disarray found
also in conditions like dilated cardiomyopathy, alcoholic cardiomyopathy [235],
hypertension, coronary heart disease, and cor pulmonale [236]. Furthermore, interstitial
drug mobility may be considerably reduced in the setting of cardiac fibrosis that develops
with hypertension, age, long-term athletic activity, myocardial ischemia [237],
hemochromatosis, restrictive cardiomyopathy, aortic stenosis, viral myocarditis, and
radiation and drug effects [238]. Other unique pathologic structural states that may
dramatically hinder drug penetration include hyperthyroidism, which exhibits nonspecific
hypertrophy that may constrict interstitial space; hypothyroidism, which exhibits
myofiber swelling accompanied by interstitial mucopolysaccharide-rich edema fluid that
may alter interstitial space and viscosity; cardiac amyloidosis, which exhibits interstitial
amyloid deposits around myofibers [239] that may impede drug diffusion; and muscular
dystrophy, which exhibits a cardiomyopathy comprised of myofiber size variation,
myocyte degeneration and fatty replacement, necrosis, and interstitial fibrosis [240] that
may variably reduce both drug mobility and accessible space. Architectural changes in
each of these states may underlie the pharmacokinetic environment upon which altered
contraction dynamics associated with such altered architecture, such as diastolic stiffness
and abnormal contractile tone associated with interstitial cardiac fibrosis [241], may
further impact drug transport.
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The relationship between drug uptake and target tissue functional architecture and
contraction presents new insights on the significance of biologic form and function. A
physiologic volumetric range less than equilibrium volume, falling on the ascending half
of the Frank-Starling and porosity relationships and descending half of the total mural
strain relationship with LV volume, suggests reduction of residual mural strain opens
interstitial space and increases porosity during diastolic filling. Diastolic filling that
reflects relief of mural contractile tone rather than imposition of distensile strain up to
equilibrium volume reveals a physiologic mechanism that uses internal restoring forces
or elastic recoil to generate negative chamber pressures in early diastole that facilitate
ventricular filling through a process of diastolic suction [242]. This mechanism may
reflect biologic adaptation that relies on the passive mechanical properties of the ventricle
to conserve energy during filling with the overall aim of maximizing cardiac functional
efficiency. This adaptive measure for maximizing operational efficiency based solely on
tissue structure spans not only diastolic, but also systolic function. Progressive LV filling
is associated with increased porosity corresponding to diminished mural strain that by
consequence renders a structural environment better suited for drug uptake. We
hypothesize that maximal porosity occurs at the minimum-strain associated architectural
configuration - equilibrium volume - which dictates peak contractile performance,
because of the design of physiologic form based on its interrelationship with function.
Greater porosity and reduced intramuscular pressure towards equilibrium volume may
allow optimal coronary blood flow in diastole [243] to sustain the necessary rate of
metabolic substrate delivery and waste removal to meet the demands of peak contractile
performance, thus optimizing functional efficiency. Reciprocally, peak contractile
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performance occurs in the structural configuration that facilitates optimal blood flow to
sustain the production of such peak function. The aim of such structural design to
maximize functional efficiency may also explain the adaptive advantage of having a
greater relative duration of diastole during the cardiac cycle [244], which enables a
greater duration for coronary perfusion and consequently drug uptake as well.
We subscribe to the concept that biologic adaptation centers the physiologic range
of skeletal muscle extensibility and operation on peak contractile performance at optimal
length to maximize contractile effectiveness during locomotion and postural stability. In
contrast, biologic adaptation grants the greatest evolutionary advantage to an organ as
vital to survival as the heart by setting its physiologic range of contractile performance on
the ascending half of the Frank-Starling curve to render an intrinsic robustness to
fluctuating volume status, maximizing the capacity of the heart to maintain circulatory
homeostasis. As a consequence, we hypothesize the biologic significance of operating on
the ascending portion of the porosity curve, which peaks with contractile performance at
equilibrium volume, is to provide a structurally mediated functional reserve in coronary
blood flow rate that is robust to the energetic and metabolic demands of dynamic
contractile performance. Correlation of maximal drug penetration with optimal muscle
function through constitutive tissue porosity reflects biologic design that harmonizes the
reciprocal interaction between tissue and its physical environment. Architecturally and
functionally dictated optimal pharmacokinetic conditions suggest the existence of
potential therapeutic windows that correspond to unique setpoints in the physiologic
operating range of all target tissues and organs.
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4.5.6 Conclusions
Cardiac tissue presents an active pharmacokinetic environment in which drug
transport is influenced by the interrelated effects of architectural configuration and
functional mechanics. Architectural configuration, dictated by contractile tone and
intraventricular volume, enables maximal drug penetration in the equilibrium state devoid
of intrinsic material strain from either contractile tone or ventricular distension. Mural
configuration impacts drug permeability across different drug physicochemical and
binding properties. The dispersive effects of cyclic cardiac function enhance drug
penetration above architecturally defined transport. Correlation of maximal drug
penetration, tissue porosity, and LV functional efficiency elucidates the resonant nature
of cardiac muscle interaction with the physical environment. Such biologic design and
mechanisms not only elucidate the pharmacokinetic impact of functional cardiac
architecture, but also introduce new strategies for controlled drug delivery.
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5. CONCLUSIONS
Muscle tissue presents an exclusive transport environment in which dynamic,
mechanically active architecture may present a predominant influence on the
pharmacokinetics of locally delivered agents. The work described in this thesis used a
systematic approach to elucidate the mechanistic underpinnings and physiologic
significance of the impact of architectural configuration and its interaction with motion
and mechanical loading on intramuscular drug transport. Findings from this work have
elucidated a quantitative understanding of not only the pharmacokinetic role of muscle
mechanics such as structural strain, cyclic tension, and rhythmic contraction, but also the
integral function of tissue structural design in mediating both mechanical activity and the
pharmacokinetic environment within skeletal and cardiac physiologic paradigms.
The work in this thesis endeavored to develop a quantitative schema with which
to consider the mechanically influenced pharmacokinetic environment of skeletal and
cardiac muscle. Insights derived from this work have significant impact on not only
current knowledge of intramuscular pharmacokinetics, but also on understanding of
biologic design in general and the potential pharmacokinetic significance of functional
architecture in all target tissues. These insights further yield important implications for
drug transport investigations, which should now duly consider the pharmacokinetic
impact of the physiologic operational domain of its targeted tissues. Ultimately, we hope
the fundamental findings from this work on how mechanical forces govern drug transport
will contribute to the rational design, development, optimization, and clinical application
of clinical drug delivery strategies to dynamic tissue targets such as skeletal and cardiac
muscle.
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6. FUTURE WORK
The work in this thesis highlighted the relevant mechanical issues involved in
local intramuscular pharmacokinetics. The interactions between physicochemical and
binding properties of delivered drug, structural properties of targeted tissues, and
mechanical forces that these tissues sustain were quantitatively examined in the context
of local drug delivery. Findings on the pharmacokinetic influence of functional
architecture may ultimately provide insight on how drug transport associated with
physiologic mechanical loading paradigms subserves transport in structural and
mechanical dysfunction in the setting of muscular pathology and prompt the informed
investigation of such processes.
As local pharmacologic approaches for treating coronary heart disease and
peripheral arterial disease become realized and assessed in clinical trials, a detailed
understanding of local pharmacokinetics in targeted tissues becomes important. In the
clinical setting, tissue architecture and functional mechanics can undergo dramatic
changes in pathologic states such as ischemic injury. Thus, intramuscular
pharmacokinetics in the setting of ischemic dysfunction must be understood and further
investigated. Currently, no investigations have elucidated the impact of spatially
disrupted architecture and loading during ischemic pathology, which exhibits mechanical
strain gradients across ischemic border zones. Further pharmacokinetics investigations
using our experimental approach intend to determine the unique effects of
heterogeneously disrupted cardiac tissue structure and mechanical loading on
intramyocardial drug penetration and distribution. Ultimately, this work may provide a
better understanding of the clinically relevant transport environment of ischemic muscle.
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Pharmacokinetics in Ischemic Myocardium
The purpose of therapeutic angiogenesis in the heart is to restore blood supply and
normal performance to a poorly functioning ischemic myocardium. Thus, patients with
ischemic heart diseases with salvageable lesions such as hibernating myocardium or
acute coronary occlusions may likely benefit from therapeutic angiogenesis. However,
there exists no clear understanding of how to maximize myocardial distribution and
retention of angiogenic growth factors, or how to target specific sites of reversible
ischemia or ischemic "border zones." Therefore, the local transport forces predominating
in ischemic myocardium need to be understood.
A heart with ischemic tissue can present a very heterogeneous and disordered
mechanical loading environment for drug transport. In particular, there may be a region
of dysfunctionally contracting ischemic tissue adjacent to regions of normally contracting
healthy tissue. In these cases, the ischemic region may introduce variable degrees of
ventricular regional wall motion and thickening abnormalities that may occur with stress
and can be either reversible or progressive. As a result, the ischemic heart can present a
dramatically different and even more complicated mechanical loading environment
compared to the coordinated loading environment found in a healthy heart wall. And
since the goal of therapeutic angiogenesis is to deliver drugs to ischemic tissues, it is
vitally important to gain a clear understanding of the local transport forces exerted on a
drug by such a pathological tissue environment. This understanding may help to improve
drug delivery strategies for CAD because the wall motion heterogeneities experienced in
a heart with an ischemic lesion may substantially affect drug pharmacokinetics in, as of
yet, unanticipated ways. More importantly, the local motion heterogeneities surrounding
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a lesion, which stem from its very presence, may present the most significant local
transport forces for a drug that targets that lesion.
In myocardial ischemia, temporally disordered and spatially nonhomogeneous
dysfunction of both the ischemic and non-ischemic ventricular tissues occurs throughout
the contractile cycle. Within seconds of the sudden onset of severe myocardial ischemia
resulting from acute coronary occlusion, contractile function of the heart becomes
impaired. Systolic function in the ischemic segment, as detected by echocardiography,
can exhibit hypokinesia (depressed contractile function) or akinesia (absence of
contractile shortening) during ejection. After a prolonged period, there is left ventricular
dysfunction, or myocardial stunning. If the coronary obstruction is subtotal, the
contractile activity of the ischemic, yet viable, segment may remain akinetic. This results
in chronically ischemic or hibernating myocardium.
However, if there is complete coronary obstruction leading to transmural
ischemia, the impaired contractile shortening in the ischemic zone may progressively
worsen to dyskinesia within the first 30 minutes after the acute onset. In dyskinesia, the
injured tissue becomes compliant, displays greater local in-plane stretching and radial
thinning during diastolic filling, and bulges paradoxically during isovolumetric systolic
contraction. This is then followed by rapid recoiling of the stretched wall during
isovolumetric relaxation. As a result, total systolic function is depressed, and global
performance is altered. The adjacent non-ischemic myocardium compensates with
hyperkinetic contractility, which incorporates increased fiber lengths and augmented
shortening of normal segments, in order to sustain global ventricular function. The
dyskinesia also impairs ventricular relaxation, which decreases peak filling rate and
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increases preload on the non-ischemic heart muscle. This leads to increased wall strain
and dilation [228, 245, 246]. As a result, these global effects may alter the distribution
and transport of a drug to the ischemic lesion.
Moreover, segmental dyskinesia results in hypokinesia at the transitional margin
between the central ischemic segment and the non-ischemic myocardium. This creates a
functional border zone where contraction is reduced despite normal perfusion to the local
tissue. In this zone, tethering between perfused and under-perfused myocardium affects
the mechanics of both the inner and outer ventricular layers during systole. In the
subepicardium and midwall, end-systolic wall thickening, normal strain between mural
layers, and longitudinal shortening are decreased, while circumferential shear is
increased. In the subendocardium, systolic fiber stretch and end-systolic shear between
sheets are increased. Likewise, tethering at the border zone also affects the strains
experienced in diastole, during which there are increased lengthening and thinning strains
in response to the increased filling pressures and decreased peak filling rate [229].
Consequently, such characteristics of mechanical loading and strain in the ischemic
border zone can have a significant impact on the local pharmacokinetics of drugs targeted
to the ischemic segment.
Therefore, the heterogeneous and dramatically disrupted loading patterns caused
by an ischemic lesion can introduce distinct effects on drug transport. Some of these
enter simply as an escalation of physiological loading. For instance, hyperkinesia acts to
increase the degree of redistribution of interstitial space, wall strain, or buildup of
intramuscular pressure that is normally associated with physiologic contraction of the
ventricular wall. Other effects modulate physiological function. Hypokinesia and
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akinesia diminish the normal level of contraction while increasing the level of wall strain
in the ischemic zone. And, still other effects introduce an altogether rearranged loading
environment. For example, the ischemic border zone alters the strain patterns between
the subepicardium and subendocardium and generates potential strain gradients between
the ischemic and non-ischemic zones. The altered effect may influence the nature of
drug uptake at the border zone. Thus, it is important to determine the local effect on
transport caused by the juxtaposition of a zone with disrupted loading next to one with
physiologic loading. The relevant questions then are how will focal dysfunction of
mechanical loading patterns in the heart affect drug transport, and how will the border
zone between functional zones mediate drug uptake. Perhaps, impairment of interstitial
convection in akinetic regions may reduce drug transport into these regions. Or, focal
drug concentration gradients of drug may develop at the border zone between
functionally loaded and dysfunctionally loaded regions as a result of differential transport
forces. Elucidating these effects would enable us to build upon the present comparison of
transport in uniaxial and multiaxial loading environments to achieve a more complete
characterization of how mechanical loading conditions affect drug transport. Also, this
would enable us to synthesize a quantitative approach that not only extrapolates the
transport role that uniaxial loading plays in multiaxial loading, but also defines how
transport associated with both loading paradigms underlies the transport in a disrupted
loading environment such as ischemic myocardium. Ultimately, this framework would
give us a better understanding of the relevant transport environment experienced by
growth factors targeted to ischemic lesions in the clinical setting.
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* Specific Aim:
Regional ischemia results in local dysfunction of the mechanical loading pattern
in the ventricular wall. This dysfunction leads to locally irregular convective forces and
interstitial space variations that may modulate the transport of drug to the ischemic
region. Thus, this study seeks to determine how penetration and local distribution of
epicardially delivered drug is influenced by regional wall motion abnormalities
resulting from acute ischemia. This will provide a better understanding of the transport
environment resulting from a steep gradient of mechanical loading between functional
and dysfunctional muscle.
* Methods:
Pharmacokinetic Effects of Mechanical Loadingz and Coronary Blood Flow in Cardiac
Muscle
The pharmacokinetic impact of mechanical loading was compared to that of
coronary flow by investigating epicardial drug penetration into the LV of in vivo beating
rat hearts, control in situ hearts that were not beating but were receiving coronary
perfusion, and control in situ hearts that were not beating and not receiving coronary
perfusion.
Male Sprague-Dawley rats (600-800 g) were anesthetized by an induction dose of
80 mg/kg Ketamine and 10 mg/kg Xylazine via intraperitoneal injection, and
maintenance doses of 40 mg/kg Ketamine and 5 mg/kg Xylazine every 20 min.
For the beating heart experiment group, the rat was intubated with a 2.0 mm
endotracheal tube for positive pressure ventilation with 02 at a rate of 72 breaths/min and
tidal volume of 2.7 ml. Thoracotomy was performed with minimal bleeding by a midline
146
incision from the xiphoid process to just inferior of the suprasternal notch. The ribcage
was held open by an Aim retractor, and the pericardial sac was resected to expose the
beating heart. The left carotid artery was cannulated with PE50 tubing connected to a
blood pressure transducer and base amplifier (Blood Pressure XDCR and XDCR Base
Amplifier, Kent Scientific). Pressure signals were acquired using a National Instruments
DAQPAD-6015 data acquisition board and recorded with LabView 7.0. Heart rate
averaging 180 BPM and blood pressure between 90-120 mmHg were recorded
throughout the surgical procedure and duration of drug delivery.
For the in situ non-beating heart control groups, rats were euthanized by
Ketamine and Xylazine via intraperitoneal injection. Thoracotomy was performed and
the pericardial sac was resected to expose the passive heart. For hearts receiving
coronary perfusion, the superior vena cava and pulmonary artery were ligated, the aorta
was cannulated, and the coronary vasculature was retrogradely perfused by bovine serum
(Gibco) maintained at a constant pressure head of 100 mmHg and a temperature of 37*C
by heat exchanger. Outflow from the inferior vena cava was collected. For hearts
receiving no coronary perfusion, the aorta was cannulated and the coronary vasculature
was retrogradely flushed with bovine serum. Immediately after coronary blood was
cleared from the vasculature, coronary outflow was stopped by clamping both the right
atria and pulmonary artery to allow the coronary vasculature to remain open but without
the presence of perfusion flow.
In all groups, the rat was laid in a prostrate position on an elevated platform with
a rectangular opening for access to the thoracic cavity. The heart was allowed to hang
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through the opening and sit in a reservoir containing 961 Da Evans Blue dye (1% w/v in
PBS) for 1 h. This position did not alter heart rate or blood pressure in beating hearts.
A cylindrical plug of LV myocardium was harvested from each group using an 8
mm-diameter biopsy punch (Miltex Instrument Company). Tissue samples were snap-
frozen in -145°C Isopentane. 8 gm cross-sections were cut on a radial plane from tissue
plugs using a cryostat (Leica CM1850). Evans Blue dye in tissue sections was imaged
using epifluorescence microscopy (Leica DMRA2, 50x magnification, Hamamatsu
ORCA 286, Metamorph 6.3, ex: 560 nm / em: 645 nm bandpass). Unidirectional drug
penetration at the epicardial surface of the cross-section was quantified in Matlab.
Intramuscular penetration depth was defined as the perpendicular distance from the
surface at which fluorescence intensity decreased to 5% of the surface intensity.
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Figure 6.1. Effects of cardiac beating and coronary flow on penetration of Evans Blue into
the LV. Penetration at baseline ("no" contraction, "no" flow) is reduced by the presence of
coronary flow ("no" contraction, "yes" flow), suggesting drug is possibly convected away
from myocardial tissue via coronary perfusion. Penetration is enhanced by contractile
beating at 144 BPM ("yes" contraction, "yes" flow), suggesting dynamic mechanical loading
resulting from myocardial contraction and distension during the cardiac cycle increases
drug transport. Because in vivo cardiac beating naturally includes physiologic coronary
flow, the pharmacokinetic impact of contractile function to enhance drug penetration
appears to outweigh that of coronary flow to remove drug from the tissue.
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Figure 6.2. LV drug penetration profiles (A) in the absence of either contraction or
coronary perfusion (No Contraction : No Flow), (B) in the presence of coronary perfusion
without contractile function (No Contraction : Flow), and (C) in the presence of both
contractile function and coronary flow (Contraction : Flow). In both groups A and B, drug
concentration experiences a sharp drop in concentration, while in group C, the effect of
mechanical loading appears to dampen this sudden drop, resulting in a greater spread of
penetrating drug into the tissue.
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Figure 6.3. Total drug deposition, calculated from the area under the drug penetration
profile, for each group corresponds with drug penetration depth.
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Coronary Ligation
A surgical technique for creating acute myocardial ischemia in the LV of rat heart
will be used. The distal left anterior descending (LAD) coronary artery will be ligated to
induce local ischemia and disrupt regional wall motion and mechanics (Figure 6.4).
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Figure 6.4. Coronary ligation. Ligation of the LAD results in ventricular regional loss of
perfusion and regional wall motion abnormalities.
Echocardiography
Echocardiography using a SONOS 5500 (Agilent) Ultrasound system will be
performed to assess left ventricular chamber size and wall thickness changes on the
ventricular short-axis during diastole and systole (Figure 6.5). Regional wall motion
abnormalities that results from acute ischemia will be characterized.
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Figure 6.5. Echocardhographic quantllcatlon ot caranac wan motion.
These experiments will correlate the uptake and distribution of 20 kDa FITC-
dextran with the presence of regional wall thickening abnormalities associated with the
onset of acute ischemia. Delivery of FITC-dextran will be performed as described for
previous myocardial experiments, with the additional step of coronary ligation. Drug
distribution will be visualized by epifluorescence microscopy in short-axis cross-sections
of the ventricular chamber in order to quantify distribution in both the radial and
circumferential directions. Regional ischemia will be histologically quantified in short-
axis cross-sections by tetrazolium stain and correlated to both echocardiographic
assessment of wall motion and fluorescent assessment of drug distribution. Special
interest will be directed toward drug deposition around the ischemic border zone.
151
7. REFERENCES
1. Heart Disease and Stroke Statistics: 2008 Update. 2008, American Heart
Association: Dallas, TX 75231.
2. Ness, J., et al., Prevalence of symptomatic peripheral arterial disease, modifiable
risk factors, and appropriate use of drugs in the treatment ofperipheral arterial
disease in older persons seen in a university general medicine clinic. J Gerontol A
Biol Sci Med Sci, 2005. 60(2): p. 255-7.
3. Criqui, M.H., et al., Mortality over a period of 10 years in patients with
peripheral arterial disease. N Engl J Med, 1992. 326(6): p. 381-6.
4. Shamoun, F., N. Sural, and G. Abela, Peripheral artery disease: therapeutic
advances. Expert Rev Cardiovasc Ther, 2008. 6(4): p. 539-53.
5. Levy, P.J., Epidemiology and pathophysiology ofperipheral arterial disease. Clin
Cornerstone, 2002. 4(5): p. 1-15.
6. Mukherjee, D., et al., Direct myocardial revascularization and angiogenesis--how
many patients might be eligible? Am J Cardiol, 1999. 84(5): p. 598-600, A8.
7. Hughes, G.C. and B.H. Annex, Angiogenic therapy for coronary artery and
peripheral arterial disease. Expert Rev Cardiovasc Ther, 2005. 3(3): p. 521-35.
8. Kornowski, R., Collateral formation and clinical variables in obstructive
coronary artery disease: the influence of hypercholesterolemia and diabetes
mellitus. Coron Artery Dis, 2003. 14(1): p. 61-4.
9. Svet-Moldavsky, G.J. and K.L. Chimishkyan, Tumour angiogenesis factorfor
revascularisation in ischaemia and myocardial infarction. Lancet, 1977. 1(8017):
p. 913.
10. Carmeliet, P., Angiogenesis in health and disease. Nat Med, 2003. 9(6): p. 653-
60.
11. Simons, M., Integrative signaling in angiogenesis. Mol Cell Biochem, 2004.
264(1-2): p. 99-102.
12. Pepper, M.S., et al., Potent synergism between vascular endothelial growth factor
and basic fibroblast growth factor in the induction of angiogenesis in vitro.
Biochem Biophys Res Commun, 1992. 189(2): p. 824-31.
13. Folkman, J. and C. Haudenschild, Angiogenesis in vitro. Nature, 1980. 288(5791):
p. 551-6.
14. Montesano, R., et al., Basic fibroblast growth factor induces angiogenesis in
vitro. Proc Natl Acad Sci U S A, 1986. 83(19): p. 7297-301.
15. Schumacher, B., et al., The stimulation of neo-angiogenesis in the ischemic heart
by the human growth factor FGF. J Cardiovasc Surg (Torino), 1998. 39(4): p.
445-53.
16. Akimoto, T. and M.R. Hammerman, Fibroblast growth factor 2 promotes
microvessel formation from mouse embryonic aorta. Am J Physiol Cell Physiol,
2003. 284(2): p. C371-7.
17. Bikfalvi, A., et al., Biological roles offibroblast growth factor-2. Endocr Rev,
1997. 18(1): p. 26-45.
18. Harada, K., et al., Vascular endothelial growth factor administration in chronic
myocardial ischemia. Am J Physiol, 1996. 270(5 Pt 2): p. H1791-802.
152
19. Walder, C.E., et al., Vascular endothelial growth factor augments muscle blood
flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc
Pharmacol, 1996. 27(1): p. 91-8.
20. Hopkins, S.P., et al., Controlled delivery of vascular endothelial growth factor
promotes neovascularization and maintains limb function in a rabbit model of
ischemia. J Vase Surg, 1998. 27(5): p. 886-94; discussion 895.
21. Lopez, J.J., et al., VEGF administration in chronic myocardial ischemia in pigs.
Cardiovasc Res, 1998. 40(2): p. 272-81.
22. Chleboun, J.O., et al., bFGF enhances the development of the collateral
circulation after acute arterial occlusion. Biochem Biophys Res Commun, 1992.
185(2): p. 510-6.
23. Unger, E.F., et al., Basic fibroblast growth factor enhances myocardial collateral
flow in a canine model. Am J Physiol, 1994. 266(4 Pt 2): p. 111588-95.
24. Lazarous, D.F., et al., Effects of chronic systemic administration of basic
fibroblast growth factor on collateral development in the canine heart.
Circulation, 1995. 91(1): p. 145-53.
25. Yang, H.T., et al., Basic fibroblast growth factor increases collateral blood flow
in rats with femoral arterial ligation. Circ Res, 1996. 79(1): p. 62-9.
26. Lopez, J.J., et al., Basic fibroblast growth factor in a porcine model of chronic
myocardial ischemia: a comparison of angiographic, echocardiographic and
coronary flow parameters. J Pharmacol Exp Ther, 1997. 282(1): p. 385-90.
27. Watanabe, E., et al., Effect of basic fibroblast growth factor on angiogenesis in
the infarcted porcine heart. Basic Res Cardiol, 1998. 93(1): p. 30-7.
28. Rajanayagam, M.A., et al., Intracoronary basic fibroblast growth factor enhances
myocardial collateral perfusion in dogs. J Am Coll Cardiol, 2000. 35(2): p. 519-
26.
29. von Degenfeld, G., et al., Selective pressure-regulated retroinfusion offibroblast
growth factor-2 into the coronary vein enhances regional myocardial blood flow
and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol, 2003.
42(6): p. 1120-8.
30. Schumacher, B., et al., Induction of neoangiogenesis in ischemic myocardium by
human growth factors: first clinical results ofa new treatment of coronary heart
disease. Circulation, 1998. 97(7): p. 645-50.
31. Laham, R.J., et al., Local perivascular delivery of basic fibroblast growth factor
in patients undergoing coronary bypass surgery: results of a phase I randomized,
double-blind, placebo-controlled trial. Circulation, 1999. 100(18): p. 1865-71.
32. Ruel, M., et al., Long-term effects of surgical angiogenic therapy with fibroblast
growth factor 2 protein. J Thorac Cardiovasc Surg, 2002. 124(1): p. 28-34.
33. Hendel, R.C., et al., Effect of intracoronary recombinant human vascular
endothelial growth factor on myocardial perfusion: evidence for a dose-
dependent effect. Circulation, 2000. 101(2): p. 118-21.
34. Laham, R.J., et al., Intracoronary basic fibroblast growth factor (FGF-2) in
patients with severe ischemic heart disease: results of a phase I open-label dose
escalation study. J Am Coll Cardiol, 2000. 36(7): p. 2132-9.
35. Pecher, P. and B.A. Schumacher, Angiogenesis in ischemic human myocardium:
clinical results after 3 years. Ann Thorac Surg, 2000. 69(5): p. 1414-9.
153
36. Udelson, J.E., et al., Therapeutic angiogenesis with recombinantfibroblast
growth factor-2 improves stress and rest myocardial perfusion abnormalities in
patients with severe symptomatic chronic coronary artery disease. Circulation,
2000. 102(14): p. 1605-10.
37. Unger, E.F., et al., Effects of a single intracoronary injection of basicfibroblast
growth factor in stable angina pectoris. Am J Cardiol, 2000. 85(12): p. 1414-9.
38. Henry, T.D., et al., Intracoronary administration of recombinant human vascular
endothelial growth factor to patients with coronary artery disease. Am Heart J,
2001. 142(5): p. 872-80.
39. Simons, M., et al., Pharmacological treatment of coronary artery disease with
recombinant fibroblast growth factor-2: double-blind, randomized, controlled
clinical trial. Circulation, 2002. 105(7): p. 788-93.
40. Lederman, R.J., et al., Therapeutic angiogenesis with recombinantfibroblast
growth factor-2for intermittent claudication (the TRAFFIC study): a randomised
trial. Lancet, 2002. 359(9323): p. 2053-8.
41. Rajagopalan, S., et al., Regional angiogenesis with vascular endothelial growth
factor in peripheral arterial disease: a phase II randomized, double-blind,
controlled study of adenoviral delivery of vascular endothelial growth factor 121
in patients with disabling intermittent claudication. Circulation, 2003. 108(16): p.
1933-8.
42. Isner, J.M., et al., Treatment of thromboangiitis obliterans (Buerger's disease) by
intramuscular gene transfer of vascular endothelial growth factor: preliminary
clinical results. J Vasc Surg, 1998. 28(6): p. 964-73; discussion 73-5.
43. Baumgartner, I., et al., Constitutive expression ofphVEGF165 after intramuscular
gene transfer promotes collateral vessel development in patients with critical limb
ischemia. Circulation, 1998. 97(12): p. 1114-23.
44. Shyu, K.G., et al., Intramuscular vascular endothelial growth factor gene therapy
in patients with chronic critical leg ischemia. American Journal of Medicine,
2003. 114(2): p. 85-92.
45. Cooper, L.T., Jr., et al., Proteinuria in a placebo-controlled study of basic
fibroblast growth factor for intermittent claudication. Vase Med, 2001. 6(4): p.
235-9.
46. Lazarous, D.F., et al., Pharmacodynamics of basicfibroblast growth factor: route
of administration determines myocardial and systemic distribution. Cardiovasc
Res, 1997. 36(1): p. 78-85.
47. Laham, R.J., et al., Therapeutic Angiogenesis Using Basic Fibroblast Growth
Factor and Vascular Endothelial Growth Factor Using Various Delivery
Strategies. Curr Interv Cardiol Rep, 1999. 1(3): p. 228-233.
48. Nakajima, H., et al., Therapeutic angiogenesis by the controlled release of basic
fibroblast growth factor for ischemic limb and heart injury: toward safety and
minimal invasiveness. Journal of Artificial Organs, 2004. 7(2): p. 58-61.
49. Davda, J. and V. Labhasetwar, An update on angiogenesis therapy. Crit Rev
Eukaryot Gene Expr, 2001. 11(1-3): p. 1-21.
50. Lopez, J.J., et al., Angiogenic potential ofperivascularly delivered aFGF in a
porcine model of chronic myocardial ischemia. Am J Physiol, 1998. 274(3 Pt 2):
p. H930-6.
154
51. Zisch, A.H., M.P. Lutolf, and J.A. Hubbell, Biopolymeric delivery matrices for
angiogenic growth factors. Cardiovascular Pathology, 2003. 12(6): p. 295-310.
52. Laham, R.J., M. Rezaee, and L. Garcia, Tissue and Myocardial Distribution of
Intracoronary, Intravenous, Intrapericardial, and Intramyocardial 1251-labeled
basic fibroblast growth factor (bFGF) favor intramyocardial delivery. Journal of
the American College of Cardiology, 2000. 35: p. 10A. Abstract.
53. Laham, R.J., et al., Intrapericardial administration ofbasicfibroblast growth
factor: myocardial and tissue distribution and comparison with intracoronary
and intravenous administration. Catheter Cardiovasc Interv, 2003. 58(3): p. 375-
81.
54. Celletti, F.L., et al., Vascular endothelial growth factor enhances atherosclerotic
plaque progression. Nature Medicine, 2001. 7(4): p. 425-9.
55. Nabel, E.G., et al., Recombinant fibroblast growth factor-i promotes intimal
hyperplasia and angiogenesis in arteries in vivo. Nature, 1993. 362(6423): p.
844-6.
56. Gonzalez, A.M., et al., Distribution of basicfibroblast growth factor in the 18-day
rat fetus: localization in the basement membranes of diverse tissues. J Cell Biol,
1990. 110(3): p. 753-65.
57. Vlodavsky, I., et al., Endothelial cell-derived basic fibroblast growth factor:
synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad
Sci U S A, 1987. 84(8): p. 2292-6.
58. Kanematsu, A., et al., Type I collagen can function as a reservoir of basic
fibroblast growth factor. J Control Release, 2004. 99(2): p. 281-92.
59. Presta, M., et al., Fibroblast growth factor/fibroblast growth factor receptor
system in angiogenesis. Cytokine Growth Factor Rev, 2005. 16(2): p. 159-78.
60. Coughlin, S.R., et al., Acidic and basic fibroblast growth factors stimulate
tyrosine kinase activity in vivo. J Biol Chem, 1988. 263(2): p. 988-93.
61. Moscatelli, D., High and low affinity binding sites for basic fibroblast growth
factor on cultured cells: absence of a role for low affinity binding in the
stimulation ofplasminogen activator production by bovine capillary endothelial
cells. J Cell Physiol, 1987. 131(1): p. 123-30.
62. Colin, S., et al., In vivo involvement of heparan sulfate proteoglycan in the
bioavailability, internalization, and catabolism of exogenous basic fibroblast
growth factor. Mol Pharmacol, 1999. 55(1): p. 74-82.
63. Damon, D.H., et al., Heparin potentiates the action ofacidicfibroblast growth
factor by prolonging its biological half-life. J Cell Physiol, 1989. 138(2): p. 221-
6.
64. Mueller, S.N., et al., Stabilization by heparin of acidicfibroblast growth factor
mitogenicity for human endothelial cells in vitro. J Cell Physiol, 1989. 140(3): p.
439-48.
65. Schonherr, E. and H.J. Hausser, Extracellular matrix and cytokines: a functional
unit. Dev Immunol, 2000. 7(2-4): p. 89-101.
66. Bashkin, P., et al., Basic fibroblast growth factor binds to subendothelial
extracellular matrix and is released by heparitinase and heparin-like molecules.
Biochemistry, 1989. 28(4): p. 1737-43.
155
67. Saksela, O., et al., Endothelial cell-derived heparan sulfate binds basic fibroblast
growth factor and protects it from proteolytic degradation. J Cell Biol, 1988.
107(2): p. 743-51.
68. Flaumenhaft, R., D. Moscatelli, and D.B. Rifkin, Heparin and heparan sulfate
increase the radius of diffusion and action of basicfibroblast growth factor. J Cell
Biol, 1990. 111(4): p. 1651-9.
69. Sellke, F.W., et al., Enhanced microvascular relaxations to VEGF and bFGF in
chronically ischemic porcine myocardium. Am J Physiol, 1996. 271(2 Pt 2): p.
H713-20.
70. Ray, P.S., et al., Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2
and their receptors in the rat myocardium: implications for myocardial
angiogenesis. Mol Cell Biochem, 2000. 213(1-2): p. 145-53.
71. Xu, X., et al., Expression of vascular endothelial growth factor and its receptors
is increased, but microvascular relaxation is impaired in patients after acute
myocardial ischemia. J Thorac Cardiovasc Surg, 2001. 121(4): p. 735-42.
72. Li, J., et al., Macrophage-dependent regulation ofsyndecan gene expression. Circ
Res, 1997. 81(5): p. 785-96.
73. Nakahama, M., et al., Expression ofperlecan proteoglycan in the infarct zone of
mouse myocardial infarction. J Mol Cell Cardiol, 2000. 32(6): p. 1087-100.
74. Li, J., et al., VEGF, flk-1, and flt-I expression in a rat myocardial infarction
model ofangiogenesis. Am J Physiol, 1996. 270(5 Pt 2): p. H1803-11.
75. Rissanen, T.T., et al., Expression of vascular endothelial growth factor and
vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal
muscle and its regeneration. Am J Pathol, 2002. 160(4): p. 1393-403.
76. Meyer, G., R. Merval, and A. Tedgui, Effects ofpressure-induced stretch and
convection on low-density lipoprotein and albumin uptake in the rabbit aortic
wall. Circ Res, 1996. 79(3): p. 532-40.
77. Han, S., et al., Changes in ADC caused by tensile loading of rabbit achilles
tendon: evidence for water transport. Journal of Magnetic Resonance, 2000.
144(2): p. 217-27.
78. Quinn, T.M., V. Morel, and J.J. Meister, Static compression of articular cartilage
can reduce solute diffusivity and partitioning: implications for the chondrocyte
biological response. Journal of Biomechanics, 2001. 34(11): p. 1463-9.
79. Quinn, T.M., et al., Preservation and analysis of nonequilibrium solute
concentration distributions within mechanically compressed cartilage explants. J
Biochem Biophys Methods, 2002. 52(2): p. 83-95.
80. Burstein, D., et al., Diffusion of small solutes in cartilage as measured by nuclear
magnetic resonance (NMR) spectroscopy and imaging. J Orthop Res, 1993. 11(4):
p. 465-78.
81. Bonassar, L.J., et al., Mechanical and physicochemical regulation of the action of
insulin-like growth factor-I on articular cartilage. Arch Biochem Biophys, 2000.
379(1): p. 57-63.
82. Papadopoulos, S., K.D. Jurgens, and G. Gros, Protein diffusion in living skeletal
muscle fibers: dependence on protein size, fiber type, and contraction.
Biophysical Journal, 2000. 79(4): p. 2084-94.
156
83. Constable, S.H., et al., Muscle glucose transport: interactions of in vitro
contractions, insulin, and exercise. Journal of Applied Physiology, 1988. 64(6): p.
2329-32.
84. Holloszy, J.O. and H.T. Narahara, Studies of tissue permeability. X Changes in
permeability to 3-methylglucose associated with contraction of isolated frog
muscle. Journal of Biological Chemistry, 1965. 240(9): p. 3493-500.
85. Cho, K.W., et al., Mechanical control of extracellular space in rabbit atria: an
intimate modulator of the translocation of extracellular fluid and released atrial
natriureticpeptide. Exp Physiol, 2002. 87(2): p. 185-94.
86. Page, E., J. Upshaw-Earley, and G. Goings, Permeability of rat atrial
endocardium, epicardium, and myocardium to large molecules. Stretch-dependent
effects. Circ Res, 1992. 71(1): p. 159-73.
87. Cappelli, V., et al., Inulin uptake and washout in contracting and quiescent rat
papillary muscle. Arch. Int. Physiol. Biochim., 1982. 90(4): p. 231-6.
88. Zechner, C., F. Beyersdorf, and T. Doenst, The role of calcium in the regulation
of glucose uptake in isolated working rat heart. Mol Cell Biochem, 2002. 232(1-
2): p. 75-80.
89. Young, D.A., Factors controlling the washout of the interstitial space of the
isolated, perfused rat heart. J Physiol, 1968. 196(3): p. 747-59.
90. Aslesen, R., et al., Glucose uptake and metabolic stress in rat muscles stimulated
electrically with different protocols. Journal of Applied Physiology, 2001. 91(3):
p. 1237-44.
91. Gissel, H. and T. Clausen, Excitation-induced Ca(2+) influx in rat soleus and
EDL muscle: mechanisms and effects on cellular integrity. American Journal of
Physiology: Regulatory, Integrative and Comparative Physiology, 2000. 279(3):
p. R917-R924.
92. Abraham, K.A. and R.L. Terjung, Phosphate uptake in rat skeletal muscle is
reduced during isometric contractions. Journal of Applied Physiology, 2004.
97(1): p. 57-62.
93. Abel, E.D., Glucose transport in the heart. Front Biosci, 2004. 9: p. 201-15.
94. Ihlemann, J., T. Ploug, and H. Galbo, Effect offorce development on contraction
induced glucose transport in fast twitch rat muscle. Acta Physiologica
Scandinavica, 2001. 171(4): p. 439-44.
95. Ihlemann, J., et al., Effect of tension on contraction-induced glucose transport in
rat skeletal muscle. American Journal of Physiology: Endocrinology and
Metabolism, 1999. 277(2 Pt 1): p. E208-E214.
96. Ihlemann, J., et al., Effect of stimulation frequency on contraction-induced
glucose transport in rat skeletal muscle. American Journal of Physiology:
Endocrinology and Metabolism, 2000. 279(4): p. E862-E867.
97. Nara, E., et al., Contribution of interstitial diffusion in drug absorption from
perfused rabbit muscle: effect of hyaluronidase on absorption. Chemical &
Pharmaceutical Bulletin, 1992. 40(3): p. 737-40.
98. Segal, S.S., T.P. White, and J.A. Faulkner, Architecture, composition, and
contractile properties of rat soleus muscle grafts. Am J Physiol, 1986. 250(3 Pt
1): p. C474-9.
157
99. McComas, A.J., Skeletal Muscle: Form and Function. 1996, Champaign, IL:
Human Kinetics.
100. Borg, T.K. and J.B. Caulfield, Morphology of connective tissue in skeletal muscle.
Tissue Cell, 1980. 12(1): p. 197-207.
101. DiMario, J., et al., Fibroblast growth factor in the extracellular matrix of
dystrophic (mdx) mouse muscle. Science, 1989. 244(4905): p. 688-90.
102. Jarvinen, T.A., et al., Organization and distribution of intramuscular connective
tissue in normal and immobilized skeletal muscles. An immunohistochemical,
polarization and scanning electron microscopic study. Journal of Muscle
Research and Cell Motility, 2002. 23(3): p. 245-54.
103. Purslow, P.P., Strain-induced reorientation of an intramuscular connective tissue
network: implications for passive muscle elasticity. Journal of Biomechanics,
1989. 22(1): p. 21-31.
104. Purslow, P.P. and J.A. Trotter, The morphology and mechanical properties of
endomysium in series-fibred muscles: variations with muscle length. Journal of
Muscle Research and Cell Motility, 1994. 15(3): p. 299-308.
105. Williams, P.E. and G. Goldspink, Connective tissue changes in immobilised
muscle. Journal of Anatomy, 1984. 138 (Pt 2): p. 343-50.
106. Willems, M.E. and P.A. Huijing, Mechanical and geometrical properties of the
rat semimembranosus lateralis muscle during isometric contractions. Journal of
Biomechanics, 1994. 27(9): p. 1109-18.
107. Trombitas, K., et al., Contraction-induced movements of water in single fibres of
frog skeletal muscle. Journal of Muscle Research and Cell Motility, 1993. 14(6):
p. 573-84.
108. Canale, E.D., et al., Cardiac Muscle. 1986, New York: Springer-Verlag.
109. Brecher, G.A. and P.M. Galletti, Functional Anatomy of Cardiac Pumping, in
Handbook of Physiology, Section II, Circulation, Volume II, W.F. Hamilton and
P. Dow, Editors. 1963, American Physiological Society: Baltimore, MD.
110. Hunter, P., M. Nash, and G. Sands, Computational Electromechanics of the
Heart, in Computational Biology of the Heart, A.V. Panfilov and A.V. Holden,
Editors. 1997, Wiley & Sons: U.K.
111. Young, A.A., et al., Extended confocal microscopy of myocardial laminae and
collagen network. J Microsc, 1998. 192 (Pt 2): p. 139-50.
112. Caulfield, J.B. and T.K. Borg, The collagen network of the heart. Lab Invest,
1979. 40(3): p. 364-72.
113. MacKenna, D.A., J.H. Omens, and J.W. Covell, Left ventricular perimysial
collagen fibers uncoil rather than stretch during diastolic filling. Basic Res
Cardiol, 1996. 91(2): p. 111-22.
114. Factor, S.M., et al., The effects of acutely increased ventricular cavity pressure on
intrinsic myocardial connective tissue. J Am Coll Cardiol, 1988. 12(6): p. 1582-9.
115. Waldman, L.K., et al., Relation between transmural deformation and local
myofiber direction in canine left ventricle. Circ Res, 1988. 63(3): p. 550-62.
116. Ashikaga, H., et al., Transmural left ventricular mechanics underlying torsional
recoil during relaxation. Am J Physiol Heart Circ Physiol, 2004. 286(2): p. H640-
7.
158
117. Tischler, M. and J. Niggel, Left ventricular systolic torsion and exercise in normal
hearts. J Am Soc Echocardiogr, 2003. 16(6): p. 670-4.
118. Takayama, Y., K.D. Costa, and J.W. Covell, Contribution of laminar myofiber
architecture to load-dependent changes in mechanics ofLV myocardium. Am J
Physiol Heart Circ Physiol, 2002. 282(4): p. H1510-20.
119. Harrington, K.B., et al., Direct measurement of transmural laminar architecture
in the anterolateral wall of the ovine left ventricle: new implications for wall
thickening mechanics. Am J Physiol Heart Circ Physiol, 2005. 288(3): p. H1324-
30.
120. Sinusas, A.J., et al., Quantification of 3-D regional myocardial deformation:
shape-based analysis of magnetic resonance images. Am J Physiol Heart Circ
Physiol, 2001. 281(2): p. H698-714.
121. Cheng, A., et al., Transmural cardiac strains in the lateral wall of the ovine left
ventricle. Am J Physiol Heart Circ Physiol, 2005. 288(4): p. H1546-56.
122. Sreter, F.A., Distribution of water, sodium, and potassium in resting and
stimulated mammalian muscle. Canadian Journal of Biochemistry and
Physiology, 1963. 41: p. 1035-45.
123. Huang, C.Y. and W.Y. Gu, Effects of tension-compression nonlinearity on solute
transport in charged hydrated fibrous tissues under dynamic unconfined
compression. Journal of Biomechanical Engineering, 2007. 129(3): p. 423-9.
124. Helmer, K.G., et al., Water movement in tendon in response to a repeated static
tensile load using one-dimensional magnetic resonance imaging. Journal of
Biomechanical Engineering, 2006. 128(5): p. 733-41.
125. Fry, D.L., R.W. Mahley, and S.Y. Oh, Effect of arterial stretch on transmural
albumin and Evan's blue dye transport. American Journal of Physiology: Heart
and Circulatory Physiology, 1981. 240(4): p. H645-H649.
126. Epstein, S.E., et al., Therapeutic interventions for enhancing collateral
development by administration of growth factors: basic principles, early results
and potential hazards. Cardiovascular Research, 2001. 49(3): p. 532-42.
127. Ettema, G.J., Mechanical behaviour of rat skeletal muscle during fatiguing
stretch-shortening cycles. Experimental Physiology, 1997. 82(1): p. 107-19.
128. Ettema, G.J., J.T. Goh, and M.R. Forwood, A new method to measure elastic
properties ofplastic-viscoelastic connective tissue. Medical Engineering and
Physics, 1998. 20(4): p. 308-14.
129. Loeffler, L., 3rd and K. Sagawa, A one-dimensional viscoelastic model of cat
heart muscle studied by small length perturbations during isometric contraction.
Circulation Research, 1975. 36(4): p. 498-512.
130. Templeton, G.H., et al., Dynamic stiffness ofpapillary muscle during contraction
and relaxation. American Journal of Physiology, 1973. 224(3): p. 692-8.
131. Segal, S.S. and J.A. Faulkner, Temperature-dependent physiological stability of
rat skeletal muscle in vitro. American Journal of Physiology: Cell Physiology,
1985. 248(3 Pt 1): p. C265-C270.
132. Petrofsky, J.S. and A.R. Lind, The influence of temperature on the isometric
characteristics offast and slow muscle in the cat. PfliUgers Archiv: European
Journal of Physiology, 1981. 389(2): p. 149-54.
159
133. Blomstrand, E., L. Larsson, and L. Edstrom, Contractile properties, fatiguability
and glycolytic metabolism in fast- and slow-twitch rat skeletal muscles of various
temperatures. Acta Physiologica Scandinavica, 1985. 125(2): p. 235-43.
134. Osman, F.H., J.L. Munson, and D.M. Paton, Estimation of extracellular space in
rabbit detrusor muscle. Comp Biochem Physiol A, 1971. 40(1): p. 45-54.
135. Rutili, G. and K.E. Arfors, Fluorescein-labelled dextran measurement in
interstitialfluid in studies of macromolecular permeability. Microvascular
Research, 1976. 12(2): p. 221-30.
136. Elmquist, S., et al., Dextrans as markers for endocytosis in innervated and
denervated skeletal muscle. Muscle Nerve, 1992. 15(8): p. 876-84.
137. Lovich, M.A. and E.R. Edelman, Tissue average binding and equilibrium
distribution: an example with heparin in arterial tissues. Biophysical Journal,
1996. 70(3): p. 1553-9.
138. Mehvar, R., Dextrans for targeted and sustained delivery of therapeutic and
imaging agents. Journal of Controlled Release, 2000. 69(1): p. 1-25.
139. Schroder, U., K.E. Arfors, and 0. Tangen, Stability offluorescein labeled
dextrans in vivo and in vitro. Microvascular Research, 1976. 11(1): p. 57-66.
140. Pringsheim, P., Fluorescence and Phosphorescence. 1963, New York:
Interscience Publishers, Inc. p. 347.
141. Ryall, J.G., et al., Beta 2-agonist fenoterol has greater effects on contractile
function of rat skeletal muscles than clenbuterol. American Journal of
Physiology: Regulatory, Integrative and Comparative Physiology, 2002. 283(6):
p. R1386-R1394.
142. Rankin, L.L., et al., Coexistence of twitch potentiation and tetanic force decline in
rat hindlimb muscle. Journal of Applied Physiology, 1988. 65(6): p. 2687-95.
143. Cappelli, V., et al., Tritiated water (HTO) and inulin spaces in isolated skeletal
and cardiac muscles: influence of contractile activity. Experientia, 1981. 37(8): p.
849-50.
144. Creese, R., J.L. D'Silva, and S.E. Hashish, Inulin space andfibre size of
stimulated rat muscle. Journal of Physiology, 1955. 127(3): p. 525-32.
145. Ward, D.S., M.T. Hamilton, and P.D. Watson, Measurement of tissue volume
during non-steady state high-intensity muscle contraction. American Journal of
Physiology: Regulatory, Integrative and Comparative Physiology, 1996. 271(6 Pt
2): p. R1682-R1690.
146. Baker, C.H. and D.L. Davis, Isolated skeletal muscle blood flow and volume
changes during contractile activity. Blood Vessels, 1974. 11(1-2): p. 32-44.
147. Sreter, F.A., Cell Water, Sodium, And Potassium In Stimulated Red And White
Mammalian Muscles. American Journal of Physiology, 1963. 205: p. 1295-1298.
148. McDermott, J.C. and A. Bonen, Lactate transport in rat sarcolemmal vesicles and
intact skeletal muscle, and after muscle contraction. Acta Physiologica
Scandinavica, 1994. 151(1): p. 17-28.
149. Gissel, H. and T. Clausen, Excitation-induced Ca2+ uptake in rat skeletal muscle.
American Journal of Physiology: Regulatory, Integrative and Comparative
Physiology, 1999. 276(2 Pt 2): p. R331-R339.
150. Armstrong, R.B., et al., Elevations in rat soleus muscle [Ca2+] with passive
stretch. Journal of Applied Physiology, 1993. 74(6): p. 2990-7.
160
151. Hawkins, D. and M. Bey, Muscle and tendon force-length properties and their
interactions in vivo. Journal of Biomechanics, 1997. 30(1): p. 63-70.
152. Wisnes, A. and A. Kirkebo, Regional distribution of blood flow in calf muscles of
rat during passive stretch and sustained contraction. Acta Physiologica
Scandinavica, 1976. 96(2): p. 256-66.
153. Baskin, R.J. and P.J. Paolini, Muscle volume changes. Journal of General
Physiology, 1966. 49(3): p. 387-404.
154. Gauthier, M.G. and G.W. Slater, Exactly solvable Ogston model of gel
electrophoresis. IX Generalizing the lattic model to treat high field intensities.
Journal of Chemical Physics, 2002. 117(14): p. 6745-6756.
155. McCarthy, M.J., D.S. Soong, and E.R. Edelman, Control of Drug Release From
Polymer Matrices Impregnated with Magnetic Beads - A Proposed Mechanism
and Model for Enhanced Release. Journal of Controlled Release, 1984. 1: p. 143-
147.
156. Zuurbier, C.J. and P.A. Huijing, Changes in geometry of actively shortening
unipennate rat gastrocnemius muscle. Journal of Morphology, 1993. 218(2): p.
167-80.
157. van Donkelaar, C.C., et al., Skeletal muscle transverse strain during isometric
contraction at different lengths. Journal of Biomechanics, 1999. 32(8): p. 755-62.
158. Saltzman, W.M. and W.L. Olbricht, Building drug delivery into tissue
engineering. Nat Rev Drug Discov, 2002. 1(3): p. 177-86.
159. Gu, F., B. Amsden, and R. Neufeld, Sustained delivery of vascular endothelial
growth factor with alginate beads. J Control Release, 2004. 96(3): p. 463-72.
160. Guan, J., J.J. Stankus, and W.R. Wagner, Biodegradable elastomeric scaffolds
with basic fibroblast growth factor release. Journal of Controlled Release, 2007.
120(1-2): p. 70-8.
161. Tabata, Y., et al., Controlled release of vascular endothelial growth factor by use
of collagen hydrogels. Journal of Biomaterials Science, Polymer Edition, 2000.
11(9): p. 915-30.
162. Richardson, T.P., et al., Polymeric system for dual growth factor delivery. Nature
Biotechnology, 2001. 19(11): p. 1029-34.
163. Hosaka, A., et al., Gelatin hydrogel microspheres enable pinpoint delivery of
basic fibroblast growth factor for the development offunctional collateral vessels.
Circulation, 2004. 110(21): p. 3322-8.
164. Boodhwani, M., et al., The future of therapeutic myocardial angiogenesis. Shock,
2006. 26(4): p. 332-41.
165. Freedman, S.B. and J.M. Isner, Therapeutic angiogenesisfor coronary artery
disease. Annals of Internal Medicine, 2002. 136(1): p. 54-71.
166. Fannon, M., K.E. Forsten, and M.A. Nugent, Potentiation and inhibition of bFGF
binding by heparin: a model for regulation of cellular response. Biochemistry,
2000. 39(6): p. 1434-45.
167. Kang, S.S., et al., Selective stimulation of endothelial cell proliferation with
inhibition of smooth muscle cell proliferation byfibroblast growth factor-i plus
heparin delivered from fibrin glue suspensions. Surgery, 1995. 118(2): p. 280-6;
discussion 286-7.
161
168. Carmeliet, P., Mechanisms ofangiogenesis and arteriogenesis. Nature Medicine,
2000. 6(4): p. 389-95.
169. Peirce, S.M. and T.C. Skalak, Microvascular remodeling: a complex continuum
spanning angiogenesis to arteriogenesis. Microcirculation, 2003. 10(1): p. 99-
111.
170. Lu, H., et al., Combinatorial protein therapy of angiogenic and arteriogenic
factors remarkably improves collaterogenesis and cardiac function in pigs. Proc
Natl Acad Sci U S A, 2007. 104(29): p. 12140-5.
171. Zakrzewska, M., et al., Highly stable mutants of human fibroblast growth factor-i
exhibit prolonged biological action. Journal of Molecular Biology, 2005. 352(4):
p. 860-75.
172. Takeshita, S., et al., Therapeutic angiogenesis. A single intraarterial bolus of
vascular endothelial growth factor augments revascularization in a rabbit
ischemic hind limb model. J Clin Invest, 1994. 93(2): p. 662-70.
173. Masuoka, K., et al., The interaction of chitosan with fibroblast growth factor-2
and its protection from inactivation. Biomaterials, 2005. 26(16): p. 3277-84.
174. Epstein, S.E., et al., Angiogenesis therapy: amidst the hype, the neglected
potential for serious side effects. Circulation, 2001. 104(1): p. 115-9.
175. Carpenter, A.E., et al., CellProfiler: image analysis software for identifying and
quantifying cell phenotypes. Genome Biol, 2006. 7(10): p. R100.
176. Gilbert, D.L. and S.W. Kim, Macromolecular release from collagen monolithic
devices. Journal of Biomedical Materials Research, 1990. 24(9): p. 1221-39.
177. Khaled, A.-R.A. and K. Vafai, The role ofporous media in modeling flow and
heat transfer in biological tissues. International Journal of Heat and Mass
Transfer, 2003. 46(26): p. 4989-5003.
178. El-Kareh, A.W., S.L. Braunstein, and T.W. Secomb, Effect of cell arrangement
and interstitial volume fraction on the diffusivity of monoclonal antibodies in
tissue. Biophysical Journal, 1993. 64(5): p. 1638-46.
179. Nicholson, C. and J.M. Phillips, Ion diffusion modified by tortuosity and volume
fraction in the extracellular microenvironment of the rat cerebellum. Journal of
Physiology, 1981. 321: p. 225-57.
180. Chen, K.C. and C. Nicholson, Changes in brain cell shape create residual
extracellular space volume and explain tortuosity behavior during osmotic
challenge. Proceedings of the National Academy of Sciences of the United States
of America, 2000. 97(15): p. 8306-11.
181. Nicholson, C., Diffusion and related transport mechanisms in brain tissue.
Reports on Progress in Physics, 2001. 64(7): p. 815-884.
182. Blum, J.J., et al., Effect of cytoskeletal geometry on intracellular diffusion.
Biophysical Journal, 1989. 56(5): p. 995-1005.
183. Nugent, L.J. and R.K. Jain, Plasma pharmacokinetics and interstitial diffusion of
macromolecules in a capillary bed. Am J Physiol, 1984. 246(1 Pt 2): p. H129-37.
184. Bensoussan, A., J.L. Lions, and G. Papanicolaou, Asymptotic Analysis for
Periodic Structures. 1978, New York: North Holland Science Publishers.
185. H. Gordon Harris, J. and S.L. Goren, Axial diffusion in a cylinder with pulsed
flow. Chemical Engineering Science, 1967. 22: p. 1571-1576.
162
186. Thomas, A.M. and R. Narayanan, Physics of oscillatory flow and its effect on the
mass transfer and separation ofspecies. Physics of Fluids, 2001. 13(4): p. 859-
866.
187. Azer, K., Taylor diffusion in time-dependentflow. International Journal of Heat
and Mass Transfer, 2005. 48(13): p. 2735-2740.
188. Fung, Y.C., Biomechanics: Mechanical Properties of Living Tissues. 2 ed. 1993,
New York: Springer-Verlag.
189. Formaggia, L. and F. Nobile, A stability analysis for the arbitrary lagrangian
eulerianformuation with finite elements. East-West Journal of Numerical
Mathematics, 1999. 7(2): p. 105-131.
190. Leypoldt, J.K. and L.W. Henderson, Molecular charge influences transperitoneal
macromolecule transport. Kidney Int, 1993. 43(4): p. 837-44.
191. Deen, W.M., Analysis of Transport Phenomena. Topics in Chemical Engineering:
A Series of Textbooks and Monographs, ed. K.E. Gubbins. 1998, New York:
Oxford University Press. p. 19.
192. Hill, D.K., The organization of the inter-fibre space in the striated muscle of the
toad, and the alignment ofstriations of neighbouring fibres. Journal of
Physiology, 1965. 179(2): p. 368-84.
193. Kobayashi, N. and K. Yonemura, The extracellular space in red and white
muscles of the rat. Japanese Journal of Physiology, 1967. 17(6): p. 698-707.
194. Sreter, F.A. and G. Woo, Cell Water, Sodium, And Potassium In Red And White
Mammalian Muscles. American Journal of Physiology, 1963. 205: p. 1290-4.
195. Gajdosik, R.L., Passive extensibility of skeletal muscle: review of the literature
with clinical implications. Clinical Biomechanics, 2001. 16(2): p. 87-101.
196. Bozler, E., Determination of extracellular space in amphibian muscle. Journal of
General Physiology, 1967. 50(5): p. 1459-65.
197. Neville, M.C. and R.T. Mathias, The extracellular compartments offrog skeletal
muscle. Journal of Physiology, 1979. 288: p. 45-70.
198. Davis, J., K.R. Kaufman, and R.L. Lieber, Correlation between active andpassive
isometric force and intramuscular pressure in the isolated rabbit tibialis anterior
muscle. Journal of Biomechanics, 2003. 36(4): p. 505-12.
199. Sejersted, O.M. and A.R. Hargens, Intramuscular Pressures For Monitoring
Different Tasks and Muscle Conditions, in Fatigue, S.C. Gandevia, Editor. 1995,
Plenum Press: New York. p. 339-350.
200. Mulherkar, P. and R.v. Reis, Flex test: a fluorescent dextran test for UF
membrane characterization. Journal of Membrane Science, 2004. 236(1-2): p.
171-182.
201. Sahagun, G., S.A. Moore, and M.N. Hart, Permeability of neutral vs. anionic
dextrans in cultured brain microvascular endothelium. Am J Physiol, 1990. 259(1
Pt 2): p. H162-6.
202. Tanford, C., Physical Chemistry ofMacromolecules. 1961, New York: John
Wiley and Sons, Inc.
203. Han, J. and J. Herzfeld, Macromolecular diffusion in crowded solutions. Biophys
J, 1993. 65(3): p. 1155-61.
163
204. Huijing, P.A., Muscle as a collagen fiber reinforced composite: a review offorce
transmission in muscle and whole limb. Journal of Biomechanics, 1999. 32(4): p.
329-45.
205. Passerieux, E., et al., Physical continuity of the perimysium from myofibers to
tendons: involvement in lateral force transmission in skeletal muscle. Journal of
Structural Biology, 2007. 159(1): p. 19-28.
206. Neering, I.R., et al., Nonuniform volume changes during muscle contraction.
Biophysical Journal, 1991. 59(4): p. 926-33.
207. Balcells, M., et al., Cells influidic environments are sensitive toflowfrequency.
Journal of Cellular Physiology, 2005. 204(1): p. 329-35.
208. Yin, F.C. and H. Yamada, The effects of left ventricular stretch versus cavity
pressure on intramyocardial pressure. Cardiovasc Res, 1997. 34(2): p. 299-305.
209. Rademakers, F.E., et al., Relation of regional cross-fiber shortening to wall
thickening in the intact heart. Three-dimensional strain analysis by NMR tagging.
Circulation, 1994. 89(3): p. 1174-82.
210. Chen, J., et al., Regional ventricular wall thickening reflects changes in cardiac
fiber and sheet structure during contraction: quantification with diffusion tensor
MRI. Am J Physiol Heart Circ Physiol, 2005. 289(5): p. H1898-907.
211. Iwakura, A., et al., Intramyocardial sustained delivery of basicfibroblast growth
factor improves angiogenesis and ventricular function in a rat infarct model.
Heart Vessels, 2003. 18(2): p. 93-9.
212. Elbrink, J. and I. Bihler, The effect of stimulating frequency and of ouabain on the
intracellular penetration ofL-arabinose in rabbit ventricular muscle, in vitro.
Life Sci II, 1973. 12(2): p. 79-87.
213. Peterson, M.B. and M. Lesch, Protein synthesis and amino acid transport in the
isolated rabbit right ventricular papillary muscle. Effect of isometric tension
development. Circ Res, 1972. 31(3): p. 317-27.
214. Lesch, M., R. Gorlin, and E.H. Sonnenblick, Myocardial amino acid transport in
the isolated rabbit right ventricular papillary muscle. General characteristics and
effects ofpassive stretch. Circ Res, 1970. 27(3): p. 445-60.
215. Rosen, M.R. and H. Gelband, Effects of ouabain on canine Purkinje fibers in situ
orperfused with blood. J Pharmacol Exp Ther, 1973. 186(2): p. 366-72.
216. Lullmann, H., T. Peters, and U. Ravens, Studies on the kinetics of(3H)-ouabain
uptake and exchange in the isolated papillary muscle of the guinea-pig. Br J
Pharmacol, 1975. 53(1): p. 99-107.
217. Huang, Y.F., et al., Tachycardia alone fails to change the myocardial
pharmacokinetics and dynamics of lidocaine, thiopental, and verapamil after
intravenous bolus administration in sheep. J Pharm Sci, 1998. 87(7): p. 854-8.
218. Lloyd, B.L. and R.R. Taylor, Influence of myocardial mechanical activity and
coronary blood flow on myocardial digoxin uptake. Cardiovasc Res, 1976. 10(4):
p. 487-93.
219. Cieslar, J., M.T. Huang, and G.P. Dobson, Tissue spaces in rat heart, liver, and
skeletal muscle in vivo. Am J Physiol, 1998. 275(5 Pt 2): p. R1530-6.
220. Berne, R.M. and M.N. Levy, eds. Physiology. 4th ed. 1998, Mosby, Inc.:
Philadelphia, PA. 361.
164
221. Poole-Wilson, P.A., P.D. Bourdillon, and D.P. Harding, Influence of contractile
state on the size of the extracellular space in isolated ventricular myocardium.
Basic Res Cardiol, 1979. 74(6): p. 604-10.
222. Rabbany, S.Y., J.Y. Kresh, and A. Noordergraaf, Intramyocardial pressure:
interaction of myocardialfluid pressure and fiber stress. Am J Physiol, 1989.
257(2 Pt 2): p. H357-64.
223. Stein, P.D., et al., Comparison of the distribution of intramyocardial pressure
across the canine left ventricular wall in the beating heart during diastole and in
the arrested heart. Evidence of epicardial muscle tone during diastole. Circ Res,
1980. 47(2): p. 258-67.
224. Stein, P.D., H.N. Sabbah, and M. Marzilli, Intramyocardial pressure and
coronary extravascular resistance. J Biomech Eng, 1985. 107(1): p. 46-50.
225. Dinbergs, I.D., L. Brown, and E.R. Edelman, Cellular response to transforming
growth factor-betal and basic fibroblast growth factor depends on release
kinetics and extracellular matrix interactions. J Biol Chem, 1996. 271(47): p.
29822-9.
226. Liu, L., et al., Adult cardiomyocytes express functional high-affinity receptors for
basicfibroblast growth factor. Am J Physiol, 1995. 268(5 Pt 2): p. H1927-38.
227. Dowd, C.J., C.L. Cooney, and M.A. Nugent, Heparan sulfate mediates bFGF
transport through basement membrane by diffusion with rapid reversible binding.
J Biol Chem, 1999. 274(8): p. 5236-44.
228. Gallagher, K.P., et al., The distribution offunctional impairment across the
lateral border of acutely ischemic myocardium. Cire Res, 1986. 58(4): p. 570-83.
229. Rodriguez, F., et al., Alterations in transmural strains adjacent to ischemic
myocardium during acute midcircumflex occlusion. J Thorac Cardiovasc Surg,
2005. 129(4): p. 791-803.
230. Finsen, A.V., et al., Increased syndecan expression following myocardial
infarction indicates a role in cardiac remodeling. Physiol Genomics, 2004. 16(3):
p. 301-8.
231. Kresh, J.Y., M.A. Cobanoglu, and S.K. Brockman, The intramyocardial pressure:
a parameter of heart contractility. J Heart Transplant, 1985. 4(2): p. 241-6.
232. Henning, R.J., et al., Increased heart rate accelerates norepinephrine washout
from normal myocardium. Am J Physiol, 1987. 253(6 Pt 2): p. H1581-5.
233. Fagard, R., Athlete's heart. Heart, 2003. 89(12): p. 1455-61.
234. Hughes, S.E., The pathology of hypertrophic cardiomyopathy. Histopathology,
2004. 44(5): p. 412-27.
235. Roberts, W.C. and V.J. Ferrans, Pathologic anatomy of the cardiomyopathies.
Idiopathic dilated and hypertrophic types, infiltrative types, and endomyocardial
disease with and without eosinophilia. Hum Pathol, 1975. 6(3): p. 287-342.
236. van der Bel-Kahn, J., Muscle fiber disarray in common heart diseases. Am J
Cardiol, 1977. 40(3): p. 355-64.
237. Sun, Y. and K.T. Weber, Infarct scar: a dynamic tissue. Cardiovasc Res, 2000.
46(2): p. 250-6.
238. Lakhan, S.E. and L. Harle, Cardiac fibrosis in the elderly, normotensive athlete:
case report and review of the literature. Diagn Pathol, 2008. 3: p. 12.
165
239. Schoen, F.J., The Heart, in Robbins Pathologic Basis ofDisease, R.S. Cotran, V.
Kumar, and T. Collins, Editors. 1999, W.B. Saunders Company: New York, NY.
p. 586-587.
240. Perloff, J.K., A.C. de Leon, Jr., and D. O'Doherty, The cardiomyopathy of
progressive muscular dystrophy. Circulation, 1966. 33(4): p. 625-48.
241. Burlew, B.S. and K.T. Weber, Connective tissue and the heart. Functional
significance and regulatory mechanisms. Cardiol Clin, 2000. 18(3): p. 435-42.
242. Nikolic, S., et al., Passive properties of canine left ventricle: diastolic stiffness
and restoring forces. Cire Res, 1988. 62(6): p. 1210-22.
243. Duncker, D.J. and R.J. Bache, Regulation of coronary blood flow during exercise.
Physiol Rev, 2008. 88(3): p. 1009-86.
244. Plehn, G., et al., Loss of diastolic time as a mechanism of exercise-induced
diastolic dysfunction in dilated cardiomyopathy. Am Heart J, 2008. 155(6): p.
1013-9.
245. Braunwald, E. and M.A. Pfeffer, Ventricular enlargement and remodeling
following acute myocardial infarction: mechanisms and management. Am J
Cardiol, 1991. 68(14): p. 1D-6D.
246. Holmes, J.W., T.K. Borg, and J.W. Covell, Structure and mechanics of healing
myocardial infarcts. Annu Rev Biomed Eng, 2005. 7: p. 223-53.
247. Zilberman, M. and M. Sofer, A mathematical model for predicting controlled
release of bioactive agents from composite fiber structures. J Biomed Mater Res
A, 2007. 80(3): p. 679-86.
166
8. ACKNOWLEDGMENTS
Sources of Funding
These studies were supported in part by graduate fellowships from the
Department of Defense, the Whitaker Foundation for Biomedical Engineering, and the
Harvard-MIT Division of Health Sciences and Technology Medical Engineering and
Medical Physics Program to Peter I. Wu, the "Progetto Roberto Rocca" MIT-Politecnico
di Milano collaboration to Sara Minisini, the Department of Anesthesiology and Pain
Medicine at Caritas St. Elizabeth's Medical Center, Brighton, MA, and a research grant
from the National Institutes of Health (NIH/NIGMS R01/HL049039) to Elazer R.
Edelman.
Chapter 2
Thank you to Gerry Wentworth and Mark Belanger from the M.I.T. Laboratory of
Manufacturing and Productivity for providing technical advice and assistance on the
manufacturing process of the mechanical loading system. Thank you to Martin J.
Kushmerick, M.D., Ph.D. from the University of Washington Physiology and Biophysics
Department for providing expertise and insight on experimental techniques related to
muscle physiology. Thank you to Kha N. Le for discussions on the conceptual design of
the mechanical loading system and setup of drug transport experiments.
167
Chapter 3
Thank you to Sara Minisini for providing mathematical expertise and producing
the mathematical analyses and computational models that were used to characterize drug
transport in skeletal muscle. Thank you to Abraham Wei for providing assistance on
surgical, experimental, and histologic work.
Chapter 4
Thank you to Mark A. Lovich, M.D., Ph.D. for providing expertise on
anesthesiology and cardiovascular pharmacology, as well as supplying the MPVS 300
data acquisition system. Thank you to Robert P. Marini D.V.M., D.A.C.L.A.M. from the
M.I.T. Division of Comparative Medicine for serving as a resource on surgical protocol
and techniques. Thank you to Michael J. Raher from the Massachusetts General Hospital
Department of Anesthesia and Critical Care for serving as a technical resource on
hemodynamic monitoring of small rodents in the surgical setting. Thank you to Abraham
Wei for providing assistance on growth factor production and surgical, experimental, and
histologic work. Thank you to Philip Seifert, Leslie Arnold, Gilan Hashemi, and Gee
Wong for technical assistance in histology.
168
APPENDIX A: MATLAB SOURCE CODE TO SIMULATE RESTING MUSCLE
RESPONSES TO LENGTH PERTURBATIONS
Simulation of Step Response
clear
clc
% Parameter Values for Inertial Mass, Muscle Stiffnesses, and Damping
Coefficients
% In SI Units, Newton, Kg, Meter, Seconds
% Amplitude of length perturbation
A=.002; %m
kO=10*9.806658*20; %N/m
kl=3*9.80665*20; %N/m
k2=2.5*9.80665*20; %N/m
cl=.1625*9.80665*20; %N.s/m
c2=6*9.80665*20; %N.s/m
conversion from g/mm to N/m multiplied by
cross-sectional area of 20 mm^2
% Time-Domain
Equations
t=linspace(0, 10,100);
first=A*kO;
second=A*kl *exp(-t/(c l /kl ));
third=A*k2*exp(-t/(c2/k2));
fp=first+second+third;
max(fp)
plot(t,fp)
title('Passive Tension Response of Muscle to Step Displacement of 0.002m')
xlabel('Time (sec)')
ylabel('Force (N)')
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Simulation of Frequency Response
clear
clc
% Parameter Values for Inertial Mass, Muscle Stiffnesses, and Damping
Coefficients
% In SI Units, Newton, Kg, Meter,
Seconds
% Total Mass Estimate of muscle and loading assembly components
m=0.2; %kg
% Model
Parameters
kO=10*9.806658*20; %N/m
k1=3*9.80665*20; %N/m
k2=2.5*9.80665*20; %N/m
cl=.1625*9.80665*20; %N.s/m
c2=6*9.80665*20; %N.s/m
% State Space
Model
A=[0 (-1/m) (-1/m)
B=[(1/m); 0;0;0];
C=[1 0 00];
D=[0];
sys=ss(A,B,C,D);
conversion from g/mm to N/m multiplied by
cross-sectional area of 20 mm^2
(-1/m); kl (-kl/cl) 0 0; k2 0 (-k2/c2) 0; kO 0 0 0 ];
% Vm/Fin Transfer
Function
sys2=tf(sys);
% Creation of the Fin/Xm Transfer
Function
den=[5 94.39 38.46 0];
num=[1 18.88 1.521e004 2.316e005 7.544e004 0];
% Maximum
Estimate
%Transfer function
% 5 s^3 + 94.39 s^2 + 38.46 s
170
%---------------------------------------------------------
%s^4 + 18.88 s^3 + 1.521e004 s^2 + 2.316e005 s + 7.544e004
% Bode Plot of Displacement Input and Force
Output
w=logspace(0,1.3,1000);
bode(num,den,w)
[MAG,PHASE,W] = BODE(num,den,w);
%Multiply the Force by a 20% displacement for a 10mm length of muscle
%or a 2mm length perturbation
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APPENDIX B: LOADING SYSTEM COMPONENT DESIGNS
Fibula Mounting Block (all units are in inches)
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APPENDIX C: MOTOR SPECIFICATIONS
Linmot@ Linear Motor Specifications
Linear Motor LinMot® P01-3 7x240/60x260
Servo Controller E 00-MT
Power Supply 48VDC, 150W
Peak Force, Fp 120N (271bf)
Continuous Force, Fc 55N (12.41bf)
Limit Force, Fb 72N (16.21bf)
Force Constant, cF 40N/A (91bf/A)
Maximum Stroke, s 260mm (10.2in)
Shortened Stroke, SS 60mm (2.4in)
Zero Position, ZP 75mm (3in)
Max. Acceleration, a 144m/s
2 (5700in/s2)
Max. Velocity, v 1.3m/s (5 lin/s)
Position Repeatability ± 0.1mm (± 0.004in)
Linearity ± 0.3%
Slider Mass, mS 829g (1.831b)
Slider Length, IS 395mm (15.6in)
12 ---- ---- .-..
-20 -------------- -----
.
40 ------- ---
- 
--------S I
-250 -200 -150 -100 -50 0 50
Stroke jmm]
It I I'
-- --- 
- •---
-- -
----- 
--
I
100 150 200 250
Servo Controller:
-
Series 1000
supply voltage 72 V DC
phase current 5.0 A
-- - Series 100
supply voltage 48 V DC
phase current 3.0 A
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T
--- •-
--- I
C---;-
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Controller Settings: CFG I ST.CFGR
User Name: user
P'assw\ord: savior
System Info I lardware l)evice 0
Type: E200-MT/V2A
Serial No Iigh: 2322
Serial No I.ow: 133 O
Memory
Flash Type: 514
II'PROM Type: 3075
RAM Type: 257
Softwtare
Release: R 1.3.8
Monitor: I inMon/V 1.6.1 1
Base: l,inBase/VI.3.40
Application: MT/V 1.3.1 I/T[02
Tree Type: 3
Tree Version: 4
Error H andling Error Mask (all selected)
I)DCI.V Poer'l Too low
)CIV Power Too High
DCIV Signal Too L,ow
DCLV Signal T'oo iligh
Electronic Fault
Warn Mask (all selected)
D)CIV Power Too Io\w
DCIV Po\ver Too I ligh
I)CI.V Signal 'oo Low
DCI.V Signal Too High
Electronic Fault
Msg Mask (none selected)
DCLV Power Too l.owv
DCLV Po\wer Too Hi gh
I)CI.V Signal Too Iow
D)CIV Signal Too I ligh
Electronic Fault
Drive Type Mismatch
Curve Error
Slider Missing
Init Failed
I)rive Following Error
Drive Too Hot Calculated
Drive Too I lot Sensor
in Position
Logging Mask (all selected except italics)
DCLV Power Too Lo~w
I)CIV Powver Too I ligh
I)CI.V Signal Too Low
DCLV Signal Too High
Electronic Fault
Drive Type Mismatch
Curve Error
Slider Missine
Init Failed
Drive Following 'tError
Drive Too Hot Calculated (l)efault selected)
D)rive Too I lot Sensor
DCLV Monitoring
llPoer Low\ Warn: 21.123V
Power I ligh Warn: 50.859V
Power Low\ Error: 18.252V
Po\wer I ligh Error: 53.73 V
Signal Lovx Warn: 21.123V
Signal I ligh Wanr: 50.859V
Signal Low Error: 18.252V
Signal High Error: 53.73V
Startup Mode (selected, except italics)
Auto Start (default selected)
Init Together
10 Configuration (all selected except italics)
Run Input
hiii InIit
Iieeze Input
Emnerg Stop Input
Analog/Trig Drive A
Analog/ Trig Drive B
Error Output
Warn Output
Pos Frror Output
.lsg Outipt
Command Interface
AT
MT
ASCII RS232
ASCII RS485
Application
Time
I fours: 5h
Seconds: 2986s
Drives Drive A Type
No Drive
LinMot POx-23
LinMot POx-37
I inMot POx-37F
Stepper
Magnet
Sin/Cos Position Sensor
Initialization Init Mode
Actual Position
Auto Move Out
Auto Move In (Delhult selected)
Trig Move Out
Trig Move In
Set Value Gieneration
Init Switches
Init Once (D)etault selected)
Init Config (Defaults in Parentheses)
Init Speed: 24.414 mm/s (Doesn't matter) (48.828mm/s)
I lome Position: 0 mm (0 mm)
Check Init Position: 0 mm (39.997 mm) depends on strain
Initial Position 0 mm (19.999 mm)
Run Mode
Serial
Analog (D)efault selected)
Continuous Curve
Trigger Curve
T wo Point
Set Value Configuration
Minimal Position: -9.999 mm (-629.959 mm)
Maximal Position: 9.999 mm (629.959 mm)
Curve Number: i (1)
Curve Position Offset: 0 mm (0 mm)
Curve Amplitude: 100% (I 00%)
Curve Speed: 100% (100%)
Filter Parameter (Doesn't matter when motion profile is being run)
Max Speed: 4.687 m/s (0.781 m/s)
Max Acceleration: 366.211 m/s- (30.518 m's-)
Position Monitoring
Pos Range Min: -9.999 mm
Pos Range Max: 9.999 mm
11n Position : 0.098 mml
11n Position -: 0.098 mm
Follo ming Error -: 0.3 91 mm
Follow ing Error : 0.391 rmm
(-9.999 mm)
(9.999 mm)
(0.996 mm) Active in on interfaces modes MT, ASCII, PROFIBUS
(0.996 nmm)
(2.5 mm)
(2.5 mm)
Control Switches
Current 3A
Control Parameters (Default) ITuned|
Maximal Current: 2.995 A
Current OtlTset: OA
P: 3.5A/mmn
1): 4.005 A*s/mn
1: 1.005 A/(mm*s)
FF Friction: 0.l164A
FF Acceleration 4 mA'/( i/s)
FI Deceleration 4 mA/(m/s )
Error I landling
(2.995 A)
(0 A) [-0.047 Aj
(0.999 Aimm) [3 A/mm]
(3.99 A*s/mm) [6 A*s/m]
(0 A/(mm*s)) 13.016 A/(mmn*s))
(0 A)
(0 mA/(mn/s))
(0 mAi/(m/s 2 ))
10.023 A
138 mA/(m/s- ) based on 720g load w/o slider
[38 mA/(m/s 2)] based on 720g load w/o slider
Error Mask (all selected except italics)
Drive T'pe Mismatch
Curve Error
Slider Missing
Init Failed
Drive Follot'ing Error
Drive Too lHot Caiculatted (Default selected)
Drive Too Hlot Sensor
Warn Mask (all selected except italics)
Slider Missing
Drive Init Not I)one
Drive Following Error
Pos Range Indicator
I)rive Hot Calculted ( [)efault Selected)
Drive I lot Sensor
lII tositiSto
Emergency Stop Emergency Stop Mode
Off( l)ethult selected)
Freeze
Goto Position
Emergency Configuration
Max Acceleration: 30.518mr/s
Commutation
Sine (D)elhult)
Trapezoid
Block
Master / Booster
Master
Booster Parallel
Booster Reverse
Advanced
Gantry Slave parallel
Position Sensor
Internal Sensor 20gtm
Internal Sensor 40ptm
External 20 .Lm
External 10 pm
External 5 upm
External 2.5 [tpm
External 1.25 pm
AB Enc I lX
AB Inc I 2X
Al EInc 1 4X
AB Enc 2 IX
AB Enc 2 2X
AB Enc 2 4X
Load Mass is 238.4 2 g (includes the rack and pinion, w\ith 4 Lexan pieces, bearings, and bolts)
Round up to 250g
P01 -37x240/60x260
Application Data
Load Mass Igl:
Add:
DrN Friction [N]:
External Force [N]:
Angle Idegl:
Current (lOfset IA j:
FF Friction [A]:
FF Acceleration:
FF Deceleration:
720g
Slider Mass
0.95N (Estimate)
2N (External constant force like Mag Spring, Rounded for 3mm * 500N/m spring constant - 1.5N)
0 deg
-0.049A
0.023
37.966 mA/( m/s 2)
37.966 mA/( m/s- )
Tuning Tool
Motor Data
Motor Type:
Matlab Source Code for Generating Strain Profiles for Linear Motor
% Generate a Curve for the Linmot Median Strain 5%
% Enter the Frequency (Hz) and the Length of the Muscle (mm) and the Desired
% Strain (Decimal)
clear
clc
% n Points in time
% Frequency (Hz)
frequency=1;
% 1000 milliseconds divided by 5ms intervals (200 points / sec) divided by the
% frequency = NUMBER OF POINTS / PERIOD (or oscillation)
% Frequency 3 Hz, One period is 333.333ms, with 5ms points = 67 points
n=round(1000/5/frequency)
% 0 --> n counting by ones in each oscillation = N POINTS (3Hz = 67 points)
interval=linspace(0,n,n+ 1);
% 0 to 1 in n number of points
t=(interval/n);
% Sinusoidal Curve (mm)
% Length of Muscle (mm)
A=26;
% Strain
s=0.05;
curve=A*(s/4)*sin(2*pi*t);
% One complete cycle or oscillation with amplitude 1/4 of the desired strain
% Set Muscle at Amplitude Strain first, then start motor
% Single Step Conversion for Linmot (mm --> singlesteps)
ss=(1024/20)*curve;
% Round
values=round(ss')
% Specify in Linmot the time (ms) in which you want the curve to run
time=1/frequency* 1000
% time of 1/frequency (or period) -- (3Hz = 1/3s or 333.333ms)
% Erase the last point in the generated values as this is a redundancy in
% the oscillation
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APPENDIX E: THEORETICAL BACKGROUND ON HOMOGENIZATION
THEORY
Transport through a complex medium composed of smaller elements can be
represented on multiple scales. For muscle tissues, micro-scale corresponds to the
cellular or myofiber level while macro-scale corresponds to the tissue or muscle bundle
level. On the cellular level, free diffusion is influenced by boundary conditions defined
by cell geometry. On the tissue level, transport occurs across a continuous medium.
Diffusion of drug through muscle can be studied using a multi-scale approach [ 178]
starting with:
= V -(D(X) Vc) (El)
at
where X=(X1, X2, X3) denotes the three-dimensional coordinate system on the cellular
length scale L,. The diffusivity tensor D(X), which Dint defines on the cellular level, is a
continuous function of the position X. D(X) = 0 inside muscle fibers where no diffusion
occurs.
Homogenization was used to derive macro-scale behaviors in the tissue based on
micro-scale phenomena. This technique accounts for spatial variations in drug
concentration on the cellular level to characterize drug concentration profiles on the
tissue level (Figure E. 1).
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Figure E.1. Homogenization theory accounts for drug concentration on the cellular level in
interstitial spaces (green lines) to characterize concentration gradients on the tissue level
(green shade). A myofiber is outlined in black.
As fibers in the muscle can be considered repeating elements, a representative
volume describing a periodic distribution of fiber elements that compose the macro-scale
tissue was introduced. In our model, muscle fibers are represented by white diamond
elements arranged in a staggered periodically repeating array, and diffusion occurs in the
pink interstitial space between them (Figure 3.3B). As the axial length of our muscle
sample is significantly greater than its radial cross-sectional area, the representative
volume can be defined by a two dimensional configuration and solved on a reduced
computational domain Q (Figure 3.3B, inset), which is a periodic or repeating unit that
sufficiently characterizes the symmetrical aspects of the problem. This idealized
configuration was used to derive continuous behaviors on the tissue length scale (Lt), e.g.
muscle diameter, by averaging or "homogenizing," variations on the cellular length scale
(Lj), e.g. myofiber diameter. The homogenized version of Equation El [178, 184] on the
tissue level has the form:
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! o
a(c) Di a2(c) (E2)
at Cf ax ax.
where x = (xl, X2, X3) denotes the three-dimensional coordinate system on the tissue
length scale Lt, Deff is the macroscopic diffusion coefficient, (c) is average concentration,
and ij = (1,2,3). Homogenization takes place for X = x/I in the theoretical limit as Kc-0,
where K-=Lc/Lt is a small parameter representing the periodicity of repeating elements.
Macro-scale concentration, (c), was represented in Q as the sum of a linear
function of position, e, reflecting the assumption of steady state diffusion, and a function
X(x,y) on the micro-scale that is periodic with period Lc. For the canonically defined
concentration gradient, V(c)= -1, with unit amplitude:
V(c) = -e + Vx (E3)
where e is a unit vector defining the direction of macro-scale transport (Figure 3.3B) and
X is the small periodic component of the macroscopic concentration field used in the
periodic domain Q to represent perturbations to diffusion posed by the myofiber
elements. X is bounded by conditions F1, at interstitial borders of Q, and F2, on myofiber
surfaces (Figure 3.3C). Components of FT are conditions of symmetry that represents
zero net flux (Rn. VX = 0) at interstitial boundaries parallel to e, and of periodicity that
represents unconstrained flux (X = 0) at interstitial boundaries perpendicular to e [180].
F2 is a boundary condition of myofiber impermeability defined by the non-homogeneous
Neumann condition:
n1 V = n. e (E4)
which is equivalent to V(c) = o according to Equation E3.
X satisfies the Laplacian equation:
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V2X = 0 (E5)
in Q [184] under boundary conditions F 1 and F2. The solution of X is used in an integral
summation of micro-scale flux to calculate space averaged macro-scale effective
diffusivity. Total flux in the direction of e is calculated using Equation E3 by:
D ff VcA = Dint e -(-e + V ) d (E6)
where Deff is macro-scale effective diffusivity, Dint is micro-scale diffusivity in the
interstitium, and A is the area of domain Q. Macro-scale effective diffusivity is then
calculated by reformulating Equation E6 according to the following general form [178,
184]:
D = iD(X).. - D(X) dX (E7)
where Vp is the volume of the periodic unit P, which is in our case is Q, and 8ij is the
Kronecker delta. From Equation E6, effective diffusivity in the direction of e is:
_ D.
Deff Dinlt ( 1 - e. VX ) dQ (E8)
A
D2 in Equation 1 accounts for the effects of interstitial fluid viscosity and possible
hydrodynamic interactions of the drug with muscle fibers due to the relative size of the
drug. Because drug size is substantially smaller than pore size, D2 is independent of
tissue porosity. Also, it is assumed that in vitro incubated muscle samples are infiltrated
by saline media and that the interstitial fluid has the physical characteristics of water.
Thus, Dint = Dw, the free diffusivity of the drug in water, which is 1.026x1 0-4 mm2 /s for
20 kDa dextran [183]. With these assumptions, D2 = 1, and Equation E8 becomes:
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D - De ff I(le-V )d (E9)
Dw A
Here, D1 accounts for the effects of porosity and fiber geometry and arrangement on
effective diffusivity. D1 is generally recognized as:
D, = = (El0)D w  A
where cp is porosity, which describes the volume fraction of tissue accessible to diffusing
drug, and X is the geometric tortuosity factor (Figure E.2), which is the ratio of the actual
length of the transport path to the linear length or thickness of the tissue [247].
Tortuosity is a parameter that accounts for the transport effects of fiber geometry and
arrangement to describe the average hindrance to transport in a complex medium relative
to that in an obstacle-free medium.
Figure E.2. Definition of tortuosity.
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Matlab Source Code of the Static Model used in COMSOL Multiphysics®
% COMSOL Multiphysics Model M-file
% Generated by COMSOL 3.2b (COMSOL 3.2.0.304, $Date: 2006/04/04 14:56:13 $)
flclear fem
% COMSOL version
clear vrsn
vrsn.name = 'COMSOL 3.2';
vrsn.ext = 'b';
vrsn.major = 0;
vrsn.build = 304;
vrsn.rcs = '$Name: $';
vrsn.date = '$Date: 2006/04/04 14:56:13 $';
fem.version = vrsn;
% Geometry
gl=square2('2.2','base','center','pos', {'2','2'} ,'rot','45');
gl 1=square2('2','base','center','pos', {'2','2'},'rot','45');
garr=geomarrayr(gl 1,3,3,3,3);
[g12,g13,g14,gl5,gl6,gl 7,gl 8,gl9,g20]=deal(garr {: );
g21 =square2('2','base','center','pos', {'7/2','7/2'} ,'rot','45');
garr=geomarrayr(g21,3,3,2,2);
[g22,g23,g24,g25]=deal(garr {:});
g26=square2('6','base','comer','pos', {'2','2'} ,'rot','0');
g27=-rect2('1 .5','6','base','corner','pos', {'(5+8)/2','(5+8)/2'} ,'rot','0');
g28=-rect2('1 .5','6','base','corner','pos', {'(5+8)/2','2'} ,'rot','O');
g29=-rect2('1.5','6','base','comer','pos', {'5','2'},'rot','0');
clear s
s.objs={gl l,g13,gl4,gl5,gl6,gl7,gl 8g19,g 20,g2 1,g23,g24,g25,g26,g29};
s.name={'SQI','SQ2','SQ3','SQ4','SQ5','SQ6','SQ7','SQ8','SQ9','SQ10', ...
'SQ11','SQ12','SQ13','SQ14','R1'};
s.tags= {'gl l','g13','gl4','gl 5','g16','g 17','g 18','g19 2'g20','g21',...
'g23','g24','g25','g26','g29'};
fem.draw=struct('s',s);
% (Default values are not included)
% Application mode 1
clear appl
appl.mode.class = 'Poisson';
appl.sshape = 2;
appl.assignsuffix = '_poeq';
clear pnt
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pnt.weak = {};
pnt.dweak = {};
pnt.constr = { };
pnt.name = {};
pnt.ind = [];
appl.pnt = pnt;
clear bnd
bnd.type = {};
bnd.r = {};
bnd.h = {};
bnd.weak = { };
bnd.dweak = {};
bnd.constr = {};
bnd.g = {};
bnd.q = {};
bnd.name = {};
bnd.ind = [];
appl.bnd = bnd;
clear equ
equ.gporder = { };
equ.init = {};
equ.c= {};
equ.f= {};
equ.weak = {};
equ.dweak = {};
equ.usage = { };
equ.constr = { };
equ.cporder = {};
equ.name = { };
equ.ind = [];
appl.equ = equ;
fem.appl {1} = appl;
fem.sdim = {'x','y'};
fem.frame = {'ref };
fem.border = 1;
fem.units = 'SI';
% Multiphysics
fem=multiphysics(fem);
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APPENDIX F: CALCULATIONS FOR AMPLITUDE OF RADIAL
OSCILLATION IN DYNAMIC MODEL
An elastic material satisfies the law:
AV AL
= -L (1- 2v) (F1)V L
where AV is the change in total volume, v is the Poisson ratio, and AL is the change in
axial length. The Poisson ratio is defined as the ratio between the transverse, str, and
axial strain, Sax:
AR
v= " R (F2)AL
ax L
For an incompressible material, whose Poisson ratio is 0.5, volume is conserved during
deformation, and no volume change occurs with axial strain according to Equation Fl.
For a cylindrical sample of nominal radius RO and length LO:
AV= 7nR 2L-nR2LO = 0 (F3)
where R and L are the radius and the length, respectively, of the sample after
deformation. R is determined by:
R =RO 0 (F4)
FL
The length and radius at each mean strain are:
Ln = LO + n%LO
Rn=RO 1 (F5)
1+ n%
where LO and RO are the nominal length and radius, respectively, of the muscle, and n =
0, 5, 10, and 20, corresponding to the value of axial strain (Figure F.1).
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For cyclic strains, the maximum and minimum values for length and radial
deformations are:
LD = Ln ± 0.025 * LO
RDRn Ln
FLn ± 0.025 * LO
where n = 0, 5, 10, and 20. The absolute value of the amplitude of radial deformation
during cyclic strain is:
AR= IRn-RDI
(F6)
(F7)
4 *.# **
R(t) = Rn+ARsin(ot)
AL = 0.7 mm -) AR = 12 Lm
Figure F.1. Model of skeletal muscle dimensions. A picture of soleus skeletal muscle
mounted for linear tensile loading and a schematic of muscle mechanics as modeled by an
incompressible circular cylinder that relates length changes to radius changes by Poisson's
ratio.
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APPENDIX G: THEORETICAL BACKGROUND ON DYNAMIC MODEL -
ARBITRARY LAGRANGIAN EULERIAN FORMULATION
During cyclic strain, the boundary of the radial section moves according to the
sinusoidal law:
r(t) = Rn (1 + a sin(cot))
where a is the radial strain amplitude relative to the mean radius, Rn:
AR
Rn
r(t) is the radial coordinate in the moving domain, QD(r,O,t) = {O < r(t) < Rn (1 + a
(G1)
(G2)
sin(ot)), 0 < 0 < 2a }. And, R is the radial coordinate in the reference domain, Qo(R,®) =
({0< R_< Rn, 0 < 0<52x }.
The transport equation is:
ac D
D u a , 2c = 0 in QD(t) (G3)
which can be formulated on Eulerian coordinates such that:
a- DsI~m~ V2c - W.Vc= 0
t no
in fD(t) (G4)
where w is the oscillatory velocity of the domain 2D(t).
Using cylindrical coordinates (r,6) and considering the axial symmetry of the
problem in 0, Equation G4 can be written as:
8I cac 
- Dac.R V 2C- Wr- =:0at no ar in QD(t)
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(G5)
sLtmI. t
where wr is the radial component of w, and reformulated in the reference domain Qo with
the boundary conditions as follows:
V2c - Roa cos(ct) c = 0
1 + asin(ot) OR in 9o0
R=Ro, t>0
O<R <Ro, t=O
(G6)
Concentration at the final time is computed by averaging over the final period as follows:
(G7)C2 c(R, t) dtc(R, T,) = T2 -T1
where T1 = Tf- (T/2), T2 = Tf+ (T/2), T is the period of a cycle, and R is the radial
coordinate used to describe the domain o0.
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staticRn
Sa sin(co)) 2
ac
at (1-
c(t) = co
c=O
APPENDIX H: MATLAB SOURCE CODE FOR IMAGE PROCESSING
Image Montagin2 - Horizontal
clear
clc
% Load Image File
load clOwt
% Define Images to be Joined
leftimage=c10wdv;
rightimage=cl0wev;
% X = 480 Rows, Y = 640 Columns
% Least Squares Matrix Comparison
diff=[ ];
startright=1
endright=70
for k=startright:endright, % K is the index for the columns in the rightimage
diff(k)= sum(sum((leftimage(:,260:360)-rightimage(:,k:(k+100))).A2));
end
ly=259;
[minimum ry]-=min(diff(startright:endright));
figure(3); plot(diff)
diff
minimum
ly
ry=ry+startright- 1
newimage=[leftimage(:,1 :ly) rightimage(:,ry:640)];
% V-Intensity Value Scale
V=[O 1];
figure(4); imagesc(newimage); CAXIS(V); colorbar
%figure(5); newimage=[leftimage(:, 1 :ly) rightimage(:,ry:640)]; imagesc(newimage)
% Preliminary Pictures
c10wabcdev=[c10wav(:,1:529) c10wbv(:,14:520) c10wcv(:,76:499) c10wdv(:,50:259)
cl0wev(:,11:640)];
cl0wabcde=[cl0wa(:, 1:529,:) c10wb(:,14:520,:) c10wc(:,76:499,:) c10wd(:,50:259,:)
cl0we(:, 11:640,:)];
figure(6); imagesc(clOwabcdev); CAXIS(V); colorbar
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figure(7); imagesc(cl0wabcde)
save c l0wabcdepics c 10wabcde c l0wabcdev
% Joined Images
%figure(1); imagesc(cl0wav); CAXIS(V); pixval; figure(2); imagesc(cl0wbv);
CAXIS(V); pixval;
%figure(1); imagesc(cl0wbv); CAXIS(V); pixval; figure(2); imagesc(cl0wcv);
CAXIS(V); pixval;
%figure(1); imagesc(cl0wcv); CAXIS(V); pixval; figure(2); imagesc(cl0wdv);
CAXIS(V); pixval;
%figure(1); imagesc(cl0wdv); CAXIS(V); pixval; figure(2); imagesc(cl0wev);
CAXIS(V); pixval;
Ima2e Montaging - Vertical
clear
cle
% Load Image File
load clOwt
V=[O 1];
% Define Images to be Joined
topimage=c l0tbv;
bottomimage=c lOtcv;
% X = 480 Rows, Y = 640 Columns
% Least Squares Matrix Comparison
diff--[ ];
startbottom=200;
endbottom=250;
for k=startbottom:endbottom, % K is the index for the rows in the bottomimage
diff(k)= sum(sum((topimage(450:479,:)-bottomimage(k:(k+29),:)).^2));
end
tx=449;
[minimum bx]=min(diff(startbottom:endbottom));
figure(3); plot(diff)
%diff
minimum
tx
bx=bx+startbottom- 1
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newimage=[topimage(l:tx,:); bottomimage(bx:480,:)];
% V-Intensity Value Scale
V=[0 1];
figure(4); imagesc(newimage); CAXIS(V); colorbar
%figure(5); newimage=[topimage( 1 :tx,:); bottomimage(bx:480,:)]; imagesc(newimage)
% Final Picture
c 10tabcv=[c10tav(1:299,:); c10tbv(14:449,:); cl0tcv(217:480,:)];%; c3tdv(22:480,:)];
cl0tabc=[c10ta(1:299,:,:); cl0tb(14:449,:,:); cl0tc(217:480,:,:)];%; c3td(22:480,:,:)];
figure(6); imagesc(cl0tabcv); CAXIS(V); colorbar
figure(7); imagesc(cl0tabc)
save cl0tabcpics cl0tabcv cl0tabc
% Preliminary Pictures
%figure(1); imagesc(cl0tav); CAXIS(V); pixval; figure(2); imagesc(cl0tbv); CAXIS(V);
pixval;
%figure(1); imagesc(cl0tbv); CAXIS(V); pixval; figure(2); imagesc(cl0tcv); CAXIS(V);
pixval;
%figure(l); imagesc(c4tcv); CAXIS(V); pixval; figure(2); imagesc(c4tdv); CAXIS(V);
pixval;
Measurement of Drug Penetration
figure(1); imagesc(cl0tabcv); pixval; grid minor
v=[.844153 .042208];
figure(2); imcontour(cl0tabcv,v,b"o'); grid minor
figure(1); imagesc(cl0wabcdev); pixval; grid minor
v=[.844153 .042208];
figure(2); imcontour(c 10wabcdev,v,'b'); grid minor
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